

November 2025

CURRICULUM VITAE

J. Silvio Gutkind, Ph.D.

American Cancer Society Research Professor
Distinguished Professor and Chair, Department of Pharmacology, School of Medicine
Associate Director, Basic Science, Moores Cancer Center
University of California, San Diego
3855 Health Sciences Drive MC0803, Room 2344
La Jolla, CA 92093
sgutkind@health.ucsd.edu (email) • (858) 534-5980 (office) • (240) 423-3514 (cell)

[Gutkind lab website](#)

[UC San Diego profile](#)



Education:

1976-1980 Pharmacy Degree (M.Sc.), University of Buenos Aires, Argentina
1976-1983 Biochemistry Degree (M.Sc.), University of Buenos Aires, Argentina.
1985 Ph.D. in Pharmacy and Biochemistry (*Pharmacology*), University of Buenos Aires, Argentina

Employment History:

2020-Present Chair, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), USA
2019-Present Distinguished Professor, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), USA
2015-Present Associate Director of Basic Science, UCSD Moores Cancer Center, and Co-Director, Head and Neck Cancer Center
2015-Present Co-Director, Hanna and Mark Gleiberman Head and Neck Cancer Center
2015-2019 Professor, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), USA
1998-2015 Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA
1997-2015 Chief, Cell Growth Regulation Section and Molecular Carcinogenesis Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA
1996-1997 Acting Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, USA
1993-1997 Chief, Molecular Signaling Unit, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA
1992-1993 Head, Molecular Signaling Group, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA
1989-1992 Visiting Associate, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA
1988-1989 Fogarty Visiting Fellow, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA
1987-1988 Fogarty Visiting Fellow, NIDR, Guest Researcher at the Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, USA

1986-1987	International Fogarty Fellow, Laboratory of Clinical Science, National Institute of Mental Health, NIH, Bethesda, USA
1983-1986	Research Assistant, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina
1981-1983	Part-time Instructor, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina
1979-1980	Part-time Instructor, Department of Organic Chemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina

Honors and Awards:

2026	Organizer, 2026 ASBMB Annual Meeting, "The Hippo Signaling Pathway in Health and Disease mini-symposium", Washington, DC
2025	Chair, Gordon Research Conference, "Harnessing the Power of Advanced Multimodal Approaches to GPCR Drug Discovery", Molecular Pharmacology GRC, Ventura Beach, CA
2024	Chair, Major Symposium "Novel Immune Checkpoints: Beyond PD1 and CTLA4", American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA Elected, American Cancer Society Research Professor (ACS)
2023	Member, NCI Board of Scientific Counselors (BSC), NIH, Bethesda, MD Susan Band Horwitz Award in Cancer Pharmacology (ASPET) Keynote Lecture, Gordon Research Conference, Salivary Glands and Exocrine Biology, Ventura, CA
2022	Fellow, the American Society for Pharmacology and Experimental Therapeutics (ASPET) Fellow, American Society of American Society for Biochemistry and Molecular Biology (ASBMB) Keynote Lecture, New Frontier in RTK Signaling & Therapeutics, A Joint Cancer Signaling Networks and Developmental Therapeutics Retreat, Yale Cancer Center, New Haven, CT (virtual)
2021	UC San Diego Chancellor's award for Excellence in Postdoctoral Scholar Mentoring Cancer Research Institute - V Foundation CLIP Investigator UC San Diego Moores Cancer Center Faculty Award for Excellence in Translational Research Elected, National Academy of Pharmacy and Biochemistry, Argentina
2020	Certificate of recognition, United States Senate, for outstanding contributions to the advancement of medical sciences, health care, and public health Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET)
2019	Elected, National Academy of Medicine (NAM), USA, for outstanding contributions in the understanding of cancer signaling networks, and pioneering the study of the <i>PIK3CA</i> -mTOR signaling circuitry in head and neck cancer progression, metastasis, and in therapy resistance Elected Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET)
2017	Elected Co-Chair, Gordon Conference in Molecular Pharmacology, Ventura CA International Association of Dental Research (IADR), Distinguished Scientist Award

Keynote Lecture, ASPET 2017, Division for Molecular Pharmacology
Postdoctoral Scientist Award

2015 Pharmaceutical Research and Manufacturers of America (PhRMA), 2015
Research & Hope Award for “Excellence in Academic Research”, for the seminal
work on GPCR Function in Cancer
Keynote Lecture, ASPET Upstate New York Pharmacology Society 4th Annual
Meeting, Rochester, NY

2014 Keynote Lecture, 2014 American Head and Neck Society (AHNS) Annual
Meeting and 5th World Congress-IFHNOS
Distinguished Lecture Series at Massachusetts Eye and Ear Infirmary/Schepens
Eye Research Institute, Harvard University, MA
Keynote Speaker, Dental Research in Review, University of North Carolina,
Chapel Hill, NC
Keynote Speaker, Fifth Annual Cancer Biology Research Retreat, University of
Maryland-Baltimore

2013 PABMB (Pan-American Association for Biochemistry and Molecular Biology)
Plenary Lecture, Madrid, Spain
Elected, Keynote Lecture, 2014 American Head and Neck Society (AHNS)
Annual Meeting and 5th World Congress-IFHNOS
Elected, Councilor, Basic Research, International Academy/Association
of Oral Oncology (IAOO)
International Keynote speaker at the Weizmann-Brazil Signal Transduction
meeting, “Novel Angiogenic and Antiangiogenic Signaling Circuitries”, The
Weizmann Institute of Science, Israel
Honorary Professor, West China School of Stomatology, Sichuan University,
Chengdu, China

2012 Elliot Osserman Award, Israel Cancer Research Foundation

2011 Raices Award, Ministry of Science, Presidency of Argentina, for scientific
contributions and efforts in enhancing research training and technology
development, Argentina.
Keynote Speaker, (IADR, Chile) Asociación Internacional de Investigación Dental
– División Chile, Chile
Keynote Speaker, NCI Frederick Spring Research Festival, Frederick, MD
Visiting Professor, Georgetown University, Washington DC

2010 Visiting Professor and Clinical Ground Round Speaker, Memorial Sloan Kettering
Cancer Center, New York, NY
Keynote Speaker, 6th Annual International Head and Neck Symposium, Los
Angeles, CA, July 2010
Honorary Professor, University of Buenos Aires, Argentina
Keynote Speaker, The First South American Spring Symposium in Signal
Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina

2009 Keynote Lecture, Symposium on Molecular Medicine, Virginia Commonwealth
University, Richmond, VA
Keynote Speaker, School of Dentistry University of Michigan Research Day, Ann
Arbor, MI
Keynote speaker at the Annual Meeting of the Chilean Society of Biochemistry
and Molecular Biology, Concepcion, Chile
Keynote Inaugural Lecture, Annual meeting of the Argentine Society of Research
in Biochemistry and Molecular Biology, Tucuman, Argentina

2008 Hyman Niznik Memorial Keynote Lectureship, Annual Joint Meeting of the Great
Lakes: G Protein-Coupled Receptor Retreat, Bromont, Canada

	Merk Frosst Lecture, Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Canada
	R.M. Tiwari Oration, National Conference, Foundation for Head and Neck Oncology, Bhubaneswar, India
2007	Frank Brook Memorial Lecture, American Pancreatic Association, Chicago, IL
2006	Elected, Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", 2008
2006	Miguel Aleman Lecture, Miguel Aleman Foundation, Mexico DF, Mexico
2005	NIH Director's Award
2005	Elliot Osserman Award, Israel Cancer Research Foundation
2004	International Association of Dental Research (IADR) Distinguished Scientist Award, Oral Medicine and Pathology
2003	NIH Hispanic Heritage Month Celebration: Hispanic Contributions to Research in the United States, Lecture
2000	NIDCR Director's Exemplary Service Award
1999	EEO Special Achievement Award, NIDCR, NIH
1998	Appointment as member of the Senior Biomedical Research Services (SBRS)
1997	NIDCR Director's Exemplary Service Award
1996	NIH Merit Award
1989	Funds for Young Scientists, Travel Award, Organizing Committee of the 7th International Conference on Protein Phosphorylation, Kobe, Japan
1986	International Fogarty Fellowship, National Institutes of Health, USA
1983	Gold Medal Award and Diploma of Honor, first rank student of the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.

Editorial Responsibilities:

1998-2003	Member, Editorial Board, Journal of Biological Chemistry
1998-2000	Editor, Book on Signaling Networks and Cell Cycle Control, Humana Press
2000-2003	Co-Editor, Book on Head and Neck Cancer, Emerging Perspectives, Wiley & Co
2000-2023	Member, Editorial Board, Oral Oncology
2001-2011	Member, Editorial Board, Biochemistry
2001-2006	Member, Editorial Board, Revista de Oncologia, Mexico-Spain
2002-2003	Co-Editor, Book on Signal Transduction and Human Disease, Wiley & Co
2002-2017	Member, Faculty 1000, Reviewing Editor
2003-2005	Member, Editorial Board, Drug Discovery Today: Disease Mechanisms
2005-2019	Member, Editorial Board, Molecular Biology of the Cell
2008-present	Member, Editorial Board, Cancer Prevention Research
2009-2019	Member, Editorial Board, Molecular and Cellular Biology
2009-2015	Member, Editorial Board, Genes & Cancer
2010-2014	Member, Editorial Board, Journal of Biological Chemistry
2012-present	Member, Editorial Board, Science Signaling
2013	Co-editor, Current Opinion in Cell Biology, Cell Regulation Issue
2015-present	Member, Editorial Advisory Board for Molecular Pharmacology
2017-2018	Co-Editor, Journal of Dental Research, Oral Cancer Special Issue
2023-present	Member, Editorial Board, PNAS Nexus
2023-present	Special Section Guest Editor, Journal of Pharmacology and Experimental Therapeutics

Ad-hoc Reviewer:

Biochemical and Biophysical Acta; Blood; British Journal of Cancer; Cancer Cell; Cancer Research; Clinical Cancer Research; Cell; Cell Stem Cell; Cell Growth and Differentiation; Clinical Cancer Research; Current Biology; Developmental Cell; EMBO Journal; FEBS letters; Journal of Biological Chemistry; Journal of Cell Biology; Journal of Cell Physiology; Journal of Clinical Investigation; Journal of Immunology; Journal of Neurochemistry; Molecular and Cellular Biology; Molecular and Cellular Neurobiology; Molecular Cell; Molecular Pharmacology; Nature; Nature Cell Biology; Nature Communications; Nature Genetics; Nature Medicine; Oncogene; Oral Oncology; Trends in Biological Science; Proceedings of the National Academy of Science, USA; Science, Science Signaling, Science Translational Medicine

Membership and Activity in Professional Societies:

Executive Committee Member, and Past Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET)
 American Association of Cancer Research (AACR)
 American Society for Biochemistry and Molecular Biology (ASBMB)
 International Association for Dental Research (IADR)
 American Association for Dental Research (AADR)
 Founding Member, International Academy of Oral Oncology (IAOO)
 Association of Medical School Pharmacology Chairs (AMSPC)

Extramural Activities:

NIH Extramural and Professional Organizations

1997	Ad-hoc member, Program Project Review Panel, DER, NCI
1999-2000	Member, Grant Review Panel, Division of Basic Science, NCI
2002	Ad-hoc Member, NIH Study Section, CDF-4
2002	Co-chair, FY2004 NIDCR Initiatives, Head and Neck Cancer, Molecular Anatomy of Head and Neck Cancer: A Genomic/Proteomic Approach
2003-2004	Member AIDS Malignancies Consortium, NIH
2003	Member, Biological Pathways and Networks Group, NIH Road Map Initiative
2004-2007	Member, NIH extramural Study Section, NDT
2005	Member, NIGMS, Special Emphasis Review Panel
2005	Member, Review Panel NRSA-NIH, Fellowships: Molecular and Cellular Mechanisms
2007	Ad-hoc Member, NIH extramural Study Section, Intercellular Interactions (ICI)
2008	Ad-hoc Member, NIH extramural Study Section, Tumor Microenvironment (TME) Ad-hoc Member, NIH extramural Study Section, Molecular and Integrative Signal Transduction (MIST)
2008-2012	Member, NIH extramural Study Section, Tumor Microenvironment (TME)
2009	Member, NIH extramural Study Section, NIH Challenge Grants in Health and Science Research, American Recovery and Reinvestment Act of 2009
2010	Site Visit Review Panel, Laboratory of Biochemistry, Office of Biotechnology Products, Center for Biologics Evaluation and Research, FDA
2012	Reviewer, NIH extramural Study Section, Center for Scientific Review Special Emphasis Panel, Cancer Biology -2
2012	Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI
2013	Reviewer, NIH extramural Study Section, NCI Omnibus R03/R21 Grant Application Review, Cancer Biology-2

2013	Reviewer, NIH extramural Study Section, Special Emphasis Panel/Scientific Review Group Basic Translational (OBT)
2014	Participant, Center for Scientific Review's Pilot Study, evaluation of relative quality of grant applications, NIH
2014	Reviewer, NIH/NCI extramural Study Section, Center for Scientific Review Special Emphasis Panel/Scientific Review Group ZCA1 SRB-C R
2014	Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI
2015	Reviewer, NCI Outstanding Investigator Award (OIA)
2016	Reviewer, NIH Study Section, Basic Mechanisms of Cancer Therapeutics (BMCT)
2016	Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI
2016	Reviewer, NCI Special Emphasis Panel, PROGRAM PROJECT III (P01)
2017	Reviewer, NIH Study Section, Basic Mechanisms of Cancer Therapeutics (BMCT)
2017-2023	Member, NIH Study Section, Mechanisms of Cancer Therapeutics (MCT1)
2019	Board of Scientific Counselors (BSC) for the Division of Intramural Research (DIR) in the National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
2020	Chair, AACR Ocular Melanoma research Grants Scientific Review Committee
2020	Co-Chair, NCI CTEP program on AKT inhibitors for Cancer Treatment
2023-2028	Member, NCI Board of Scientific Counselors (BSC), NIH, Bethesda, MD

International

1996-present	Reviewer, The Israel Science Foundation
1997-present	Reviewer, Italian Association for Scientific Research
1997-2002	Reviewer, German-Israeli Foundation for Scientific Research & Development
1997-2006	Reviewer, National Science Foundation
1998-2001	Member, Cancer Genome Anatomy Program
1998-2004	Member, Reviewing Council, FONCYT, Argentina
2003-2005	Member Reviewing Panel, The Israel Cancer Research Foundation
2008-2017	Member Scientific Advisory Board, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany, Germany
2009	Review Panel, Regional Collaborative Program SFB/TR23, Vascular Differentiation, and Remodeling, Mannheim, Germany
2010-2017	Comité Científico Asesor Externo de la Red Temática de Investigación Cooperativa en Cáncer (RTICC), Spain
2010-2012	Member Reviewing Panel, The Israel Cancer Research Foundation
2013	Review Panel, Regional Collaborative Program SFB/TR23, Vascular Differentiation, and Remodeling, Mannheim, Germany
2013	Site Visit Review, Foundation Leloir Institute, Buenos Aires, Argentina
2015	Site Visit Review, Life Sciences Center, McGill University, Montreal, Canada
2016	Site Visit Review, Foundation Leloir Institute, Buenos Aires, Argentina
2018	Review Panel, Collaborative Research Centre (CRC) 1366 "Vascular Control of Organ function", Mannheim, Germany
2024-present	Science Advisor, U.S.-Israel Binational Science Foundation

UCSD Institutional Committees

2015-present	UC San Diego Moores Cancer Center, Executive Committee
--------------	--

2015-present UC San Diego Moores Cancer Center Shared Resources Oversight Committee (SROC)
 2018-present Co-Chair, UC San Diego Moores Cancer Center, Pilot Grants Committee
 2019-present Chair, UC San Diego Moores Cancer Center, Space Committee
 2019-present SDSU/UCSD Partnership Program Steering Committee (PSC) Meeting
 2020-present UC San Diego Biomedical Sciences Graduate Program Diversity Committee
 2020-present Chair, UC San Diego Department of Pharmacology, Seminar Committee
 2020-present UC San Diego Moores Cancer Center, Board Committee for Education, Mentorship and Fellowships
 2021-present UC San Diego, Animal Program Oversight Committee (APOC)
 2021-2023 Chair, Frederick National Laboratory for Cancer Research (FNLCR), University of California Steering Committee
 2022-present Ex Officio Committee Member, San Diego State University FUERTE Faculty Search, Cancer Disparity Research Area
 2023-present UC San Diego, Program in Immunology Council

Invited Presentations (past 12 years and planned)

2025- Invited Speaker, University of Washington, Seattle, WA
 Elkin Lecture, Emory Winship Cancer Institute, Atlanta, GA
 Invited Speaker, AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy, San Diego, CA
 Chair, Gordon Research Conference, Molecular Pharmacology, Ventura, CA
 Invited Speaker, ENT Grand Rounds, University of North Carolina Medical School, ENT Grand Rounds, Chapel Hill, NC
 Invited Speaker, Oral Potentially Malignant Disorders Day, University of Zagreb, Zagreb, Croatia (virtual)
 Invited Speaker, Cedars-Sinai, Department of Surgery, Los Angeles, CA
 Invited Speaker, Cancer Research UK, The Cancer Prevention Research Conference 2025, London, UK
 Invited Speaker, Gordon Research Conference, Synthetic Lethality Approaches in Oncology, Portland, MA
 Invited Speaker, 2025 Salk Mechanisms and Models of Cancer Conference, The Salk Institute for Biological Studies, La Jolla, CA
 Invited Speaker, Boston Head & Neck Cancer Symposium, Boston, MA
 Invited Speaker, Vall D'Hebron Research Institute, Barcelona, Spain (virtual)
 Invited Speaker, CT2 Program, Moores Cancer Center, La Jolla, CA
 Keynote Speaker, 5th Translational Genomics and Epigenomics Symposium, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY
 Distinguished Scientist Lecture, Fox Chase Cancer Center, Philadelphia, PA
 Invited Speaker, Universidad de Chile, Santiago, Chile (virtual) (upcoming)
 Goodman Lecture, Oregon Health and Science University, Portland, OR (upcoming)

2024- ITMAT Kyoto University International Symposium, Kyoto, Japan
 Annual Meeting of the American Association for Dental, Oral and Craniofacial Research (AADOCR), New Orleans, LA
 Chair and Invited Talk, Major Symposium "Novel Immune Checkpoints: Beyond PD1 and CTLA4", American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA
 Lecture, The Herbert Wertheim UF Scripps Institute, Jupiter, FL
 Invited Speaker, Gordon Research Conference, Phosphorylation and G-Protein Mediated Signaling Networks, Waterville, NH

Keynote Speaker, 2024 Fanconi Anemia Scientific Symposium, Charlotte, NC
 American Cancer Society (ACS)- Jiller Professor and Fellows Conference,
 Tucson, AZ (upcoming)
 Invited Speaker, Center for Cancer Immunotherapy and Immunobiology (CCII)
 Symposium, Kyoto University, Kyoto, Japan (upcoming)
 2023- 1st Joint Israel-UCSD symposium on the Advances of Head & Neck Cancer, Tel
 Aviv, Israel
 Keynote Lecture, Gordon Research Conference, Salivary Glands and Exocrine
 Biology, Ventura, CA
 Distinguished Lecture, Wistar Institute, Philadelphia, PA
 Duke University, Durham, NC
 Invited Speaker, I-SCORE, National Cancer Institute, National Institutes of
 Health, Rockville, MD
 Department of Immunobiology, University of Arizona, Tucson, AZ
 18th Industry/Academia Next Generation Precisions Oncology Symposium, The
 Alexandria, La Jolla, CA
 Workshop on Cancer Immunotherapy –organized by Dr. Tasuku Honjo, Nobel
 prize winner, Les Treilles, France
 UCSF Helen Diller Family Comprehensive Cancer Center Seminar Series, San
 Francisco, CA
 Molecular Pharmacology, Gordon Conference, Les Diablerets, Switzerland
 Lecture, Dana-Farber Brigham Cancer Center, Boston, MA (virtual)
 UC Davis Keynote Lecture- Annual Cancer Center retreat, Pasadena, CA
 La Jolla Immunology Conference, La Jolla, CA
 International GCPR Retreat, Montebello, Canada
 20th International Congress, Society for Melanoma Research, Philadelphia, PA
 2022- Weinman Symposium, University of Hawaii Cancer Center, Honolulu, Hawaii
 Association of Medical School Pharmacology Chairs (AMSPC) (virtual)
 Distinguished Speaker, January Seminar Series, Sanford Prebys Burnham
 Medical Discovery Institute, La Jolla, CA (virtual)
 Keynote, New Frontier in RTK Signaling & Therapeutics, A Joint Cancer
 Signaling Networks and Developmental Therapeutics Retreat, Yale Cancer
 Center, New Haven, CT (virtual)
 Medical School Pharmacology Chairs (AMSPC) (virtual)
 Gordon Research Conference, Phosphorylation and G-Protein Mediated
 Signaling Networks, Southbridge, MA
 8th World Congress of the International Academy of Oral Oncology, Chicago, IL
 FASEB Meeting on GRKs and Arrestins, Jupiter, FL
 Translational Advances in Cancer Prevention Development (TACPAD), NIH/NCI
 (virtual)
 Multidisciplinary Head and Neck Cancer Care Conference and 5th New Horizons
 in Immunotherapy Conference, San Diego, CA
 18th Industry/Academia Next Generation Precisions Oncology Symposium, La
 Jolla, CA
 Delivering Discoveries: Updates in Cancer Care, Hyatt Regency, La Jolla, CA
 National Foundation for Cancer Research (NFCR), New Frontiers for Cancer
 Research, Washington DC
 2021- Translational Science Head & Neck Cancer Subcommittee, NRG Oncology
 (virtual)
 17th Industry/Academia Next Generation Precision Oncology Symposium, La
 Jolla, CA

Delivering Discoveries: Updates in Oncology, CME meeting, La Jolla, CA
 Neuroscience and Pharmacology Department Seminar Series, University of Iowa, Iowa City, IA (virtual)
 Domain Therapeutics GPCR Symposium, France/Canada (virtual)
 2021 CRC1366 Vascular control of Organ function International Meeting, Heidelberg, Germany (virtual)

2020- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
 The 11th Weinman Symposium, University of Hawaii Cancer Center, Honolulu, Hawaii
 Feist-Weiller Cancer Center Spring Seminar Series, Shreveport, LA
 Seminar series Universidad de San Martin, Buenos Aires, Argentina (virtual)
 Cedars-Sinai Grand Rounds Lecture Series, Los Angeles, CA (virtual)
 Tisch Cancer Center Institute, Mount Sinai School of Medicine, New York City, NY (virtual)
 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT (virtual)
 PCB Seminar Series, UCSF, San Francisco, CA (virtual)

2019- Keynote, German PharmTox Summit, Stuttgart, Germany
 Purdue University NCI Cancer Center, West Lafayette, IN
 Experimental Biology Symposium, Orlando, FL
 AACR Special Conference on “The Hippo Pathway, Signaling, Cancer, and Beyond”, San Diego, CA
 IADR Presidential Symposium, Vancouver, Canada
 AACR Think Tank on Combination Therapies, Washington DC
 Molecular Therapeutics of Cancer Center Conference, Tahoe resort, CA
 International Symposium on Pharmacology of 7TM-receptors and downstream signaling, UCSD
 Signaling Pathways, University of Bonn, Germany
 UT Health School of Dentistry, Houston, TX
 Baylor College of Medicine, Houston, TX
 Boston University, Boston, MA
 NYU Langone Health, Perlmutter NCI-Designated Comprehensive Cancer Center, New York, NY
 Tohoku University Cancer Symposium, Sendai, Japan

2018- Keystone Meeting on GPCRs. Santa Fe, NM
 Pathology Research Seminar Series at the Weill Cornell Medical College, NYC
 AACR Annual Meeting, Chicago, IL
 Experimental Biology Meeting, San Diego, CA
 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
 Gordon Research Conference on “Phosphorylation and G-Protein Mediated Signaling Networks”, University of New England, Biddeford, ME
 3rd New Horizons in Immunotherapy and Head and Neck Cancer, Pittsburgh, PA
 NIH Head & Neck/Thyroid SPORE Workshop, Rockville, MD
 AACR-LACOG Translational Cancer Medicine Conference, Sao Paulo, Brazil
 Fourth South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2018, Bariloche, Argentina
 9th Xiamen Winter Symposium on the Hippo Signaling in Development & Disease, Xiamen, China
 British Pharmacological Society-Molecular Pharmacology of GPCRs meeting, Monash University, Parkville, Victoria, Australia

2017- Keynote Speaker, 9th ÖGMBT Annual Meeting & 8th Life Science Meeting, Innsbruck, Austria
Stanley S. Scott Cancer Center Invited Speaker Series, New Orleans, LA
Loma Linda University, Loma Linda, CA
IADR, International Association of Dental Research Annual Meeting, San Francisco, CA
Symposium: "12 years SFB-TR23: From Vascular Differentiation and Remodeling to Organotypic Vasculature", Heidelberg, Germany
AACR-Head and Neck Cancer Meeting, San Diego, CA
G Protein Coupled Receptor Meeting, Boon, Germany
VanTol symposium at the 18th annual joint meeting of the Great Lakes GPCR Retreat, Ottawa, Canada

2016- UCSF Helen Diller Comprehensive Cancer Center Director's Seminar Series, San Francisco, CA
Cancer Prevention Summit, American Association of Cancer Research (AACR), Leesburg, VA
The Salk Post-Translational Regulation of Cell Signaling Meeting, La Jolla, CA
Gordon Research Conference, Phosphorylation & G-Protein Mediated Signaling Networks, Biddeford, Maine
MedImmune, Gaithersburg, MD
3rd Annual Meeting of the International Ovarian in conjunction with International Symposium on Tumor Microenvironment & Therapy Resistance, Oklahoma City, OK
International Symposium ROOTS Program, Winning The War Against Cancer, Buenos Aires, Argentina
AAAS Annual Meeting. Session on Oral Cancer Epidemiology, Mechanism, and Early detection. Washington DC
Global Cancer Forum, New York City, NY
Experimental Biology, ASPET Symposium on GPCR signaling through Rho GTPases, San Diego, CA
Society of Clinical Investigation & Society of Pharmacology, joint Annual Meeting. Mar Del Plata, Argentina.

2015- Bioquant and University of Heidelberg, Heidelberg, Germany
American Association of Cancer Research (AACR), Philadelphia, PA
American Society of Clinical Oncology (ASCO), Chicago, IL
Cancer Prevention Think Tank, National Cancer Institute, Bethesda, MD
Keynote Lecture, ASPET Upstate New York Pharmacology Society 4th Annual Meeting, Rochester, NY
UNC Lineberger Comprehensive Cancer Center's Seminar Series, University of North Carolina (UNC), Chapel Hill, NC
The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2015, Argentina
The Dean's Biomedical Research Seminar, Virginia Commonwealth University, Richmond, VA
University of Virginia, Charlottesville, VA
University of California Los Angeles (UCLA), Vascular Biology Lecture, LA, CA
UCSD Moores Cancer Center, San Diego, CA
Gordon Research Conference, "Molecular Pharmacology", Ventura, CA

2014- Great Lakes GPCR Retreat, Bromont, Canada, upcoming.
Keynote Lecture, 2014 American Head and Neck Society (AHNS) Annual Meeting and 5th World Congress-IFHNOS

	Clinical Grand Rounds, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
	UCSD Moores Cancer Center, San Diego, CA
	Keynote Speaker, Dental Research in Review, University of North Carolina, Chapel Hill, NC
	Distinguished Lecture Series at Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard University, MA
	Mini-Symposium, Cancer Biology, Medical School, University of Chile, Chile
	Summer Course, Cancer Biology: From Basic to Clinic, University of Concepcion, Chile
	IVMB, The 18 th International Vascular Biology Meeting, Kyoto, Japan
	West China School of Stomatology, Sichuan University, Chengdu, China
	Leuven University, Leuven, Belgium
	Maastricht University, Netherlands
2013-	University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA
	The Weizmann Institute of Science, Israel
	PABMB (Pan-American Association for Biochemistry and Molecular Biology)
	Plenary Lecture, Madrid, Spain
	Annual Meeting, American Society for Biochemistry and Molecular Biology, ASBMB, Boston, MA
	West China School of Stomatology, Sichuan University, Chengdu, China
	GPCR Workshop, Maui, Hawaii
	UC Berkeley, San Francisco, CA
2012-	Ocular Melanoma Workshop, Melanoma Society, Philadelphia, PA
	Keystone Meeting, G Protein-Coupled Receptors: Molecular Mechanisms and Novel Functional Insights, Alberta, Canada
	NIH 2012 Demystifying Medicine Course, NIH, Bethesda, MD
	Gordon Research Conference, Phosphorylation & G-Protein Mediated Signaling Networks, Biddeford, Maine
	First Symposium on Head and Neck Cancer Stem Cells, Ann Arbor, MI
	8th International Conference on Head & Neck Cancer, Toronto
	NIH Clinical Center Grand Rounds
	The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2012, Argentina
	University of Sydney, Sydney, Australia
	Australian Health & Medical Research Congress, Adelaide, Australia
	Centro de Investigacion del Cancer IBMSS, Salamanca, Spain

Symposia Organized:

1995	Workshop on Signaling through G proteins, NIH
1996	Workshop on Signal Transduction from the Membrane to the Nucleus, NIH
1996	Third Annual Signal Transduction Therapy Conference, San Diego, California
1996	Symposium on Regulation of Protein Kinases Involved in Cell Division, Congress of the Pan American Association of Biochemistry and Molecular Biology, Pucon, Chile
1998	Workshop on G proteins, 10th International Conference on Second Messengers & Phosphoproteins, Jerusalem, Israel
1999	Workshop on "Head and Neck Cancer Priority Setting", organizing committee, NIH

1999 Keystone Winter Symposia, "Oncogene Networks" and Session on "Cell Surface Receptors"

2002 Workshop on Exchange factors, Juan March Foundation, Madrid, Spain

2002 Symposium, Frontiers in Molecular Mechanisms in Cancer, Strategies and Application, Santander, Spain

2002 NCI, NIDCD, NIDCR, Trans-NIH Squamous Carcinogenesis Retreat

2002 International Oral Cancer Tissue Array Initiative, Organizing Meeting, NIDCR

2004 Tva-Animal Models Meeting, Bethesda, MD

2005 Advisory Organizing Committee, 10th International Congress on Oral Cancer (ICOOC), Crete, Greece

2006 "Oral Cancer", Naresuan University, Phitsanulok, Thailand

2006 Organizing Committee, "Workshop on Biology and Treatment of Malignant Salivary Gland Cancers", NIH, Bethesda, MD

2006 Elected, Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", 2008

2007 Advisory Committee, International Association of Oral Oncology, 1st World Congress, Amsterdam

2008 Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, Maine

2008 Organizing Committee, International Conference on Frontiers of Dental and Craniofacial Research, Beijing, China.

2008 Program Committee, 7th International Conference on Head and Neck Cancer, San Francisco, CA.

2008 Program Committee, Workshop on Salivary Gland Tumor Research: Current Status and Future Directions. Bethesda, MD.

2009 Scientific Advisory Committee, International Oral Oncology Meeting, Toronto, Canada.

2010 Co-Organizer, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina

2011 Scientific Advisory Committee, Cell Signaling Networks 2011, Merida, Yucatan, Mexico

2012 Program Organizing Committee, Workshop on salivary Gland Tumor Research: Current Status and Future Directions, Bethesda

2012 Co-Organizer, The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2012, Argentina

2015 Co-Organizer, The Third South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2015, Argentina

2016 Co-Organizer, Global Cancer Forum, New York City, NY, 2016

2016 Co-organizer, Symposium on Cancer Stem Cells as Pharmacological Targets, ASPET/EB Annual Meeting, San Diego, 2016

2017 Co-Organizer, AACR-AHNS Conference on Head and Neck Cancer, San Diego, CA

2017 Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA

2018 Co-Organizer, Fourth South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2018, Bariloche, Argentina

2018 Co-organizer, Symposium on G Proteins and GPCRs in Cancer, ASPET/EB Annual Meeting, San Diego, CA

2018 Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA

2019 Elected Co-Chair, Gordon Conference in Molecular Pharmacology, Ventura CA

2019 Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA

2020 Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA

2021	Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA Delivering Discoveries: Updates in Oncology, CME meeting, La Jolla, CA
2022	Advances in Immuno-oncology Research, 8th Annual C3 Symposium, NCI- Designated Cancer Centers San Diego, CA Delivering Discoveries: Updates in Cancer Care, Hyatt Regency, La Jolla, CA
2023	Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA GPCR Symposium: From Structure to Biology in Health and Disease Celebrating Discoveries, Department of Pharmacology, UCSD, La Jolla, CA Co-Organizer, Molecular Pharmacology, Gordon Conference, Les Diablerets, Switzerland
2024	Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA Co-Organizer, 2024 Fanconi Anemia Scientific Symposium, Charlotte, NC
2025	Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA Chair, Gordon Research Conference, Molecular Pharmacology, Ventura Beach, CA
2026	Organizer, UCSD Moores Cancer Center Science Retreat, La Jolla, CA Organizer, 2026 ASBMB Annual Meeting, "The Hippo Signaling Pathway in Health and Disease mini-symposium", Washington, DC

Funding and Support

Current Research Support

R01DE035393	(MPI Gutkind/Sacco)	07/01/2025-06/30/2030
NIH/NIDCR Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer The major goals of this project is to exploit synthetic lethal and gene interaction networks to expose druggable systems vulnerabilities upon HER receptor family blockade as a precision therapeutic approach for HPV- HNSCC, and to establish the impact of targeting the EGFR/HER3/HER2 (panHER) signaling network in HNSCC on the immune tumor microenvironment and response to immunotherapies.		
R01DE033909	(MPI Gutkind/Handel)	03/01/2024-01/01/2029
NIH/NIDCR Reprogramming the Tumor Immune Microenvironment With Chemokines To Potentiate Immune Oncology Treatments In Oral Cancer Exploit the ability of specific chemokines to recruit and activate key anti-tumoral immune cells and dramatically potentiate ICB therapy for enhanced tumor elimination and durable responses. The underlying mechanisms for treatment success as well mechanisms that limit responsiveness will also be explored to inform future therapeutic strategies.		
R01DE026644	(MPI Gutkind/Lippman)	07/01/2022-03/31/2027
NIH/NIDCR Targeting Signaling Vulnerabilities for Oral Cancer Prevention The major goals of this project are to discover novel genomic markers of response and resistance to metformin in oral premalignancy, to test the influence of bioenergetic pathways involving LKB1/AMPK, and mTOR and YAP inhibition in the activity of metformin, and to apply genetic screens to identify novel molecular mechanisms determining response or resistance to metformin. Role: MPI		

U01CA290479 (MPI Alexandrov/Gutkind/Lippman) 09/01/2023-08/31/2028
NIH/NCI

Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition
The overall goal will be to elucidate the molecular and immune mechanisms by which OLs progress to OSCCs, and to develop actionable predictive biomarkers

R01CA257505 (MPI Gutkind/Aplin) 04/01/2021-03/31/2026
NIH/NCI

Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma

The goals of this project are to exploit GNAQ-synthetic lethal and gene interaction networks to expose systems vulnerabilities resulting in UM cell death as a precision therapeutic approach to treat mUM. We aim at revealing novel oncogenic mechanism controlled by Gαq and how the interplay between classical and non-canonical Gαq signaling contributes to aberrant cell growth, to help identify novel multimodal precision therapies for mUM.

Role: MPI

R01DE030497 (MPI Zhang/Gutkind) 04/01/2021-03/31/2026
NIH/NIDCR

Signal Transduction by PI3K/mTOR

The overall goal is to uncover the molecular and cellular mechanisms by which mTOR signaling is spatially regulated and to elucidate the contribution of subcellular mTOR Complex 1 (mTORC1) signaling to tumorigenesis.

Role: MPI

U54CA274502 (MPI Krogan/Ideker) 09/2022-08/2027
NIH/NCI

The CCMI will seek to: (1) Generate comprehensive protein interaction networks centered on key cancer driver genes in lung squamous cells (in healthy and diseased states) as well as the PIK3CA and TP53 pathways, which are central to many tumor types; (2) Systematically extend the CCMI collection of cancer protein interaction data with protein immunofluorescent imaging and cryo-electron microscopy to formulate multi-scale cancer cell maps; (3) Dissect the functional logic of these networks and maps by systematic genetic screening experiments in the same tumor types and pathways, using a panel of scalable cell proliferation, phenotype and pathway readouts; (4) Significantly advance and harden our DrugCell interpretable deep learning system for cancer precision medicine; (5) Train the current and next generation of scientists in network biology and its applications to cancer research; and (6) Continue to build a cadre of leading investigators to expand CCMI into a global coordinated partnership.

Role: Co-Investigator

Recently Completed Grant Support:

MRA827624 (PI Gutkind) 08/01/2021-07/31/2024
Melanoma Research Alliance

Multimodal GNAQ signaling-targeted precision therapy approach for MUM

The project aims to provide a precision therapeutic approach for mUM treatment and the underlying pro-apoptotic mechanisms.

Role: PI

Stand Up to Cancer (SU2C) (PI Smogorzewska and Burtness) 08/01/2021-07/31/2024
Precision Therapy for Fanconi Anemia (FA) and HPV-related Head & Neck Cancer

Role: Co-PI

CRI3792 (PI Gutkind) 07/01/2021-12/31/2024
Cancer Research Institute
Precision immune-oncology therapy targeting HER3-PI3K/mTOR and PD-1 in HNSCC
The project aims to employ several innovative techniques with single-cell level resolution to study the tumor-intrinsic effects of targeted HER3 blockade and how these changes ultimately invigorate and synergize with immunotherapies.
Role: PI

R25CA221779 (MPI Gutkind/Sadler) 09/01/2019-08/31/2024
NIH/NCI
Multidisciplinary Educational Approach to Reducing Cancer Disparities
San Diego's three NCI-designated Cancer Centers are collaborating in this Youth Enjoy Science Research Education (YES) Program. The Program is an intensive, long term, laboratory and community-based learning opportunity for UCSD students who are from communities that are underrepresented in cancer-related health and science careers. To gain mastery of their knowledge and skills in cancer disparities research, the student participants will be matched with a faculty mentor who will give them hands-on experiences in cancer-related research. Students will also engage in a community-based cancer education campaign about cancer control, cancer disparities, and clinical trials.
Role: MPI

W81XWH2110821 (MPI Gutkind/Aplin/Aguirre/Ghiso) 09/01/2021-08/31/2024
DoD, Department of Defense
Multimodal GNAQ signaling-precision therapy for metastatic uveal melanoma prevention and treatment
The project aims to employ GNAQ-synthetic lethal and gene interaction networks to develop precision therapies to treat mUM patients and to target YAP with metformin as a novel chemopreventive approach to halt the onset of fulminant mUM.
Role: MPI

R01CA247551 (PI Gutkind) 12/01/2019-11/30/2024
NIH/NCI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
The goals of this project are to elucidate the contribution of genomic alterations in the PI3K-mTOR signaling network to anti-HER3 sensitivity and resistance, and to establish the impact of targeting and co-targeting the HER3-PI3K/mTOR signaling network on the tumor immune microenvironment and response to PD-1 blockade, aiming at achieving a single cell level understanding of the anti-cancer immune response. These studies will inform the molecular stratification for patient selection in future multimodal precision immune oncology trials.
Role: MPI

R01CA221289 (PI Tesmer) 04/01/18 - 03/31/2023
NIH/NCI
Experimental study of the structural determinants of the activation of G protein-linked RhoGEFs in cells in vivo, and the contribution of G protein-regulated RhoGEFs in cancer in terms of signaling circuitries alterations, tumorigenic activity, and metastatic potential.
Role: Co-Investigator

U01DE028227 (MPI Schoenberger/Gutkind/Rao) 09/01/2018-08/31/2023

NIH/NCI-NIDCR Cancer Moonshot Program

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers.

The goals of this project is to study experimentally the tumor-T cell ecosystem in head and neck squamous cell carcinoma (HNSCC), and will exploit the emerging information to develop novel approaches to enhance the anti-tumor immune response, resulting in tumor regression (cure).

Role: MPI

R01DE026870 (PI Gutkind) 08/01/2018-07/31/2023

NIH/NIDCR

Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy

The goals of this project are to identify novel systems vulnerabilities cetuximab and PI3K/mTORi sensitization and the impact of targeting this pathway on the tumor and immune microenvironment.

Role: PI

U54CA209891 (MPI Krogan/Ideker) 05/11/2017-4/30/2022

NIH/NCI

The Cancer Cell Map Initiative, a National Research Center for Cancer Systems Biology

The aim of the Cancer Cell Map Initiative is to apply systematic approaches to comprehensively map the molecular networks that underlie cancer and to use these maps as a key resource for precision medicine.

Role: Co-Investigator

R33CA225291 (PI Gutkind) 06/05/2018-08/31/2020

NIH/NCI

Area C: Genome-wide identification and targeting of resistance to cancer therapy.

This project aims to establish a new genome wide approach for identifying and targeting resistance pathways in cancer and experimentally test and study its applications in specific cancer types, including breast cancer, colon cancer, head and neck and melanoma.

Role: PI

The laboratory was funded from 1996-2015 by the NIDCR Intramural Research Program, NIH.

- Project Z01DE00551, Molecular Mechanisms of Growth Control and Carcinogenesis
- Project Z01DE00558, Oral Carcinogenesis

2016 PEDAL15 Research Grant Award, Pedal the Cause. The GNAS-PKA Onco-Signaling Network in Colorectal Malignancies

2015 Million Dollar Bike Ride Pilot Grant, University of Pennsylvania Orphan Disease Center. Development of next-gen animal models for fibrous dysplasia (FD)/McCune-Albright syndrome (MAS)

2004-2015 Intramural AIDS Targeted Antiviral Program (IATAP)

Study of AIDS-associated malignancies, with emphasis on Kaposi's Sarcoma and HPV+ cancers

American Asthma Foundation (GPCR-trafficking and tachyphylaxis)

Human Science Frontier Program (Clonogenic cooperation in cancer)

Clinical Protocols

- NCT05237969, M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention. UCSD Moores Cancer Center.
PI: Scott Lippman and J.S Gutkind, Ongoing.
- NCT02581137, Metformin for Oral Cancer Prevention (M4OC-Prevent). UCSD Moores Cancer Center.
PI: Scott Lippman; Gutkind J.S., Co-Lead. Completed, 2019.
- NCT01195922, A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer. NIDCR/NCI/NIDCD/MUSC.
PI: Gutkind J.S. 2011. Completed, 2018.
- 14CN018. Pilot Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan. NCI/NIDCR, 2014.
PI: Anil Chaturvedi. Open.
- T-D-0024, The Molecular Anatomy of Oral Wound Healing. NIDCR.
PI: Gutkind J.S. 2010. Completed, 2014.

Invention Reports and Patents:

- U.S. Patent 5,384,243, issued January 24, 1995. J. Silvio Gutkind and Keith C. Robbins: Method for screening an agent for its ability to prevent cell transformation.
- NIH Ref No. E-302-2008, Chemoprevention of Head And Neck Squamous Cell Carcinomas. US Patent Application No. 13/059,335 filed August 20, 2009. Canadian Patent Application No. 2734828 filed August 20, 2009. European Patent Application No. 09791732.2 filed August 20, 2009
- NIH Ref No. E-282-2009, Sustained Release Delivery Systems for the Prevention and Treatment of Head and Neck Cancers. International Patent Application No. PCT/IL2010/000694 filed August 25, 2010
- U.S. Patent 9,151,762, issued October 6, 2015. J. Silvio Gutkind, Vyomesh Patel, Alfredo Molinolo, Timothy D. Veenstra. Identification of DSG3 as a Biomarker for the Detection of Metastasis in Lymph Nodes.
- U.S. Patent 9,278,090, issued March 8, 2016. J. Silvio Gutkind, Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana p. Cotrim, Alfredo Molinolo, and James B. Mitchell. Methods of preventing the development of mucositis and related disorders.
- U.S. Application serial No. 62/832,425, filed on April 11, 2019. J. Silvio Gutkind, David Schlaepfer. New Anticancer Treatment for Uveal Melanoma.
- US San Diego Office of Innovation and Commercialization, Case No. SD2020-164, filed on October 21, 2019. J. Silvio Gutkind, Zhiyong Wang. New Multimodality Precision Immunotherapy for Head and Neck Cancer.
- U.S. Application serial No. 62/929,061, filed on October 31, 2019. J. Silvio Gutkind, Zhiyong Wang. Novel Syngeneic Animal Model of Tobacco-Associated Oral Cancer Reveals the Activity of in Situ Anti-CTLA-4.

Ph.D. Thesis Directed:

G.M. Kalinec, Ph.D., University of Cordoba, Cordoba, Argentina, 1992
M. Chiariello, M.D. Ph.D., University of Naples, Naples, Italy, 1999. Co-director
L.M. Laguinge, Ph.D., Catholic University of Cordoba, Cordoba, Argentina, 2000
C. Leethanakul, D.D.S., Ph.D., Chulalongkorn University, Bangkok, Thailand, 2000
P. Amornphimoltham, D.D.S., Ph.D., University of Maryland, 2006
M.D. Castellone, M.D., Ph.D., University of Naples, Naples, Italy, 2005. Co-director
K. Leelahavanichkul, D.D.S. Ph.D., Thammasat University, Bangkok, Thailand, 2011

X. Feng, Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2013
 Ann Hoebe, M.D., Ph.D., Catholic University of Leuven, Belgium, 2014
 Z. Wang, Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2014
 X. Wu, Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2017
 X. Zhao, D.D.S., Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2018
 X. Zhang, D.D.S., Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2019
 D. Ramms, Ph.D., University of California, San Diego, La Jolla, CA, 2021
 V. Wu, Ph.D., University of California, San Diego, La Jolla, CA, 2021
 M.M. Allevato, Ph.D., University of California, San Diego, La Jolla, CA, 2022
 N. Arang, Ph.D., University of California, San Diego, La Jolla, CA, 2022
 B. Yung, Ph.D., University of California, San Diego, La Jolla, CA, 2024
 A. Officer, Ph.D., University of California, San Diego, La Jolla, CA, 2024
 T. Hoang, Ph.D., University of California, San Diego, La Jolla, CA, 2025
 L. Clubb, Ph.D., University of California, San Diego, La Jolla, CA, 2025

Former Post-Doctoral Fellows Trained:

- Omar Coso, Ph.D., 1992-1997, Professor, Laboratory of Physiology and Molecular Biology, School of Exact Science, University of Buenos Aires, Argentina
- Piero Crespo, Ph.D., 1992-1996, Full Professor, Consejo Superior de Investigaciones Científicas, CSIC-Departamento de Biología Molecular, Facultad de Medicina, Universidad de Cantabria (IBBTEC) Santander, Spain
- Vyomesh Patel, Ph.D., 1995-2014, Group Leader (Nasopharyngeal Cancer), Cancer Research Initiatives Foundation (CARIF), Malaysia
- Decio Santos Pinto Jr., D.D.S., Ph.D., 1995-1998, Professor Department of Stomatology, University of Sao Paulo, Brazil
- Tadashi Igishi, M.D., Ph.D., 1995-1998, Professor, Center for Clinical Residency Program, Tottori University, Tottori, Japan
- Muriel Zohar, Ph.D., 1996-1998, Founder & CEO, Life Source Partners, Tel Aviv, Israel
- Maria Julia Marinissen, Ph.D., 1996-2004, HHS Office of Global Affairs Health Attaché, Mexico, and Acting Director, U.S. Section, U.S.-Mexico Border Health Commission, Washington DC
- Ernest B. Izevbigie, Ph.D., 1997-1999, Full Professor of Biology/Biochemistry, College of Science, Engineering, & Technology, Dept. of Biology, Jackson State University, Jackson, Mississippi
- Elena Tassi, Ph.D., 1997-1999, Clinical Trials Regulatory Affairs Specialist, NCI, NIH, Bethesda, MD
- Mario Chiariello, M.D., Ph.D., 1997-2001, Senior Research Scientist, Italian National Research Council, CNR
- Institute of Clinical Physiology IFC, Siena, Tuscany, Italy
- Chidchanok Leethanukul, D.D.S., Ph.D., 1997-2001, Dean and Professor, Faculty of Dentistry, Prince of Songkla University, Hat Yai, Songkhla, Thailand
- Suzana DeSousa, D.D.S., Ph.D., 1998, Professor, Department of Oral Pathology, School of Dentistry University of Sao Paulo, Brazil
- Ricardo Sanchez-Prieto, Ph.D., 1998-2001, Chief of the Molecular Oncology Laboratory, CRIB/ Medical School University of Castilla, La Mancha Albacete, Spain
- Shigetomo Fukuhara, Ph.D., 1998-2000, Professor, Dept. of Mol. Pathophysiol., Inst. of Adv. Med. Sci., Nippon Medical School, Japan

- Wendy Weinberg, Ph.D., 1998-2000, Chief, Laboratory of Molecular Oncology, Division of Monoclonal Antibodies, FDA, Rockville, Maryland
- Hiroshi Miyazaki, M.D., 1998-2003, Assistant Professor, VCU Health System, Richmond, Virginia
- Cristina Murga, Ph.D., 1999-2001, Professor, Molecular Biology Department, Universidad Autonoma de Madrid.
- Salvatore Pece, M.D., Ph.D., 1999-2001, Professor in General, Pathology University Medical School of Milan, European Institute of Oncology, Milan, Italy
- Jose Vazquez-Prado, Ph.D., 1999-2002, Professor, Pharmacology Department, CINVESTAV-IPN Mexico City, Mexico
- Silvia Montaner, Ph.D., 2000-2004, Professor, Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, MD
- Ana Barac, M.D., 2000-2003, Chair of Cardio-Oncology Section, MedStar Washington Hospital Center, Washington, DC
- Joan Marc Servitja, Ph.D., 2000-2003, Senior Researcher, Institut d'Investigacions Biomèdiques, August Pi I Sunyer, Endocrinology Unit, Hospital, Clínic de Barcelona, Spain
- Hiroki Chikumi, M.D., Ph.D., 2000-2002, Professor, Division of Infection Control, Tottori University Hospital, Tottori, Japan
- Akrit Sodhi, M.D., Ph.D., 2001-2004, The Branna and Irving Sisenwein Professorship in Ophthalmology, Associate Professor of Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, MD
- Valerie Perrot, Ph.D., 2001-2002, Statistician, Ipsen Pharmaceutical, Boulogne-Billancourt, Ile de France, France
- Virote Sriuranpong, M.D., Ph.D., 2001-2003, Professor, Medical Oncology Unit, Department of Medicine Faculty of Medicine, Chulalongkorn University, Rama IV, Pathumwan, Bangkok 10330, Thailand
- Paula Monje, Ph.D., 2001-2003, Research Assistant Professor, The Miami Project to Cure Paralysis University of Miami, School of Medicine, Miami, FL
- Hans Rosenfeldt, Ph.D., 2001-2006, Supervisory Pharmacologist, Center for Drug Evaluation and Research (CDER) Division of Oncology Drug Products, FDA
- Panomwat Amornphimoltham, D.D.S., Ph.D., 2001-2008, Acting Director of Research Center, Walailak University, International College of Dentistry, Bangkok, Thailand
- John R. Basile, D. MSc., D.D.S., 2002-2007, Associate Professor, Diagnostic Sciences & Pathology University of Maryland, Baltimore, Baltimore College of Dental Surgery, Baltimore, Maryland 21201
- Mariolina Castellone, M.D., Ph.D., 2002-2005, Researcher Scientist, Italian National Council of Research (CRN), University Federico II, Naples, Italy. Senator, Italian Senate, Italy.
- Hidemi Teramoto, M.D., Ph.D., 2002-2003, Vice-Director, Kojin Hospital, Nagoya, Japan
- Bradley Andresen, Ph.D., 2002-2004, Assistant Professor, Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
- Rogerio Castilho, D.D.S., Ph.D., 2003-2010, Associate Professor, Division of Oral Pathology/Medicine/Radiology Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI
- Wenfu Tan, M.D., Ph.D., 2003-2008, Associate Professor, Department of Pharmacology School of Pharmacy, Fudan University, Shanghai, China
- Robert Dorsam, Ph.D., 2004-2008, Pharmacologist, Center for Drug Evaluation and Research (CDER) Division Nonprescription Clinical Evaluation, FDA
- Todd Palmby Ph.D., 2004-2008, Director of Emerging Portofolio Strategy, AstraZeneca, Gaithersburg, MD
- Ana Raimondi, Ph.D., 2004-2009, Permanent Researcher, Institute of Oncology Angel Roffo, CONICET, Buenos Aires, Argentina
- Adrian Turjanski, Ph.D., 2005-2008, Professor of Bioinformatics, University of Buenos Aires,

Argentina

- Julie Gavard, Ph.D., 2005-2008, Team Chief, Center for Cancer Research and Immunology, Universite de Nantes, Nantes, France
- Cristiane Squarize, D.D.S., Ph.D., 2005-2010, Associate Professor, Division of Oral Pathology/Medicine/Radiology Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI
- Atsuko Sakurai, Ph. D, 2006-2013, Scientist, GSK Vaccines, Rockville, MD
- Jose Pedro Vaque, Ph.D., 2006-2011 Researcher, Ramon y Cajal research program, University of Cantabria, Spain
- Hiroshi Yagi, M.D., Ph.D., 2007-2010, Associate Professor, Department of Obstetrics and Gynecology, Kyushu University Medical School, Fukuoka, Japan
- Kantima Leelahavanichkul, D.D.S., Ph.D., 2008-2010, Dentist, Thammasat University, Thailand
- Constantinos Mikelis, Ph.D., 2009-2014, Associate Professor, Department of Pharmacy, University of Patras, Patras, Greece
- Patricia Dillenburg-Pilla, Ph.D., 2009-2014, Assistant Professor, University, Federal de Santa Catarina, Florianapolis, Brazil
- Nigiro Nohata, M.D., Ph.D., 2015-2016, Associate Director, MSD, Tokyo, Japan
- Kosuke Yamaguchi, M.D., Ph. D, 2015-2016, Assistant Professor, Tottori University, Tottori, Japan
- Woo-Jin Jeong, M.D, Ph.D., 2015-2016, Associate Professor, Seoul National University Bundang Hospital, Department of Otorhinolaryngology, Seoul, Korea
- Juan Luis Callejas Valera, 2015-2017, Principal Scientist at Caprion Biosciences Inc, San Francisco, CA
- Hiroki Izumi, M.D., Ph.D., 2017-2019, Assistant Professor, National Cancer Center Hospital East, Department of Thoracic Oncology, Chiba, Japan
- Yusuke Goto, M.D., Ph.D., 2017-2019, Assistant Professor, Department of Urology, Chiba University Graduate School of Medicine , Chiba, Japan
- Xiaodong Feng, Ph.D., 2014-2019, Principal Researcher, State Key Laboratory for Oral Diseases, West China College of Stomatology, Chengdu, China
- Ayush Kishore, Ph.D., 2017-2019, Senior Research Associate, Genentech, South San Francisco, CA
- Justine Paradis, Ph.D., 2018-2020, Scientist, Addex Therapeutics, Geneva, Switzerland
- Mara Gilardi, Ph.D., 2017-2020, SME Immuno-Oncology, La Jolla, CA
- Toshinori Ando, D.D.S, Ph.D., 2017-2020, Assistant Professor, Center for Oral Clinical Examination, Hiroshima University, Hiroshima, Japan.
- Robert Saddawi-Konefka, M.D., Ph.D., 2020-2022, Fellow, MD Anderson Cancer Center
- Nadia Arang, Ph.D., 2022-2023, Postdoc, UCSF
- Farhoud Faraji, M.D., Ph.D., 2020-2023, Resident Physician, Division of OTO-Head and Neck Surgery, UCSD
- Simone Lubrano, Ph.D., 2019-2023, Assistant Professor, University of Pisa, Pisa, Italy
- Keiichi Koshizuka, M.D., Ph.D., 2021-2024, Assistant Professor, Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
- Shiruyeh Schokrpur, M.D., Ph.D., 2022-2024, Assistant Professor, Division of Hematology/Oncology, University of California, Davis.
- Bryan Yung, Ph.D., 2019-2024, Scientist, Pfizer, San Diego, CA

Bibliography [Author=(Gutkind J* OR Gutkind S*)]. [PubMed](#)

Total 610 publications: 514 peer-reviewed studies, 58 review articles, 38 book chapters and proceedings, with >83981 citations and an H index of 152 [\[Google Scholar\]](#)

Selected publications, signal transduction research:

1. Crespo P, Xu N, Simonds WF, and Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein $\beta\gamma$ subunits. *Nature*, **369**:418-420, 1994.
2. Coso O, Chiariello M, Yu J-C, Crespo P, Teramoto, H, Xu N, Miki T, and Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell*, **81**:1137-1148, 1995.
3. Lopez-Illasaca M, Crespo P, Pellici PG, Gutkind JS*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ . *Science*, **275**:394-397, 1997.
4. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, and Bustelo XR. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. *Nature*, **385**:169-172, 1997.
5. Chiariello M, Marinissen MJ, and Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. *Nature Cell Biol.*, **3**:580-586, 2001.
6. Montaner S, Sodhi A, Molinolo AA, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, and Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
7. Castellone MD, Teramoto H, Williams BO, Druey KM, and Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin- β -catenin signaling axis. *Science*, **310**:1504-1510, 2005.
8. Martin D, Galisteo R, Molinolo AA, Wetzker R, Hirsch E, and Gutkind JS. PI3K γ mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell*, **19**: 805-813, 2011.
9. Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, and Gutkind JS. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**: ra60, 2011.
10. Vaqué JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A, Seeger MA, Ksander BR, Teramoto H, Gutkind JS. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing GPCR-initiated mitogenic signals. *Molecular Cell*, **49**:94-108, 2013.
11. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel T, Seshagiri S, and Gutkind JS. The emerging mutational landscape of G-proteins and G-protein-coupled receptors in cancer. (Analysis) *Nature Reviews Cancer* **13**(6):412-424, 2013.
12. Feng K, Degese MS, Iglesias-Bartolome R, Vaqué JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino M, Sodhi A, Chen Q, and Gutkind JS. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. *Cancer Cell*, **25**:831-845, 2014.
13. Iglesias-Bartolome R, Torres D, Marone R, Feng X, Martin D, Simaan M, Chen M, Weinstein LS, Taylor SS, Molinolo AA, and Gutkind JS., Inactivation of a Gas-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nature Cell Biol.*, **17**:793-803, 2015.
14. O'Hayre M, Eichel K, Avino S, Zhao X, Steffen DJ, Feng X, Kawakami K, Aoki J, Messer K, Sunahara R, Inoue A, von Zastrow M, and Gutkind JS. Genetic evidence that β -arrestins are dispensable for the initiation of β 2-adrenergic receptor signaling to ERK.

- Science Signaling*. **10(484)** pii: eaal3395, 2017.
15. Martin D, Degese MS, Vitale-Cross L, Iglesias-Bartolome R, Callejas Valera JL, Wang Z, Feng X, Yeerna H, Vadmal V, Moroishi T, Thorne R, Zaida M, Siegle B, Cheong SC, Molinolo AA, Samuels Y, Tamayo P, Guan KL, Lippman SM, Lyons JG, Gutkind JS. Assembly and Activation of the Hippo Signalome by the FAT1 Tumor Suppressor. *Nature Comm.*, **9**:2372, 2018.
 16. Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell*. **35(3)**:457-472.e5, 2019.
 17. Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes FG, Arang N, Tiago M, Coma S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, Gutkind JS. Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. *Clin Cancer Res*, **27(11)**:3190-3200, 2021.
 18. Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. The GPCR-Gas-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. *Nat Immunol*, **24(8)**:1318-1330, 2023.
 19. Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell Rep Med*, **4(11)**:101244, 2023.
 20. Lubrano S, Cervantes-Villagrana RD, Faraji F, Ramirez S, Sato K, Adame-Garcia SR, Officer A, Arang N, Rigiracciolo DC, Anguiano Quiroz PY, Martini C, Wang Y, Ferguson FM, Bacchiocchi A, Halaban R, Coma S, Holmen SL, Pachter JA, Aplin AE, Gutkind JS. FAK inhibition combined with the RAF/MEK clamp avutemetinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer Cell*, **43(3)**:428-445, 2025

Selected publications, oral cancer research:

1. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, and Gutkind JS. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, **65**:9953-9961, 2005.
2. Molinolo AA, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, and Gutkind JS. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clinical Cancer Research*, **13**:4964-4973, 2007.
3. Castilho RM, Squarize CH., Chodosh LA., Williams BO., and Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
4. Patel V, Marsh CA, Dorsam RT, Masedunskas A, Amornphimoltham P, Nathan CO, Singh B, Weigert R, Molinolo AA, and Gutkind JS. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.

5. Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, and Gutkind JS. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. *Clinical Cancer Research*, **18**:2558-2568, 2012.
6. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel P, Chen W, Schneider A, and Gutkind JS. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. *Cancer Prevention Research*, **5**:562-573, 2012.
7. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, and Gutkind JS. mTOR inhibition protects from epithelial stem cell senescence and radiation-induced mucositis. *Cell Stem Cell*, **11**:401-414, 2012.
8. Iglesias-Bartolome R, Martin D, and Gutkind JS. Exploiting the head and neck cancer oncogenome: Widespread PI3K-mTOR pathway alterations and novel molecular targets. *Cancer Discovery*, **3**:722-725, 2013.
9. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, and Gutkind JS. mTOR inhibition overcomes cetuximab resistance in head and neck cancers harboring *PIK3CA* and *RAS* mutations. *J. Natl. Cancer Inst.*, **106**(9) 1-11, 2014.
10. Carter H, Marty R, Hofree M, Gross A, Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman SM, Yeo G, Gutkind JS., Ideker T. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. *Cancer Discovery*. 7:410-423, 2017
11. Iglesias-Bartolome R, Uchiyama A, Molinolo AA, Abusleme L, Brooks SR, Callejas-Valera JL, Edwards D, Doci C, Asselin-Labat M-L, Onaitis MW, Moutsopoulos NM, Gutkind* JS, Morraso* MI (*Co-corresponding authors). Transcriptional signature primes human oral mucosa for rapid wound healing. *Sci. Transl. Med.*, 2018, 10, eaap8798
12. Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando T, Wahba A, Amornphimoltham P, Wu X, Gilardi M, Allevato M, Wu V, Steffen DJ, Tofilon P, Sonenberg N, Califano J, Chen Q, Lippman SM, Gutkind JS. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. *Cancer Res*. 2019.
13. Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. *Clin Cancer Res*. **25**(4):1156-1164, 2019.
14. Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Callejas-Valera JL, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. *Nature Commun*, **10**(1):5546, 2019.
15. Gutkind JS, Molinolo A, Wu X, Wang Z, Nachmanson D, Harismendy O, Alexandrov LB, Wuertz BR, Ondrey FG, Laronde DM, Rock LD, Rosin MP, Coffey CS, Butler VD, Bengtson L, Hsu CH, Bauman JE, Hewitt SM, Cohen EE, Chow HHS, Lippman SM, Szabo E. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. *JCI Insight*, **6**(17):e147096, 2021.
16. Wang Z, Goto Y, Allevato M, Wu V, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung B, O'Farrell A, Molinolo A, Duvvuri U, Grandis J, Califano J, Cohen E, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. *Nature Commun*, **12**(1):2383, 2021.
17. Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Foussard H, Zeng Y, O'Keefe R, Jin N, VanLandingham NK, Von Dollen J, Herrington KA, Bouhaddou M, McGregor M, Jimenez-Morales D, Obernier K, Kreisberg JF, Kim M,

- Johnson DE, Jura N, Grandis JR, Gutkind JS, Ideker T, and Krogan N. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. *Science*, **74**(6563):eabf2911, 2021.
18. Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang N-A, Al Msari R, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simo B, Fox B, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC. *Nature Commun*, **13**(1):4298, 2022.
 19. Saddawi-Konefka R, Schokrpur S, Gutkind JS. Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology. *Cancer Cell*. **10**;42(6):930-933, 2024.
 20. Faraji F, Ramirez S, Clubb LM, Sato K, Burghi V, Hoang TS, Officer A, Anguiano Quiroz PY, Galloway WMG, Mikulski Z, Medetgul-Ernar K, Marangoni P, Jones KB, Cao Y, Molinolo AA, Kim K, Sakaguchi K, Califano JA, Smith Q, Goren A, Klein OD, Tamayo P, Gutkind JS. YAP-Driven Malignant Reprogramming of Oral Epithelial Stem Cells at Single Cell Resolution. *Nature Communications*. **16** (498), 2025

Complete Bibliography

Peer Reviewed Research Articles

1. Gutkind JS and Enero MA. Noradrenaline uptake inhibitors counteract the cardiovascular effects of clonidine but not those of guanabenz. *Commun. Biol.*, **1**:319-326, 1983.
2. Gutkind JS and Enero MA. Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **327**:189-192, 1984.
3. Gutkind JS, Bogнар I, and Enero MA. Pharmacological characterization of guanabenz, clonidine-like anti-hypertensive drug. *J. Cardiol. (Argentina)*, **53**:145-147, 1985.
4. Gutkind JS, Kazanietz MG, and Enero MA. Cardiovascular effects of alpha-adrenergic drugs: differences between clonidine and guanabenz. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **332**:370-375, 1986.
5. Gutkind JS. and Enero MA. Effects of desipramine on the cardiovascular responses to clonidine and guanabenz. *Hypertension*, **8**:184-186, 1986.
6. Kazanietz MG, Gutkind JS, and Enero MA. Interaction between α_2 - and β_2 -adrenoceptor responses in the vascular system: effect of clenbuterol. *Eur. J. Pharmacol.*, **130**:119-124, 1987.
7. Castren E, Kurihara M, Gutkind JS, and Saavedra JM. Specific angiotensin II binding sites in the rat stellate and superior cervical ganglion. *Brain Research*, **422**:347-351, 1987.
8. Gutkind JS and Enero MA. Different pharmacological interaction of clonidine and guanabenz with antidepressive drugs. *Clin. Exper. Hypertension*, **A9**:1531-1547, 1987.
9. Gutkind JS., Kurihara M, Castren E, and Saavedra JM. Atrial natriuretic peptide receptors in sympathetic ganglia: Biochemical response and alterations in genetically hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149**:65-72, 1987.
10. Kurihara M, Castren E, Gutkind JS, and Saavedra JM. Lower number of atrial natriuretic peptide receptors in thymocytes and spleen cells of spontaneously hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149**:1132-1140, 1987.
11. Saito K, Gutkind JS, and Saavedra JM. Angiotensin II binding sites in the conduction system of the rat heart. *Am. J. Physiol.*, **253**: (Heart Circ. Physiol. 22), H1618-H1622, 1987.
12. Gutkind JS, Kurihara M, Castren E, and Saavedra JM. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. *J. Hypertension*, **6**:79-84, 1988.

13. Kurihara M, Gutkind JS, Saavedra JM. Alteration of atrial natriuretic peptide binding sites in spontaneously hypertensive rats. *Am. J. Hypertension*, **1**:12S-14S, 1988.
14. Kurihara M, Castren E, Gutkind JS, Saito K, and Saavedra JM. Characterization of β -adrenergic receptors in sections from human blood lymphocyte pellets by quantitative auto-radiography. *Biological Psychiatry*, **23**:746-749, 1988.
15. Nazarali AJ, Gutkind JS, and Saavedra JM. Regulation of angiotensin II binding sites in discrete rat brain nuclei after water deprivation. *Cell. Molec. Neurobiol.*, **7**:447-455, 1988.
16. Gutkind JS, Castren E, and Saavedra JM. Decreased angiotensin II binding in the anterior pituitary gland of spontaneously hypertensive rats. *Life Science*, **43**:441-451, 1988.
17. Gutkind JS, Kurihara M, Castren E, and Saavedra JM. Autoradiographic quantification of vasoactive intestinal peptide binding sites in sections from human blood lymphocytes pellets. *Neuropsychopharmacol.*, **1**:251-255, 1988.
18. Gutkind JS, Kurihara M, and Saavedra JM. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. *Am. J. Physiol.*, **255**: (Heart Circ. Physiol. 24), H646-H650, 1988.
19. Nazarali AJ, Gutkind JS, Correa FMA, and Saavedra JM. Effect of chronic administration of the converting enzyme inhibitor enalapril (MK 421) on brain atrial natriuretic peptide receptors in Wistar-Kyoto and spontaneously hypertensive rats. *Brain Research*, **475**:134-140, 1988.
20. Gutkind JS, Kazanietz MG, Armando I, Puyo A, and Enero MA. Pressor response induced by clenbuterol treatment in immobilized normotensive rats. *J. Cardiovasc. Pharmacol.*, **13**:793-798, 1989.
21. Kazanietz MG, Gutkind JS, Puyo A, Armando I, and Enero MA. Further evidence for interaction between vasodilators beta-2-adrenoceptor and vasoconstriction-alpha-2-adrenoceptor mediated responses in maintaining vascular tone in anesthetized rats. *J. Cardiov. Pharmacol.*, **14**:874-880, 1989.
22. Nazarali AJ, Gutkind JS, Correa FMA, and Saavedra JM. Selective decrease of angiotensin II receptors in the subfornical organ of spontaneously hypertensive rats after chronic treatment with a converting enzyme inhibitor. *Am. J. Physiol.*, **256**:H1609-H1614, 1989.
23. Nazarali AJ, Gutkind JS, and Saavedra JM. Calibration of [¹²⁵I]-polymer standards with [¹²⁵I]-brain paste standards for use in quantitative receptor autoradiography. *J. Neurosc. Methods*, **30**:247-253, 1989.
24. Sugita K, Gutkind JS, Katamine S, and Robbins KC. The actin domain of Gardner-Rasheed feline sarcoma virus inhibits kinase and transforming activities. *J. Virology*, **63**:1715-1720, 1989.
25. Notario V, Gutkind JS, Imaizumi M, Katamine S, and Robbins KC. Expression of the *fgr* proto-oncogene product as a function of myelomonocytic cell maturation. *J. Cell Biol.*, **109**:3129-3136, 1989.
26. Gutkind JS and Robbins KC. Mobilization of the *c-fgr* protein-tyrosine kinase as a consequence of neutrophil activation. *Proc. Natl. Acad. Sci. USA*, **86**:8783-8787, 1989.
27. Gutkind JS, Lacal PM, and Robbins KC. Thrombin-dependent association of phosphatidylinositol-3 kinase with p60^{c-src} and p59^{fyn} in human platelets, *Mol. Cell. Biol.*, **10**:3806-3809, 1990.
28. Benhamou M, Gutkind JS, Robbins KC, and Siraganian RP. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. *Proc. Natl. Acad. Sci. USA*, **87**:5327-5330, 1990.
29. Vukicevic S, Paralkar VM, Cunningham NS, Gutkind JS, and Reddi AH. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. *Dev. Biol.*, **140**:209-214, 1990.

30. Heidaran MA, Pierce JH, Lombardi D, Ruggiero M, Gutkind JS, Matsui T, and Aaronson SA. Deletion or substitution within the α PDGF receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. *Mol. Cell. Biol.*, **11**:134-142, 1991.
31. Yu J-C, Heidaran MA, Pierce JH, Gutkind JS, Lombardi D, Ruggiero M, and Aaronson SA. Tyrosine mutations within the α PDGF kinase insert domain abrogate receptor-associated PI-3 kinase activity without affecting mitogenic or chemotactic signal transduction. *Mol. Cell. Biol.*, **11**:3780-3785, 1991.
32. Gutkind JS, Link DC, Katamine S, Lacal P, Miki T, Ley TJ, and Robbins KC. A novel *c-fgr* exon utilized in Epstein-Barr virus infected B-lymphocytes but not normal monocytes. *Mol. Cell. Biol.*, **11**:1505-1507, 1991.
33. Gusovsky F and Gutkind JS. Selective effect of activation of protein kinase-C isoenzymes on cAMP accumulation. *Mol. Pharmacol.*, **39**:124-129, 1991.
34. Gutkind JS, Novotny E, Brann MR, and Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist dependent oncogenes. *Proc. Natl. Acad. Sci. USA*, **88**:4703-4707, 1991.
35. Hermouet S, Merendino J Jr, Gutkind JS, and Spiegel AM. Activating and inactivating mutations of $G\alpha_{12}$ have opposite effects on proliferation of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA*, **88**:10455-10459, 1991.
36. Sartor O, Moriuchi R, Sameshima J, Severino M, Gutkind JS, and Robbins KC. Diverse biologic properties imparted by the *c-fgr* proto-oncogene. *J. Biol. Chem.*, **267**:3460-3465, 1992.
37. Volker S, Benhamou M, Gutkind JS, Robbins KC, and Siraganian RP. Fc ϵ R1-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3): Evidence for a novel signal transduction pathway unrelated to G protein activation and phosphatidylinositol hydrolysis. *J. Biol. Chem.*, **267**:5434-5441, 1992.
38. Thompson PA, Gutkind JS, Robbins KC, Ledbetter JA, and Bolen JB. Identification of distinct populations of PI-3 kinase following T cell activation. *Oncogene*, **7**:719-725, 1992.
39. Link DC, Gutkind JS, Robbins KC, and Ley TJ. Characterization of the 5' untranslated region of the human *c-fgr* gene and identification of the major myelomonocytic *c-fgr* promoter. *Oncogene*, **7**:877-884, 1992.
40. Kalinec G, Nazarali AJ, Hermouet S, Xu N, and Gutkind JS. Mutated α subunit of the G_q protein induces malignant transformation in NIH 3T3 cells. *Mol. Cell. Biol.*, **12**:4687-4693, 1992.
41. Gutkind JS and Robbins KC. Activation of transforming G protein-coupled receptors induces rapid tyrosine phosphorylation of cellular proteins, including p125^{FAK} and the p130 v-src substrate. *Biochem. Biophys. Res. Commun.*, **188**:155-161, 1992.
42. Wang L-M, Keegan AD, Paul WE, Heidaran MA, Gutkind JS, and Pierce JH. IL-4 activates a distinct signal transduction cascade from IL-3 in factor dependent myeloid cells. *EMBO J.*, **11**:4899-1908, 1992.
43. Stephens EV, Kalinec G, Brann MR, and Gutkind JS. Transforming G protein-coupled receptors transduce potent mitogenic signals in NIH 3T3 cells independent of cAMP-inhibition or conventional protein kinase C. *Oncogene*, **8**:19-26, 1993.
44. Wang L-M, Keegan AD, Li W, Lienhard GE, Pacini S, Gutkind JS, Myers MG, Sun X-J, White MF, Aaronson SA, Paul WE, and Pierce JH. Common elements in IL-4 and insulin signaling pathways in factor dependent hematopoietic cells. *Proc. Natl. Acad. Sci. USA* **90**:4032-4036, 1993.
45. Xu N, Bradley L, Ambdukar I, and Gutkind JS. A mutant α subunit of G_{12} potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA*, **90**:6741-6745, 1993.

46. Xu N, McCormick F, and Gutkind JS. The non-catalytic domain of *ras*-GAP inhibits transformation induced by G protein coupled receptors. *Oncogene*, **9**:597-602, 1994.
47. Xu N, Voinov-Yasenetskaya T, and Gutkind JS. Potent transforming activity of the G₁₃ α subunit defines a novel family of oncogenes. *Biochem. Biophys. Res. Commun.*, **201**:603-609, 1994.
48. Calderon SN, Izenwasser S, Heller B, Gutkind JS, Mattson M, Su T-P, and Newman AH. Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma₁ ligands. *J. Med. Chem.*, **37**:2285-2291, 1994.
49. Crespo P, Xu N, Daniotti JL, Rapp UR, and Gutkind JS. Signaling through transforming G protein-coupled receptors in NIH 3T3 cells involves c-Raf activation: Evidence for a protein kinase C independent pathway. *J. Biol. Chem.*, **269**:21103-21109, 1994.
50. Crespo P, Xu N, Simonds WF, and Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein $\beta\gamma$ subunits. *Nature*, **369**:418-420, 1994.
51. Yu J-C, Gutkind JS, Mahadevan D, Li W, Meyers KA, Pierce JH, and Heidaran MA. Biological function of PDGF-induced PI-3 kinase activity: Its role in α PDGF receptor-mediated mitogenic signaling. *J. Cell Biol.*, **127**:479-488, 1994.
52. Coso O, Chiariello M, Kalinec G, Kyriakis J, Woodgett J, and Gutkind JS. Transforming G protein-coupled receptors potentially activate JNK (SAPK): evidence for a divergence from the tyrosine-kinase signaling pathway. *J. Biol. Chem.*, **270**:5620-5624, 1995.
53. Crespo P, Cachero TG, Xu N, and Gutkind JS. Dual effect of β -adrenergic receptors on MAP kinase: Evidence for a $\beta\gamma$ -dependent activation and a G α_s -cAMP-mediated inhibition. *J. Biol. Chem.*, **270**:25259-25265, 1995.
54. Crespo P, Mischak H, and Gutkind JS. Overexpression of mammalian protein kinase C- ζ does not affect the growth characteristics of NIH 3T3 cells. *Biochem. Biophys. Res. Commun.*, **213**:266-272, 1995.
55. Mahadevan D, Thakur N, Singh J, McPhie P, Zangrilli D, Wang L-M, Guerrero C, LeVine H, Humblet C, Saldanha J, Gutkind JS, and Haske T. Structural studies on the PH domains of Dbl, Sos1, IRS-1 and β ARK1 and their differential binding to G $\beta\gamma$ subunits. *Biochemistry J.* **34**:9111-9117, 1995.
56. Miyamoto S, Teramoto H, Coso O, Gutkind JS, Burbelo PD, Akiyama SK, and Yamada KM. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. *J. Cell. Biol.*, **131**:791-805, 1995.
57. Coso O, Chiariello M, Yu J-C, Crespo P, Teramoto H, Xu N, Miki T, and Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell*, **81**:1137-1148, 1995.
58. Coso O, Teramoto H, Simonds WF, and Gutkind JS. Signaling from G protein-coupled receptors to JNK/SPK involves $\beta\gamma$ subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway. *J. Biol. Chem.*, **271**:3963-3966, 1996.
59. Xu N, Coso O, Mahadevan D, De Blasi A, Goldsmith PK, Simonds WF, and Gutkind JS. The PH domain of Ras-GAP is sufficient for in vitro binding to $\beta\gamma$ subunits of heterotrimeric G proteins. *Cell. Mol. Neurobiol.*, **16**:51-59, 1996.
60. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso O, Gutkind JS, and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature*, **381**:800- 803, 1996.
61. Zhang S, Coso O, Collins R, Gutkind JS, and Simonds WF. A carboxyl-terminal mutant of the G-protein β subunit deficient in the activation of phospholipase C- β . *J. Biol. Chem.*, **271**:20208-20211, 1996.
62. Kieser A, Adler HS, Seitz T, Crespo P, Gutkind JS, Kolch W, and Mischak H. Protein Kinase C ζ inhibits cellular transformation by upregulating *jun*-B and *egr*-1 expression. *Genes and Development*, **10**:1455-1466, 1996.

63. Crespo P, Bustelo XR, Aaronson DS, Coso OA, Lopez-Barahona M, Barbacid M, and Gutkind JS. Rac-1 dependent stimulation of the JNK/SAPK pathway by Vav. *Oncogene*, **13**:455-460, 1996.
64. Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, and Finkel T. Regulation of Reactive oxygen species generation in fibroblast by Rac1. *Biochem. J.*, **318**:379-382, 1996.
65. Calderon SN, Bertha CM, Gutkind JS, Xu H, Partilla JS, Rothman RB, and Rice KC. Probes for Narcotic receptor mediated phenomena. Synthesis and characterization of optically pure [³H](+)-4-[(α R)- β -((2S,5R)-4-Propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide, [³H]SNC121, a novel high affinity and selective ligand for delta opioid receptors. *J. Labelled Comp. Radiopharm.* **38**:347-350, 1996.
66. Teramoto H, Crespo P, Coso OA, Igishi T, Xu N, and Gutkind JS. The small GTP-binding protein Rho activates JNK/SAPK in human kidney 293T cells: Evidence for a Pak-independent signaling pathway. *J. Biol. Chem.*, **271**:25731-25734, 1996.
67. Teramoto H, Coso OA, Miyata H, Igishi T, and Gutkind JS. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the JNK/SAPK pathway: A role for MLK3/PTK1, a novel member of the mixed-lineage kinase family. *J. Biol. Chem.*, **271**:27225-27228, 1996.
68. Zhang S, Coso OA, Lee C, Gutkind JS, and Simonds WF. Selective activation of effector pathways by brain-specific G protein β 5. *J. Biol. Chem.*, **271**:33575-33579, 1996.
69. Miyamoto S, Teramoto H, Gutkind JS, and Yamada KM. Integrins can synergize with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. *J. Cell Biol.*, **135**:1633-1642, 1996.
70. Herrera L, Hinrichs MV, Frías J, Gutkind JS, and Olate J. Dual transduction signaling by a xenopus muscarinic receptor: Adenylyl cyclase inhibition and MAPK activation. *J. Cell. Biochem.*, **64**:1-8, 1997.
71. Lopez-Illasaca M, Crespo P, Pellici PG, Gutkind JS*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase $\square$. *Science*, **275**:394-397, 1997.
72. Gordeladze JO, Hovik KE, Merendino JJ, Hermouet S, Gutkind JS, and Accili D. Effect of activating and inactivating mutations of G_s- and G_{i2}-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes. *J. Cell. Biochem.*, **64**:242-257, 1997.
73. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, and Bustelo XR. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. *Nature*, **385**:169-172, 1997.
74. Gutkind JS, Crespo P, Xu N, Teramoto H, and Coso OA. The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. *Life Sci.*, **60**:999-1006, 1997.
75. Teramoto H, Salem P, Robbins KC, Bustelo X, and Gutkind JS. Tyrosine phosphorylation of the vav proto-oncogene product links Fc ϵ RI to the Rac1-JNK pathway. *J. Biol. Chem.*, **272**:10751-10755, 1997.
76. Lopez-Illasaca M, Li W, Uren A, Yu J-C, Kazlauskas A, Gutkind JS, and Heidaran MA. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF- β receptors. *Biochem. Biophys. Res. Commun.*, **232**:273-277, 1997.
77. Buckbinder L, Velasco-Miguel S, Xu N, Chen Y, Talbott R, Gelbert L, Gao J, Seizinger BR, Gutkind JS, and Kley N. Inhibition of G protein-mediated activation of the MAP kinase pathway by a novel target of the p53 tumor suppressor. *Proc. Natl. Acad. Sci. U.S.A.*, **94**:7868-7872, 1997.
78. Coso OA, Montaner S, Fromm C, Teramoto H, Prywes R, Lacal JC and Gutkind JS. Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2

- transcription factor: evidence for a Novel JNK-independent pathway. *J. Biol. Chem.*, **272**:20691-20697, 1997.
79. Uren A, Jakus J, Font de Mora J, Yeudall A, Santos E, Gutkind JS, and Heidaran MA. Carboxy-terminal domain of p27Kip1 activates cdc2. *J. Biol. Chem.*, **272**:2669-2672, 1997.
 80. Fromm C, Coso OA, Montaner S, Xu N, and Gutkind JS. The small GTP-binding protein Rho links G protein-coupled receptors and G α_{12} to the serum response element and to cellular transformation. *Proc. Natl. Acad. Sci. U.S.A.*, **94**:10098-10103, 1997.
 81. Jin D-Y, Teramoto H, Giam L-Z, Chun RF, Gutkind JS, and Jeang K-T. A human suppressor of JNK activation by TNF α . *J. Biol. Chem.*, **272**:25816-25823, 1997.
 82. Liu JL, Blakesley VA, Gutkind JS, and Le Roith D. The constitutively active mutant of G α_{13} transforms mouse fibroblast cells deficient in insulin-growth factor-I receptor. *J. Biol. Chem.*, **272**:29438-29441, 1997.
 83. Bustelo XR, Crespo P, Lopez-Barahona M, Gutkind JS, and Barbacid M. Cbl-b, a member of the sli-1/c-cbl protein family inhibits Vav-mediated c-Jun N-terminal kinase activation. *Oncogene*, **15**:2511-2520, 1997.
 84. Alimandi M, Heidaran MA, Gutkind JS, Zhang J, Ellmore N, Kazalauskas VM, Pierce JH, and Li Q. PLC- γ activation is required for PDGF- β R-mediated mitogenesis and monocytic differentiation in myeloid progenitor cells. *Oncogene*, **15**:585-593, 1997.
 85. Bais C, Santomasso B, Coso OA, Arvanitakis L, Raaka E, Gutkind JS, Asch A, Cesarman E, Gershengorn MC, and Mesri E. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor is a viral oncogene and angiogenesis activator. *Nature*, **391**:86-89, 1998.
 86. Lopez-Illasaca M, Gutkind JS, and Wetzker R. Phosphoinositide 3-kinase γ is a mediator of G $\beta\gamma$ -dependent Jun kinase activation. *J. Biol. Chem.*, **273**:2505-2508, 1998.
 87. Jones TLZ and Gutkind JS. G α_{12} requires acylation for its transforming activity. *Biochemistry*, **37**:3196-3202, 1998.
 88. Igishi T and Gutkind JS. Tyrosine kinases of the Src family participate in signaling to MAP kinase from both Gq and Gi-coupled receptors. *Biochem. Biophys. Res. Commun.*, **244**:5-10, 1998.
 89. Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, Pagliai K, Gray K, Gutkind JS and Segars J. Characterization of Brx, a novel DBL family member that modulates estrogen receptor action. *Oncogene*, **16**:2513-2526, 1998.
 90. Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Francis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, and Santoro M. Signaling of the Ret receptor tyrosine kinase through the JNK: evidence for a divergence of the ERKs and JNKs pathways induced by Ret. *Oncogene*, **16**:2435-2447, 1998.
 91. Zohar M, Teramoto H, Katz B-Z, Yamada KM, and Gutkind JS. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. *Oncogene*, **17**:991-998, 1998.
 92. Murga C, Laguinge L, Wetzker R, Cuadrado A, and Gutkind JS. Activation of Akt/PKB by G protein-coupled receptors: A role for α and $\beta\gamma$ subunits of heterotrimeric G proteins acting through PI3K γ . *J. Biol. Chem.*, **273**:19080-19085, 1998.
 93. Deb TB, Wong L, Salomon DS, Zhou GC, Dixon JE, Gutkind JS, Thompson SA, and Johnson GR. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAPK, but not c-jun amino-terminal kinase activation. *J. Biol. Chem.*, **273**:16643-16646, 1998.
 94. Crespo P, de Mora JF, Aaronson DS, Santos E, and Gutkind JS. Transforming G protein-coupled receptors block insulin and ras-induced adipocytic differentiation in 3T3-L1 cells: Evidence for a PKC and MAP kinase independent pathway. *Biochem. Biophys. Res. Commun.*, **245**:554-561, 1998.

95. Okubo Y, Blakesley VA, Stannard B, Gutkind JS, and Le Roith D. Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase. *J. Biol. Chem.*, **273**:25961-25966, 1998.
96. Burstein ES, Hesterberg DJ, Gutkind JS, Brann MR, Currier EA, and Messier TL. The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. *Oncogene*, **17**:1617-1623, 1998.
97. Patel V, Senderowicz AM, Pinto D, Ensley J, Igishi T, Sausville EA, and Gutkind JS. Flavopiridol, a novel CDK inhibitor, suppresses the growth of squamous cell carcinomas by inducing apoptosis. *J. Clin. Invest.*, **102**:1674-1681, 1998.
98. Korn I, Gutkind JS, Srinivasan N, Blundell TL, Allende CC, and Allende JE. Interactions of protein kinase CK2 subunits. Interactions of protein kinase CK2 subunits. *Mol. Cell. Biochem.*, **191**:75-83, 1999.
99. Janulis M, Silberman S, Ambegaokar A, Gutkind JS, and Schultz RM. Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. *J. Biol. Chem.*, **274**:801-813, 1999.
100. Fukuhara S, Murga C, Zohar M, Igishi T, and Gutkind JS. A novel PDZ-domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. *J. Biol. Chem.*, **274**:5868-5879, 1999.
101. Heemskerk F, Zorad S, Xu N, Gutkind JS, and Saavedra JM. Characterization of AT2 receptor expression in NIH 3T3 fibroblasts. *Cell. Mol. Neurobiol.*, **19**:277-288, 1999.
102. Soon L, Flechner L, Gutkind JS, Wang L-H, Baserga R, Pierce JH, and Li W. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of IRS expression. *Mol. Cell. Biol.*, **19**:3816-3824, 1999.
103. Pece S, Chiariello M, Murga C, and Gutkind JS. Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions - Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. *J. Biol. Chem.*, **274**:19347-19351, 1999.
104. Marinissen MJ, Chiariello M, Pallante M, and Gutkind JS. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. *Mol. Cell. Biol.*, **19**:4289-4301, 1999.
105. Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind JS, Bjarnegård M, Betsholtz C, Di Fiore PP. EPS8 and E3B1 Transduce signals from Ras to Rac. *Nature* **40**:290-293, 1999.
106. Igishi T, Fukuhara S, Patel V, Katz BZ, Yamada KM, and Gutkind JS. Divergent signaling pathways link FAK to MAP kinase cascades: A role for paxillin in JNK activation. *J. Biol. Chem.*, **274**:30738-30746, 1999.
107. Lerga A, Crespo P, Berciano M, Delgado MD, Cañelles M, Calés C, Richard C, Ceballos E, Gutierrez P, Ajenjo N, Gutkind JS, and Leon J. Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. *Cell Growth Diff.*, **10**:639-654, 1999.
108. Tassi E, Biesova Z, Di Fiore PP, Gutkind JS, and Wong WT. Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by EGF. *J. Biol. Chem.*, **274**:33287-33295, 1999.
109. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, and Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. *Nature*, **403**:216-220, 2000.

110. Shillitoe EJ, May M, Leethanakul C, Patel V, Ensley JF, Strausberg RL, and Gutkind JS. Genome-wide analysis of oral cancer-Early results from the Cancer Genome Anatomy Project. *Oral Oncol.*, **36**:8-16, 2000.
111. Chiariello M, Marinissen MJ, and Gutkind JS. Multiple MAP kinase signaling pathways connect the Cot oncoprotein to the *c-jun* promoter and to cellular transformation. *Mol. Cell. Biol.*, **20**:1747-1758, 2000.
112. Majidi M, Gutkind JS, and Lichy JH. Deletion of the COOH terminus converts the ST5 p70 Protein from an inhibitor of RAS signaling to an activator with transforming activity in NIH-3T3 Cells. *J. Biol. Chem.*, **275**:6560-6565, 2000.
113. Katz BZ, Zohar M, Teramoto H, Matsumoto K, Gutkind JS, Lin DC, Lin S, and Yamada KM. Tensin can induce JNK and p38 activation. *Biochem. Biophys. Res. Commun.*, **272**: 717-720, 2000.
114. Pirone DM, Fukuhara S, Gutkind JS, Burbelo PD. SPECs, Small Binding Proteins for Cdc42. *J. Biol. Chem.*, **275**:22650-22656, 2000.
115. Sanchez-Prieto R, Rojas JM, Taya Y, and Gutkind JS. A role for the p38^{MAPK} pathway in the transcriptional activation of p53 upon genotoxic stress by chemotherapeutic agents. *Cancer Res.*, **60**: 2464-2472, 2000.
116. Izevbigie EBO, Gutkind JS, and Ray PE. Angiotensin II and Fibroblast Growth Factor mitogenic signaling pathways in human mesangial cells. *Pediatr. Res.*, **47**: 614-621, 2000.
117. Murga C, Fukuhara S, and Gutkind JS. A novel role for PI3-kinase β in signaling from G protein-coupled receptors to Akt. *J. Biol. Chem.*, **275**: 12069-12073, 2000.
118. Chiariello M, Gomez E, and Gutkind JS. Regulation of the mammalian G1/S cell cycle restriction point by MAP kinase. *J. Biochem.*, **349**:869-876, 2000.
119. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JE, Limwongse V, Emmert-Buck MR, Krizman DV, and Gutkind JS. Gene expression profiles in squamous cell Carcinomas of the oral cavity: Use of Laser Capture Microdissection for the construction and analysis of stage-specific cDNA libraries. *Oral Oncology*, **36**:474-483, 2000.
120. Leethanakul C, Patel V, Gillespie J, Pallante M, Ensley JF, Liotta LA, Emmert-Buck M, and Gutkind JS. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. *Oncogene*, **19**:3220-3224, 2000.
121. Izevbigie EBO, Gutkind JS, and Ray P. Isoproterenol inhibits FGFb-induced growth of renal epithelial cells. *Ped. Nephrology*, **14**: 726-734, 2000.
122. Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, Gutkind JS, and O'Shea JJ. Importance of MKK6/p38 pathway for IL-12-induced STAT4 serine phosphorylation and transcriptional activity. *Blood*, **96**:1844-1852, 2000.
123. Arozarena I, Aaronson DS, Sanz V, Ajenjo N, Matallanas D, Teramoto H, Iguishi T, Zabala JS, Bustelo XR, Gutkind JS, and Crespo P. Ras-GRF-induced signaling and cellular transformation requires the participation of the GTPase cdc42. *J. Biol. Chem.*, **275**: 26441-26448, 2000.
124. Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, and Li W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. *Blood*, **96**:3560-3568, 2000.
125. Du Villard JA, Wicker R, Crespo P, Russo D, Filetti S, Gutkind JS, Sarasin A, and Suarez HG. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. *Oncogene*, **19**:4896-4905, 2000.
126. Fukuhara S and Gutkind JS. A new twist for the tumour suppressor hamartin. *Nature Cell Biol.*, **2**: E76-E78, 2000.

127. Fukuhara S, Marinissen MJ, Chiariello M, and Gutkind JS. Signaling from G Protein-coupled receptors to ERK5/BMK 1 involves $G\alpha_q$ and $G\alpha_{12/13}$ families of heterotrimeric G proteins: Evidence for the existence of a novel Ras and Rho-independent pathway. *J. Biol. Chem.*, **275**: 21730-21736, 2000.
128. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, and Gutkind JS. The Kaposi's sarcoma associated Herpesvirus G protein-coupled receptor upregulates VEGF expression and secretion through MAPK and p38 pathways acting on HIF-1 α . *Cancer Research*, **60**:4873-4880, 2000.
129. Patel V, Ensley JF, Gutkind JS, and Yeudall WA. Induction of apoptosis in head and neck squamous carcinoma cells by γ -irradiation and bleomycin is p53-independent. *Internatl. J. Cancer*, **88**:737-743, 2000.
130. Fukuhara S, Chikumi H, and Gutkind JS. Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (LARG) links heterotrimeric G proteins of the G_{12} family to Rho. *FEBS Letters*, **485**:183-188, 2000.
131. Pece S and Gutkind JS. Signaling from E-Cadherins to the MAPK pathway by the recruitment and activation of EGF receptors upon cell-cell contact formation. *J Biol Chem.*, **275**:41227-41233, 2000.
132. Marinissen MJ, Chiariello M, and Gutkind JS. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 γ) MAP kinase pathway. *Genes Dev.*, **15**:535-553, 2001.
133. Patel V, Leethanakul C, and Gutkind JS. New Approaches for the understanding of the molecular basis of oral cancer. *Crit. Rev. Oral Med.*, **12**:55-63, 2001.
134. Montaner S, Sodhi A, Pece S, Mesri EA, and Gutkind JS. The Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor promotes endothelial cell survival through the activation of Akt/PKB. *Cancer Res.*, **61**:2641-2648, 2001.
135. Dong F, Gutkind JS, and Lerner AC. Granulocyte colony-stimulating factor induces erk5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C. Regulation of cell proliferation and survival. *J. Biol. Chem.*, **276**:10811-10816, 2001
136. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. *J. Biol. Chem.*, **276**:31674-31683, 2001.
137. Longenecker KL, Lewis ME, Chikumi H, Gutkind JS, and Derewenda ZS. Structure of the RGS-like domain from PDZ-RhoGEF linking heterotrimeric G protein-coupled signaling to Rho GTPases. *Structure (Cell Press)*, **9**:559-69, 2001.
138. Chiariello M, Marinissen MJ, and Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. *Nature Cell. Biol.*, **3**:580-586, 2001.
139. Sodhi A, Montaner S, Miyazaki H, and Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1 α in ras V12 upregulation of VEGF. *Biochem. Biophys. Res. Commun.*, **287**:292-300, 2001
140. Knezevic V, Leethanakul C, Bichsel BE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin III EF, and Krizman DB. Proteomic profiling of the cancer microenvironment by antibody microarrays. *Proteomics*, **10**:1271-8, 2001.
141. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, Martinez J, Larcher F, Slaga TJ, Gutkind JS, Jorcano JL, and Paramio JM. Functional roles of Akt signaling in mouse skin tumorigenesis. *Oncogene*, **21**:53-64, 2002.
142. Murga C, Zohar M, Teramoto H, and Gutkind JS. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF- κ B. *Oncogene*, **21**:207-16, 2002.
143. Sakabe K, Teramoto H, Zohar M, Behbahani B, Miyazaki H, Chikumi H, and Gutkind JS. Potent transforming activity of the small GTP-binding protein Rit in NIH 3T3 cells: Evidence for a role of a p38 γ -dependent signaling pathway. *FEBS Lett.*, **511**:15-20, 2002

144. Katz BZ, Miyamoto S, Teramoto H, Zohar M, Krylov D, Vinson C, Gutkind JS, and Yamada KM. Direct transmembrane clustering and cytoplasmic dimerization of focal adhesion kinase initiates its tyrosine phosphorylation. *Biochim. Biophys. Acta*, **1592**: 141-152, 2002.
145. Chen HW, Chen X, Oh SW, Marinissen MJ, Gutkind JS, and Hou SX. Mom identifies a receptor for the Drosophila JAK/STAT signal transduction pathway and encodes a protein distantly related to the mammalian cytokine receptor family. *Genes Dev.*, **16**:388-398, 2002.
146. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, and Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. *Cancer Cell*, **1**: 53-62, 2002.
147. Chikumi H, Fukuhara S, and Gutkind JS. Regulation of G protein-linked guanine nucleotide exchange for Rho, PDZ-RhoGEF and LARG, by tyrosine phosphorylation: Evidence of a role for FAK. *J. Biol. Chem.*, **277**:12463-12473, 2002.
148. Chen HW, Marinissen MJ, Oh SW, Chen X, Melnick M, Perrimon N, Gutkind JS, and Hou SX. CKA, a novel multidomain protein, regulates the JUN N-terminal kinase signal transduction pathway in Drosophila. *Mol. Cell. Biol.*, **22**:1792-803, 2002.
149. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja J-M, and Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. *Oncogene*, **31**:974-979, 2002.
150. Regnault KL, Leteurtre E, Gutkind JS, Gespach CP, and Emami S. Activation of adenylyl cyclases, regulation of insulin status, and cell survival by G(alpha)olf in pancreatic beta-cells. *Am. J. Physiol.*, **282**:R870-880, 2002.
151. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, and Senderowicz AM. Perifosine, a novel alkylphospholipid, induces p21^(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. *Cancer Res.*, **62**:1401-1409, 2002.
152. Patel V, Aldridge K, Ensley JF, Odell E, Boyd A, Jones J, Gutkind JS, and Yeudall WA. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. *Internatl. J. Cancer*, **99**:583-588, 2002.
153. Machado de Sousa SO, Mesquita RA, Pinto Jr DS, and Gutkind JS. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. *J. Oral Pathol.*, **31**:78-81, 2002.
154. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, and Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. *Oncogene*, **21**:5289-5300, 2002.
155. Chikumi H, Vazquez-Prado J, Servitja J-M, Miyazaki H, and Gutkind JS. Potent activation of RhoA by Gαq and Gq-coupled receptors. *J. Biol. Chem.*, **277**:27130-27134, 2002.
156. Perrot V, Vázquez-Prado J, and Gutkind JS. Plexin B Regulates Rho through the Guanine Nucleotide Exchange Factors LARG and PDZ-RhoGEF. *J. Biol. Chem.*, **277**:43115-43120, 2002.
157. Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS, and Senderowicz AM. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1. *Clin. Cancer Res.* **8**:3549-3560, 2002.
158. Aurandt J, Vikis HG, Gutkind JS, Ahn N, and Guan K-L. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. *Proc. Natl. Acad. Sci.*, **99**:12085-12090, 2002.
159. Guo YS, Cheng JZ, Jin GF, Gutkind JS, Hellmich MR, and Townsend CM Jr. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of EGF receptor. *J. Biol. Chem.*, **277**:48755-48763, 2002.

160. Leethanakul C, Knezevic V, Patel V, Amornphimoltham P, Gillespie J, Shillitoe EJ, Emkoe P, Park MH, Emmert-Buck MR, Strausberg RL, Krizman DB, and Gutkind JS. Gene Discovery in Oral Squamous Cell Carcinoma through the Head and Neck Cancer Genome Anatomy Project: Confirmation by Microarray Analysis. *Oral Oncol.*, **39**:248-258, 2003.
161. Montaner S, Sodhi A, Molinolo AA, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, and Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
162. Servitja J-M, Masgrau R, Pardo R, Sarri E, von Eichel-Streiber C, Gutkind JS, and Picatoste F. Metabotropic glutamate receptors activate phospholipase D in astrocytes through a protein kinase C-dependent and Rho-independent pathway. *Neuropharmacol.*, **44**:171-80, 2003.
163. Nishigaki K, Thompson D, Yugawa T, Rulli K, Hanson C, Cmarik J, Gutkind JS, Teramoto H, and Ruscetti S. Identification and characterization of a novel Ste-20/GCK-related kinase, PAP kinase (PAPK). *J. Biol. Chem.*, **278**:13520-13530, 2003.
164. Sriuranpong V, Park JI, Amornphimoltham P, Patel P, Nelkin BD, and Gutkind JS. EGFR-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the IL6/gp130 cytokine system. *Cancer Research*, **63**:2948-2956, 2003.
165. Teramoto H, Malek RL, Behbahani B, Castellone MD, Lee NL, and Gutkind JS. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. *Oncogene*, **22**:2689-2697, 2003.
166. Pedersen TX, Leethanakul C, Patel V, Mitola D, Lund LR, Dano K, Johnsen M, Gutkind JS, and Bugge TH. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. *Oncogene*, **22**:3964-3976, 2003.
167. Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, and Gutkind JS. Rac1 function is required for Src-induced transformation: Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. *J. Biol. Chem.*, **278**:34339-34346, 2003.
168. Monje P, Marinissen MJ, and Gutkind JS. The phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by ERK mediates the transcriptional activation of AP-1 and cellular transformation induced by PDGF. *Mol. Cell. Biol.*, **23**:7030-7043, 2003.
169. Marinissen MJ, Servitja J-M, Offermanns S, Simon MI, and Gutkind JS. The thrombin receptor PAR-1 signals through G_q and G₁₃-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. *J. Biol. Chem.*, **278**:46814-46825, 2003.
170. Iavarone C, Catania A, Marinissen MJ, Visconti R, Acunzo M, Tarantino C, Carlomagno MS, Bruni CB, Gutkind JS, and Chiariello M. PDGF controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. *J. Biol. Chem.*, **278**: 50024-50030, 2003.
171. Chikumi H, Barac A, Behbahani B, Gao Y, Teramoto H, Zheng Y, and Gutkind JS. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their *in vivo* Rho GEF activity and transforming potential. *Oncogene*, **23**:233-240, 2004.
172. Barac A, Basile J, Vazquez-Prado J, Gao Y, Zheng Y, and Gutkind JS. Direct interaction of PAK4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. *J. Biol. Chem.*, **279**:6182-6189, 2004.
173. Sodhi A, Montaner S, and Gutkind JS. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's Sarcomagenesis? *Faseb J.*, **18**:422-427, 2004.
174. Sodhi A, Montaner S, Patel V, Román JG, Li Y, Sausville EA, Sawai ET, and Gutkind JS. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. *Proc. Natl. Acad. Sci. U.S.A.*, **101**:4821-4826, 2004.

175. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, and Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01, *Clin. Cancer Research*, **10**:4029-4037, 2004.
176. Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, Kerekhanjanarong V, Supanakorn S, Supiyaphun P, Rangdaeng S, Voravud N, and Gutkind JS. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and cDNA microarrays. *Clin. Cancer Research*, **10**:4944-4958, 2004.
177. Basile JR, Barac A, Zhu T, Guan K-L, and Gutkind JS. Class IV Semaphorins promote angiogenesis by stimulating Rho-initiated pathways through Plexin-B, *Cancer Research*, **64**:5212-5224, 2004.
178. Oliva JL, Zarich N, Martínez JR, Castrillo A, Azañedo M, García-Vargas S, Juarranz A, Bosca L, Gutkind JS, and Rojas JM. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH3T3 cells but not of H-Ras. *J. Biol. Chem*, **279**:33480-33491, 2004.
179. Rosenfeldt H, Vazquez-Prado J, and Gutkind JS. P-Rex2, a novel PI-3-Kinase sensitive Rac exchange factor. *FEBS Lett.*, **572**:167-71, 2004.
180. Jeon GA, Lee J-S, Patel V, Gutkind JS, Thorgeirsson SS, Kim EC, Amornphimoltham P, and Park MH. Global gene expression profiles of human head and neck squamous carcinoma cells, *Internatl. J. Cancer*, **112**:249-258, 2004.
181. Kesavapany S, Amin N, Zheng Y-L, Nijhara R, Jaffe H, Sihag R, Gutkind JS, Takahashi S, Kulkarni A, Grant P, and Pant HC. p35/Cdk5 phosphorylation of RasGRF2 mediates Rac-dependent ERK1/2 activity, altering RasGRF2 and MAP1b distribution in neurons. *J. Neurosci.*, **24**:4421-4433, 2004.
182. Curino A, Patel V, Schnack-Nielsen B, Iskander AJ, Ensley JF, Yoo G, Holsinger C, Myers JN, Shillitoe EJ, Molinolo AA, Gutkind JS, and Bugge TH. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. *Oral Oncol.*, **40**:1026-1032, 2004.
183. Montaner S, Sodhi A, Servitja J-M, Ramsdell AK, Barac A, Sawai ET, and Gutkind JS. The small GTPase Rac1 links the Kaposi's Sarcoma Herpesvirus vGPCR to NF- κ B-mediated transcription and secretion of IL-6 and paracrine neoplasia. *Blood*, **104**:2903-2911, 2004.
184. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, and Gutkind JS. Conditional expression of K-ras in an epithelial compartment that includes the stem-cells is sufficient to promote squamous cell carcinogenesis. *Cancer Res.*, **64**:8804-8807, 2004.
185. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, and Gutkind JS. The small GTP-binding protein RhoA regulates c-Jun by a ROCK-JNK signaling axis, *Mol. Cell*, **14**:29-41, 2004.
186. Vazquez-Prado J, Miyazaki H, Castellone MD, Teramoto H, and Gutkind JS. Chimeric $G\alpha_{12}/G\alpha_{13}$ proteins reveal the structural requirements for the binding and activation of RGL-containing Rho GEFs by $G\alpha_{13}$. *J. Biol. Chem.*, **279**:54283-54290, 2004.
187. Baker H, Patel V, Molinolo AA, Myers JN, El-Naggar AK, Gutkind JS, and Hancock WS. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass-spectrometry, *Oral Oncol.*, **41**:183-199, 2005.
188. Teramoto H, Castellone MD, Malek RL, Behbahani B, Letwin N, Gutkind JS, and Lee NH. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12, *Oncogene*, **24**:489-501, 2005.
189. Brantley E, Patel V, Stinson SF, Trapani V, Hose CD, Ciolino HP, Yeh GC, Gutkind JS, Sausville EA, and Loaiza-Perez AI. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. *Anticancer Drugs*, **16**:137-143, 2005.

190. Patel V, Ramesh A, Traicoff JL, Baibakov G, Emmert-Buck MR, Gutkind JS, and Knezevic V. Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology. *Oral Oncol.*, **41**:503-508, 2005.
191. Tanos T, Marinissen MJ, Coluccio Leskow F, Hochbaum D, Martinetto H, Gutkind JS, and Coso OA. Phosphorylation of c-Fos by members of the p38 MAPK family: Role in the AP-1 response to UV. *J. Biol. Chem.*, **280**:18842-18852, 2005.
192. Yeudall WA, Miyazaki H, Ensley JF, Cardinali M, Gutkind JS, Patel V. Uncoupling of Epidermal Growth Factor-dependent proliferation and invasion in a model of squamous carcinoma progression. *Oral Oncol.*, **41**:698-708, 2005.
193. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Burke B, Murdock T, Nielsen BS, Gutkind JS, and Bugge TH. Deregulated matriptase proteolysis causes *ras*-independent multistage carcinogenesis and promotes *ras*-mediated malignant transformation. *Genes Dev.*, **19**:1934-1950, 2005.
194. Basile JR, Afkhami T, and Gutkind JS. Semaphorin 4D/Plexin-B1 Induces Endothelial Cell Migration through the Activation of PYK2, Src and the PI3K-Akt pathway. *Mol. Cell. Biol.*, **25**:6889-6898, 2005.
195. Monje P, Hernández-Losa J, Castellone MD, Lyons R, and Gutkind JS. Regulation of the transcriptional activity of c-Fos by ERK: A novel role for the prolyl-isomerase Pin1. *J. Biol. Chem.*, **280**:35081-35084, 2005.
196. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, and Gutkind JS. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, **65**:9953-9961, 2005.
197. Castellone MD, Teramoto H, Williams BO, Druey KM, and Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin- β -catenin signaling axis. *Science*, **310**:1504-1510, 2005.
198. Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, Sawai ET, and Gutkind JS. The Kaposi's sarcoma associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. *Cancer Research*, **66**:168-174, 2006.
199. Miyazaki H, Patel V, Wang H, Ensley JF, Gutkind JS, Yeudall WA. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. *Oral Oncol.*, **42**:240-256, 2006.
200. Kaur S, Castellone MD, Bedell VM, Konar M, Gutkind JS, and Ramchandran R. Robo4 signaling in endothelial cells implies attraction guidance mechanisms. *J. Biol. Chem.*, **281**: 1347-1356, 2006.
201. Raimondi RR, Vitale-Cross L, Amornphimoltham P, Gutkind JS, and Molinolo AA. Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter. *Amer. J. Pathol.*, **168**:1654-1565, 2006.
202. Kehat I, Heinridh R, Ofer B-I, Miyazaki H, Gutkind JS, and Aronheim A. Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. *Cardiovasc Res.* **70**:543-554, 2006.
203. Gu J, Wu X, Dong Q, Romeo MJ, Lin X, Gutkind JS, and Berman DM. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. *Cancer*, **106**:2716-2724, 2006.
204. Basile JR, Castilho RM, Williams VP, and Gutkind JS. Semaphorin4D provides a link between axon guidance processes and tumor-induced angiogenesis, *Proc. Natl. Acad. Sci. U.S.A.*, **103**:9017-9022, 2006.
205. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang K-Y, Schlom J, and Hodge JW. Combination chemotherapy and radiation of human squamous cell Carcinoma of the head and neck augments CTL-mediated lysis. *Clin. Cancer Research*, **12**:1897-1905, 2006.

206. Gavard J and Gutkind JS. VEGF controls endothelial cell permeability by promoting the β -arrestin-dependent endocytosis of VE-cadherin. *Nature Cell. Biol.*, **11**:1223-1234, 2006.
207. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo AA, Gutkind JS, and Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. *Cancer Cell*, **10**:133-143, 2006.
208. Squarize CH, Castilho RM, Sriuranpong V, Pinto Jr DC, and Gutkind JS. A molecular cross-talk between the NF κ B and STAT3 signaling pathways in head and neck squamous cell carcinoma. *Neoplasia*, **8**:733-746, 2006.
209. Rosenfeldt H, Castellone MD, Randazzo PA, and Gutkind JS. Rac inhibits thrombin-induced Rho activation: Evidence of a Pak-dependent GTPase crosstalk. *J. Cell Signal.*, **1**:8, 2006.
210. Tan W, Martin D, and Gutkind JS. The G α_{13} -Rho signaling axis is required for SDF-1 induced migration through CXCR4. *J. Biol. Chem.*, **281**:39542-39549, 2006.
211. Yu X, Munge B, Patel V, Jensen G, Bhirde A, Gong JD, Kim S, Gillespie J, Gutkind JS, Papadimitrakopoulos F, and Rusling JF. Carbon nanotube amplification strategies for highly sensitive immunosensing of cancer biomarkers in serum and tissue. *J. Amer. Chem. Soc.*, **128**:11199-11205, 2006.
212. Teramoto H, Miwa H, Patel V, Letwin N, Castellone MD, Imai N, Shikami M, Imamura A, Gutkind JS, Nitta M, Lee NH. Gene expression changes in a patient presenting nonleukaemic nasal granulocytic sarcoma to acute myelogenous leukaemia using 40 K cDNA microarray. *Clin. Lab. Haematol.*, **28**:262-266, 2006.
213. Sanchez VM, Crespo A, Gutkind JS, and Turjanski AG. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. *J. Phys. Chem.*, **110**:18052-18057, 2006.
214. Kesavapany S, Pareek TK, Zheng YL, Amin N, Gutkind JS, Ma W, Kulkarni AB, Grant P, and Pant HC. Neuronal nuclear organization is controlled by cyclin-dependent kinase 5 phosphorylation of Ras guanine nucleotide releasing factor-1. *Neurosignals*, **15**:157-173, 2006.
215. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, and Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. *Cancer Research*, **66**: 4279-4284, 2006.
216. Touge H, Chikumi H, Igishi T, Kurai J, Makino H, Tamura Y, Takata M, Yoneda K, Nakamoto M, Suyama H, Gutkind JS, and Shimizu E. Diverse activation states of RhoA in human lung cancer cells: Contribution of G protein coupled receptors. *Int. J. Oncol.*, **30**:709-715, 2007.
217. Basile JR, Holmbeck K, Bugge TH, and Gutkind JS. MT1-MMP controls tumor-induced angiogenesis through the release of Semaphorin 4D. *J. Biol. Chem.*, **282**:6899-6905, 2007.
218. Castilho RM, Squarize CH, Patel V, Millar SE, Zheng Y, Molinolo AA, and Gutkind JS. Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells. *Oncogene*, **26**:5078-5085, 2007.
219. Turjanski AG, Vaqué JP, and Gutkind JS. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.
220. Montero-Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind JS, Patel V, Molinolo AA, and Lanari C. Association of estrogen receptor- α and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. *Breast Cancer Res.*, **9**: R22, 2007.
221. Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Gutkind JS, and Myers JN. Molecular

- analysis of anoikis resistance in oral cavity squamous cell carcinoma. *Oral Oncol.*, **43**:440-454, 2007.
222. Patel V, Rosenfeldt H, Lyons R, Servitja J-M, Bustelo XR, Siroff M, and Gutkind JS. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR-Vav2 signaling axis involved in cell invasion. *Carcinogenesis* **28**:1145-1152, 2007.
 223. Hernandez-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernandez-Garcia R, Calderon-Salinas JV, Reyes-Cruz G, Gutkind JS, and Vazquez-Prado J. P-Rex1 links mTOR signaling to Rac activation and cell migration. *J. Biol. Chem.*, **282**:23708-23715, 2007.
 224. Honjo Y, Bian Y, Kawakami K, Molinolo AA, Longenecker G, Boppana R, Larsson J, Karlsson S, Gutkind JS, Puri RK, and Kulkarni AB. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. *Cell Cycle*, **6**:1360-1366, 2007.
 225. Liu H, Fergusson MM, Castilho RM, Liu J, Liu C, Chen J, Malide D, Rovira II, Schimel D, Kuo KJ, Gutkind JS, Hwang PM, and Finkel T. Augmented Wnt signaling in a mammalian model of accelerated aging. *Science*, **317**:803-806, 2007.
 226. Molinolo AA, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, and Gutkind JS. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clin. Cancer Research*, **13**:4964-4973, 2007.
 227. Wagenaar-Miller RA, Engelholm LH, Gavard J, Yamada SS, Gutkind JS, Behrendt N, Bugge TH, and Holmbeck K. Complementary roles of intracellular and pericellular collagen degradation pathways *in vivo*. *Mol. Cell. Biol.*, **27**:6309-6322, 2007.
 228. Kesavapany S, Patel V, Zheng YL, Pareek TK, Bjelogrić M, Albers W, Amin N, Jaffe H, Gutkind JS, Strong MJ, Grant P, and Pant HC. Inhibition of Pin1 Reduces Glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. *Mol. Biol. Cell.*, **18**:3645-3655, 2007.
 229. Martin MJ, Tanos TB, Garcia AB, Martin D, Gutkind JS, Coso OA, Marinissen MJ. The G α 12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus-G protein coupled receptor to heme oxygenase-1 expression and tumorigenesis. *J. Biol. Chem.*, **282**:34510-34524, 2007.
 230. Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes RHOA and ROK to promote the integrin-dependent activation of AKT and ERK, and endothelial cell motility. *J. Biol. Chem.*, **282**:34888-34895, 2007.
 231. Wirth A, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Örsy P, Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind S, and Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nature Medicine*, **14**:64-68, 2008.
 232. Liu S, Wang H, Currie BM, Molinolo AA, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, and Leppla SH. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. *J. Biol. Chem.*, **283**:529-540, 2008.
 233. Gavard J, Patel V, and Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. *Dev. Cell*, **14**:25-36, 2008.
 234. Wolf J, Palmby TR, Gavard J, Williams BO, and Gutkind JS. Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt Signaling through LRP6. *FEBS Lett.*, **582**:255-261, 2008.
 235. Martin D, Galisteo R, Ji Y, Montaner S, and Gutkind JS. A NF- κ B gene expression signature contributes to Kaposi's Sarcoma Virus vGPCR-induced direct and paracrine neoplasia. *Oncogene*, **27**:1844-1852, 2008.

236. Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramírez-Castillejo C, Callejas-Valera JL, Arriaga A, Fernandez Aranburo A, Ramón y Cajal S, Gutkind JS, and Sánchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin-based therapy. *Int. J. Cancer*, **122**: 289-297, 2008.
237. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, and Gutkind JS. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. *Cancer Research*, **68**:1144-1153, 2008.
238. Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted JC, Krizman DB, Veenstra TD, Gutkind JS. Proteomic analysis of laser-captured paraffin embedded tissues: A molecular portrait of head and neck cancer progression. *Clin. Cancer Research*, **14**:1002-1014, 2008.
239. Gómez-Román JJ, Garay GO, Saenz P, Escuredo K, Ibayondo CS, Junquera C, Gutkind JS, Belaustegui-Trías C, Simón L, Martínez A, Fernández-Luna JL, Val-Bernal JF. Plexin B1 is downregulated in renal neoplasms and modulates cell growth. *Trans. Res.*, **151**:134-140, 2008.
240. Zhou G, Xie T-X, Zhao M, Jasser SA, Younes MN, Sano D, Lin J, Kupferman ME, Santillan AA, Patel V, Gutkind JS, El-Naggar AK, Emberley ED, Watson PH, Matsuzawa S-I, Reed JC, and Myers JN. Reciprocal negative regulation between S100A7/psoriasin and β -catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. *Oncogene*, **25**:3527-3538, 2008.
241. Sausville J, Molinolo AA, Cheng X, Frampton J, Takebe N, Gutkind JS, and Feldman RA. RCAS/SCL-TVA animal model allows targeted delivery of PyMT oncogene to vascular endothelial progenitors in vivo, and results in rapid hemangioma. *Clin. Cancer Research*, **14**:3948-3955, 2008.
242. Turjanski AG, Gutkind JS, Best RB, and Hummer G. Binding-induced folding of a natively unstructured transcription factor. *PLoS Computational Biology*, 4:e1000060.
243. Lyons JG, Patel V, Roue N, Fok SY, Soon LL, Halliday JM, and Gutkind JS. Snail expression in oral keratinocytes up-regulates pro-inflammatory mediators and inhibits terminal differentiation. *Cancer Research*, **68**:4525-4530, 2008.
244. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. *Oncogene* **27**:5348-5353, 2008.
245. Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, Patel V, Gutkind JS, Young M, Gronthos S, Le A, Wang CY, Chen W, and Shi S. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. *PLoS ONE.*, **3**:e2615, 2008.
246. Squarize CH, Castilho RM, and Gutkind JS. Chemoprevention of experimental Cowden's Disease by mTOR inhibition with rapamycin. *Cancer Research*, **68**:7066-7072.
247. Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, and Yeudall WA. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. *Mol. Cancer. Ther.* **7**:2894-2903, 2008.
248. Gavard J and Gutkind JS. Protein Kinase C-related Kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from $G\alpha_{12/13}$ and $G\alpha_{11/q}$. *J. Biol. Chem.*, **283**:29888-29896, 2008.
249. Schneider A, Younis RH, and Gutkind JS. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. *Neoplasia* **10**:1295-1302, 2008.

250. Tan W, Palmby TR, Gavard J, Amornphimoltham P, Zheng Y, and Gutkind JS. An essential role for Rac1 in endothelial cell function and vascular development. *FASEB J.*, **22**:1829-1838, 2008.
251. Amornphimoltham A, Leelahavanichkul K, Molinolo AA, Patel V, and Gutkind JS. Inhibition of mTOR by rapamycin causes the regression of carcinogen-induced skin tumor lesions. *Clin. Cancer Research*, **14**:8094-8101, 2008.
252. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, and Gutkind JS. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. *Cancer Prevention Research*, **2**:27-36, 2009.
253. Wang H, Patel V, Miyazaki H, Gutkind JS, and Yeudall WA. Role for EPS8 in squamous carcinogenesis. *Carcinogenesis*, **30**:165-174, 2009.
254. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, and Rusling JF. Targeted killing of cancer cells *in vivo* and *in vitro* with EGF-directed carbon nanotube-based drug delivery. *Am. Chem. Soc. Nano*, **3**:307-316, 2009.
255. Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS, and Santoro M. The β -catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. *Cancer Res.* **69**:1867-1876, 2009.
256. Munge BS, Krause CE, Malhotra R, Patel V, Gutkind JS, and Rusling JF. Electrochemical immunosensors for interleukin-6. Comparison of carbon nanotube forest and gold nanoparticle platforms. *Electrochem. Commun.* **11**:1009-1012, 2009.
257. Mani V, Chikkaveeraiah BV, Patel V, Gutkind JS, Rusling JF. Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. *Am. Chem. Soc. Nano*, **3**:585-594, 2009.
258. Gavard J, Hou X, Qu Y, Masedunskas A, Martin D, Weigert R, Li X, and Gutkind JS. A Role for a CXCR2/PI3K signaling axis in acute and chronic vascular permeability. *Mol. Cell Biol.*, **29**:2469-2480, 2009.
259. Sako K, Fukuhara S, Minami T, Hamakubo T, Song H, Kodama T, Fukamizu A, Gutkind JS, Koh GY, and Mochizuki N. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. *J. Biol. Chem*, **284**:5592-5601, 2009.
260. Cheong SC, Chandramouli GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathan R, Prime SS, Teo SH, Patel V, and Gutkind JS. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. *Oral Oncol.*, **45**:712-719, 2009.
261. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates VEGF expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF κ B through the CBM (Carma3/Bcl10/Malt1) complex. *J. Biol. Chem.*, **284**:6038-6042, 2009.
262. Turjanski AG, Hummer G, and Gutkind JS. How mitogen-activated protein kinases recognize and phosphorylate their targets: A QM/MM study. *J. Amer. Chem. Soc.*, **131**:6141-6148, 2009.
263. Raimondi AR, Molinolo AA, and Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. *Cancer Research*, **69**:4159-4166, 2009.
264. Guzmán-Hernández ML, Vázquez-Macías A, Carretero-Ortega J, Hernández-García R, García-Regalado A, Hernández-Negrete I, Reyes-Cruz G, Gutkind JS, Vázquez-Prado J. Differential inhibitor of G β γ -signaling to AKT and ERK derived from Phosducin-like protein: Effect on sphingosine-1-phosphate-induced endothelial cell migration and *in vitro* angiogenesis. *J. Biol. Chem.*, **284**:18334-18346, 2009.

265. Bian Y, Terse A, Du J, Hall B, Molinolo AA, Zhang P, Chen W, Flanders KC, Gutkind JS, Wakefield LM, and Kulkarni AB. Progressive tumor formation in mice with conditional deletion of TGF- β signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. *Cancer Research*, **69**:5918-5926, 2009.
266. Bhirde AA, Sousa AA, Patel V, Azari AA, Gutkind JS, Leapman RD and Rusling JF. Single-molecule imaging and quantitation of a platinum-based drug attached to single-wall carbon nanotubes. *Nanomedicine* **4**:763-772, 2009.
267. Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF. Single-wall carbon nanotube forest arrays for immunochemical measurement of four protein biomarkers for prostate cancer. *Anal Chem* **81**:9129-9134, 2009.
268. Castilho RM, Squarize CH, Chodosh LA, Williams BO, and Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
269. Gonzalez-Pardo V, Martin D, Gutkind JS., Verstuyf A, Bouillon R, de Boland AR, and Boland RL. 1 α ,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. *Endocrinology*, **151**:23-31, 2010.
270. Malhotra R, Patel V, Vaqu  JP, Gutkind JS, and Rusling JF. Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. *Anal Chem*. **82**:3118-3123, 2010.
271. Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, and Gutkind JS. Semaphorin 3E initiates antiangiogenic signaling through Plexin-D1 by regulating Arf6 and R-Ras. *Mol. Cell Biol.*, **30**:3086-98, 2010.
272. Wang H, Teh MT, Ji Y, Patel V, Firouzabadian S, Patel AA, Gutkind JS, and Yeudall WA. EPS8 upregulates FOXM1 expression, enhancing cell growth and motility. *Carcinogenesis*, **31**:1132-41, 2010.
273. Castilho RM, Squarize CH, Leelahavanichkul K, Zheng Y, Bugge T, and Gutkind JS. Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. *PLoS ONE*, **5**: e10503, 2010.
274. Squarize CH, Castilho RM, Bugge T, and Gutkind JS. Accelerated wound healing by mTOR activation in genetically defined mouse models. *PLoS ONE*, **5**: e10643, 2010.
275. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, and Chiorini JA. Epidermal growth factor receptor is a receptor for adeno-associated virus serotype 6. *Nature Medicine*, **16**:662-664, 2010.
276. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, Santos-Pinto DD Jr, and Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. *Oral Oncol.*, **46**:880-887, 2010.
277. Hou X, Kumar A, Lee C, Wang B, Arjunan P, Dong L, Maminishkis A, Tang Z, Li Y, Zhang F, Zhang S-Z, Wardega P, Chakrabarty S, Liu B, Wu Z, Colosi P, Fariss RN, Lennartsson J, Nussenblatt R, Gutkind JS, Cao Y, and Li X. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. *Proc. Natl. Acad. Sci. U.S.A.*, **107**:12216-12221, 2010.
278. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, Gutkind JS, Rivadulla MG, Curino AC. The expression of sphingosine kinase-1 in head and neck carcinoma. *Cells Tissues Organs*, **192**:314-324, 2010.
279. Knox SM, Lombaert MA, Reed X, Vitale-Cross L, Gutkind JS and Hoffman MP. Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis. *Science*, **329**:1645-1647, 2010.
280. Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD, Gutkind JS, and Rusling JF. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. *Nanomedicine*, **5**:1535-1546, 2010.

281. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, and Kazanietz MG. Identification of the Rac-GEF P-REX1 as an essential mediator of ErbB signaling in breast cancer. *Mol. Cell*, **40**:877-892, 2010.
282. Suyarnsestakorn C, Thanasupawat T, Leelahavanichkul K, Gutkind JS, and Mutirangura A. ATM nuclear localization in head and neck cancer cells is PPP2R2B-dependent. *Asian Biomedicine*, **4**: 3, 2010.
283. Dwyer J, Le Guelte A, Sumbal M, Carlotti A, Douguet L, Gutkind JS, Grange PA, Dupin N, and Gavard J. The human herpes virus 8 G-protein coupled receptor signaling pathway is linked to the loss of vascular integrity in human Kaposi Sarcoma. *Oncogene*, **30**:190-200, 2011.
284. Cervenka I, Wolf J, Masek J, Krejci P, Wilcox WR, Kozubík A, Schulte G, Gutkind* JS, and Bryja* V. Mitogen-activated protein kinases promote WNT/ β -catenin signaling via phosphorylation of LRP6. *Mol. Cell. Biol.* **31**: 179-189, 2011.
285. Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo AA, Perou CM, Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res. Treat.* **129**:49-67, 2011.
286. Bottino MC, Cerliani JP, Rojas P, Giulianelli S, Soldati R, Mondillo C, Gorostiaga MA, Pignataro OP, Calvo JC, Gutkind JS, Amornphimoltham P, Molinolo AA, Lüthy IA, and Lanari C. Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. *Breast Cancer Res. Treat.*, **126**:621-636, 2011.
287. Munge BS, Coffey AL, Doucette JM, Somba BK, Malhotra R, Patel V, Gutkind JS, and Rusling JF. Nanostructured Immunosensor for Attomolar Detection of Cancer Biomarker Interleukin-8 Using Massively Labeled Superparamagnetic Particles. *Angew Chem Int. Ed. Engl.*, **50**:7915-7918, 2011.
288. Chikkaveeraiah BV, Mani V, Patel V, Gutkind JS, and Rusling JF. Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. *Biosens. Bioelectron.*, **26**:4477-4483, 2011.
289. Maruyama T, Li J, Vaque JP, Konkel J, Wang W, Zhang B, Zhang P, Zamarron B, Wu Y, Zhuang Y, Gutkind JS, and Chen WJ. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. *Nature Immunol.*, **12**: 86-95, 2011.
290. Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, Gutkind JS, and Bugge TH. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. *Oncogene*, **30**: 2003-2016, 2011.
291. Sansing HA, Sarkeshik A, Yates JR, Patel V, Gutkind JS, Yamada KM, and Berrier AL. Integrin $\alpha\beta 1$, $\alpha(v)\beta$, $\alpha(6)\beta$ effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. *Biochem. Biophys. Res. Commun.*, **406**: 171-176, 2011.
292. Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI, Martins R, Zeitlin E, Lamb CA, and Lanari C. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. *Cancer Res.* **71**:3720-3731, 2011.
293. Fujita M, Cha YR, Pham VN, Sakurai A, Roman BL, Gutkind JS, Weinstein BM. Assembly and patterning of the vascular network of the vertebrate hindbrain. *Development*, **138**:1705-1715, 2011.
294. Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS., Molinolo AA, Perou CM, Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res Treat.*, **129**:49-67, 2011.

295. Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD, Gutkind JS, Lee S, Chen X. Combining portable Raman probes with nanotubes for theranostic applications. *Theranostics*, **1**:310-321, 2011.
296. Sakurai A, Jian X, Lee CJ, Manavski Y, Chavakis E, Donaldson J, Randazzo PA, and Gutkind JS. PIP5 kinase and GEP100/Brag2 mediate anti-angiogenic signaling by Semaphorin 3E-Plexin-D1 through Arf6. *J. Biol. Chem.*, **286**:34335-343345, 2011.
297. Martin D, Galisteo R, Molinolo AA, Wetzker R, Hirsch E, and Gutkind JS. PI3Ky mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell*, **19**: 805-813, 2011.
298. Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, and Gutkind JS. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**:ra60, 2011.
299. Patel V, Marsh CA, Dorsam RT, Masedunskas A, Amornphimoltham P, Nathan CO, Singh B, Weigert R, Molinolo AA, and Gutkind JS. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.
300. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, and Kulkarni AB. Loss of TGF- β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. *Oncogene*, **31**:3322-3332, 2012.
301. Berendsen AD, Fisher LW, Kilts T, Owens RT, Robey PG, Gutkind JS, and Young MF. Modulation of Canonical Wnt Signaling by the ECM Component, Biglycan. *Proc. Natl. Acad. Sci., USA*, **108**:17022-17027, 2011.
302. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, Uyemura SA, Tajara EH, Gutkind JS, and Curti C. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. *Mol. Cell Biochem.*, **363**:65-74, 2012.
303. Degese MS, Mendizabal J, Gandini NA, Gutkind JS., Molinolo AA, Curino AC, Coso OM, and Facchinetti MM. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. *Lung Cancer*, **77**:168-175, 2012.
304. Giulianelli S, Vaqué JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA, Gutkind JS, and Lanari C. Estrogen receptors alpha mediate progestin induced mammary tumor growth interacting with progesterone receptors at the Cyclin D1/MYC promoters. *Cancer Research*, **72**:2416-2427, 2012.
305. Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, and Gutkind JS. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. *Clin. Cancer Research*, **18**:2558-2568, 2012.
306. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel P, Chen W, Schneider A, and Gutkind JS. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. *Cancer Prevention Research*, **5**:562-573, 2012.
307. Krejci P, Aklia A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, Mikolka P, Pospisilova T, Spoustova T, Weis MA, Paznekas W, Wolf JH, Gutkind JS., Wilcox WR, Kozubik A, Jabs EW, Bryja V, and Balek L. Receptor tyrosine kinases activate canonical WNT/ β -catenin signaling via MAP kinase/LRP6 pathway and direct β -catenin phosphorylation. *PLoS One.*, **7**:e35826, 2012.
308. Pan W, Pham VN, Stratman AN, Castranova D, Kamei M, Kidd KR, Lo BD, Shaw KM, Torres-Vazquez J, Mikelis CM, Gutkind JS, Davis GE, Weinstein BM. CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis. *Blood*, **120**: 489-498, 2012.

309. Bhirde AA, Kapoor A, Liu G, Iglesias-Bartolome R, Jin A, Zhang G, Xing R, Lee S, Leapman RD, Gutkind JS, Chen X. Nuclear Mapping of Nanodrug Delivery Systems in Dynamic Cellular Environments. *ACS Nano*, **6**:4966-4972, 2012.
310. Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr, Santoro M. Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases. *Clin. Cancer Research*, **84**: 6249-6255, 2012.
311. Malhotra R, Patel V, Chikkaveeraiah BV, Munge BS, Cheong SC, Zain RB, Abraham MT, Dey DK, Gutkind JS, and Rusling JF. Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. *Anal. Chem.*, **84**:6249-6255, 2012.
312. Gandini NA, Fermento ME, Salomón DG, Blasco J, Patel V, Gutkind JS, Molinolo AA, Facchinetti MM, Curino AC. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. *Exp. Mol. Pathol.*, **93**:237-245, 2012.
313. Dutzan N, Vernal R, Vaque JP, García-Sesnich J, Hernandez M, Abusleme L, Dezerega A, Gutkind JS, and Gamonal J. Interleukin-21 Expression and its Association with Pro-Inflammatory Cytokines in Untreated Chronic Periodontitis Patients. *J. Periodontol.*, **83**: 948-954, 2012.
314. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, and Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. *Clin. Cancer Research* **18**:5304-5313, 2012.
315. Szabo R, Sales KU, Kosa P, Shylo N, Godiksen S, Friis S, Hansen K, Gutkind JS, Vogel LK, Hummler E, Camerer E, and Bugge TH. Reduced prostatic (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation. *PLoS Genetics*, **8**: e1002937, 2012.
316. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, and Gutkind JS. mTOR inhibition protects from epithelial stem cell senescence and radiation-induced mucositis. *Cell Stem Cell*, **11**:401-414, 2012.
317. Almeida LO, Goto RN, Pestana CR, Uyemura SA, Gutkind JS, Curti C, Leopoldino AM. SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates. *FEBS J.*, **279**:4615-4628, 2012.
318. Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai Q, Klein-Szanto AJ, Gutkind JS, Hoefflich KP, and Chernoff J. p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. *Cancer Research*, **72**:5966-5975, 2012.
319. Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, Munasinghe JP, Patel V, Gutkind JS, Mitchell JB, Krishna MC. Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin. *PLoS One*, **7**(11):e49456, 2012.
320. Amornphimoltham P, Rechache K, Thompson J, Masedunskas A, Leelahavanichkul K, Patel V, Molinolo A, Gutkind JS, and Weigert R. Rab25 regulates invasion and metastasis in head and neck cancer. *Clin. Cancer Research*, **19**:1375-1388, 2013.
321. Patel V, Martin D, Malhotra R, Marsh CA, Doçi CL, Veenstra TD, Nathan CA, Sinha UK, Singh B, Molinolo AA, Rusling JF, and Gutkind JS. DSG3 as a biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using nanostructured immunoarrays. *Oral Oncology*, **49**:93-101, 2013.
322. Hoebe A, Martin D, Clement PM, and Gutkind JS. Role of GAB1 in EGFR-induced signaling in head and neck squamous cell carcinoma. *Internatl. J. Cancer*, **132**:1042-1050, 2013.

323. Xie-Zukauskas H, Das J, Short BL, Gutkind JS, and Ray PE. Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways. *Vascul. Pharmacol.*, **58**:313-318, 2013.
324. Vaqué JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A, Seeger MA, Ksander BR, Teramoto H, Gutkind JS. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing GPCR-initiated mitogenic signals. *Molecular Cell*, **49**:94-108, 2013.
325. Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, and Zhang B. TRAIL induces apoptosis in oral squamous carcinoma cells - a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. *Oncotarget*, **4**:206-217, 2013.
326. Alonso N, Fernandez N, Notcovich C, Monczor F, Simaan M, Baldi A, Gutkind JS, Davio C, and Shayo C. Cross-Desensitization and Co-internalization of H1 and H2 Histamine Receptors Reveal New Insights into Histamine Signal Integration. *Mol. Pharmacol.*, **83**:1087-1098, 2013.
327. Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, Martin D, Yagi H, Fukuhara S, Chikumi H, Galisteo R, Mukouyama Y, Bugge TH, and Gutkind JS. PDZ-RhoGEF and LARG are essential for embryo development, and provide a link between thrombin and LPA receptors and Rho activation. *J. Biol. Chem.*, **288**:12232-12243, 2013.
328. Squarize CH, Castilho RM, Abrahao AC, Molinolo AA, Lingen MW, and Gutkind JS. PTEN deficiency contributes to the development and progression of head and neck cancer. *Neoplasia*, **15**:461-471, 2013.
329. Han G, Bian L, Li F, Cotrim A, Wang D, Lu JB, Deng Y, Bird G, Sowers A, Mitchell J, Gutkind JS, Zhao R, Raben D, Dijke PT, Refaeli Y, Zhang Q, and Wang XJ. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. *Nature Medicine*, **19**:421-428, 2013.
330. Patel SJ, Molinolo AA, Gutkind JS, and Crawford NP. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. *PLoS One.*, **8**: e61848, 2013.
331. Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, and Lee JH. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR Inhibition. *Neoplasia*, **15**:620-630, 2013.
332. Wang Y, Lu X, Zhu L, Shen Y, Chengedza S, Feng H, Wang L, Jung JU, Gutkind JS, and Feng P. The IKK ϵ kinase is crucial for viral G Protein-coupled receptor tumorigenesis, *Proc. Natl. Acad. Sci. U.S.A.*, **110**:11139-11144, 2013.
333. Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J. Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. *PLoS One*, **8**: e77731, 2013.
334. Artamonov MV, Momotani K, Stevenson A, Trentham DR, Derewenda U, Derewenda ZS, Read PW, Gutkind JS, and Somlyo AV. Agonist-induced Ca²⁺-sensitization in smooth muscle: redundancy of RhoGEFs and response kinetics; a caged compound study. *J. Biol. Chem.*, **288**:34030-34040, 2013.
335. Krause CE, Otieno BA, Latus A, Faria RC, Patel V, Gutkind JS, and Rusling JF. Rapid microfluidic immunoassays of cancer biomarker proteins using disposable inkjet-printed gold nanoparticle arrays. *ChemistryOpen*, **2**:141-145, 2013.
336. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel T, Seshagiri S, and Gutkind JS. The emerging mutational landscape of G-proteins and G-protein-coupled receptors in cancer. (Analysis) *Nature Rev. Cancer*, **13**:412-424, 2013.

337. Martin D, Nguyen Q, Molinolo AA, and Gutkind JS. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. *Oncogene*, **33**:2405-2412, 2014.
338. Abrigo M, Alvarez R, Paparella ML, Calb D, Bal de Kier Joffé E, Gutkind JS, Raimondi AR. Impairing squamous differentiation by Klf4 deletion is sufficient to initiate tongue carcinoma development upon K-Ras activation in mice. *Carcinogenesis*, **35**:662-669, 2014.
339. Qi S, O'Hayre M, Gutkind JS, and Hurley JH. Structural and Biochemical Basis for Ubiquitin Ligase Recruitment by Arrestin-Related Domain-Containing Protein-3 (ARRDC3). *J. Biol. Chem.* **289**:4743-4752, 2014.
340. Nudelman Z, Friedman M, Barasch D, Nemirovski A, Findler M, Pikovsky A, Gutkind JS, Czerninski R. Levels of sirolimus in saliva and blood following mouthwash application. *Oral Dis.*, **20**:768-772, 2014.
341. Manavski Y, Carmona G, Bennewitz K, Tang Z, Zhang F, Sakurai A, Zeiher AM, Gutkind JS, Li X, Kroll J, Dimmeler S, and Chavakis E. Brag2 differentially regulates β 1- and β 3-integrin-dependent adhesion in endothelial cells and is involved in developmental and pathological angiogenesis. *Basic. Res. Cardiol.*, **109**:404, 2014.
342. Sales KU, Friis S, Konkel JE, Godiksen S, Hatakeyama M, Hansen KK, Rogatto SR, Szabo R, Vogel LK, Chen W, Gutkind JS, and Bugge TH. Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. *Oncogene*, **34**:346-356, 2014.
343. Castellone MD, Laukkanen MO, Teramoto H, Bellelli R, Alì G, Fontanini G, Santoro M, and Gutkind JS. Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma. *Oncogene*, **34**:1679-1687, 2014.
344. Leelahavanichkul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S, and Gutkind JS. A Role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. *Mol. Oncology*, **8**:105-118, 2014.
345. Adi AH, Alturkmani H, Spock T, Yohannes PW, Wargo S, Szabo E, Gutkind JS, Van Waes C. Dermatomyositis paraneoplastic syndrome prior to symptomatic tonsillar squamous cell carcinoma: A case report. *Head Neck*. **37**: E1-3, 2014.
346. Bhirde AA, Chikkaveeraiah BV, Srivatsan A, Niu G, Jin AJ, Kapoor A, Wang Z, Patel S, Patel V, Gorbach AM, Leapman RD, Gutkind JS, Hight Walker AR, Chen X. Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance. *ACS Nano.*, **8**:4177-4189, 2014.
347. González FE, Ortiz C, Reyes M, Dutzan N, Patel V, Pereda C, Gleisner MA, López MN, Gutkind JS, and Salazar-Onfray F. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells. *Immunology*, **142**:396-405, 2014.
348. Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, Gutkind JS, Curti C, Leopoldino AM. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. *Mol. Cancer*, **13**:32 (1-13), 2014.
349. Xie X, Colberg-Poley AM, Das JR, Li J, Zhang A, Tang P, Jerebtsova M, Gutkind JS, Ray PE. The Basic Domain of HIV-Tat Transactivating Protein Is Essential for Its Targeting to Lipid Rafts and Regulating Fibroblast Growth Factor-2 Signaling in Podocytes Isolated from Children with HIV-1-Associated Nephropathy. *J. Am. Soc. Nephrol.*, **25**: 1800-1813, 2014.
350. Homolya L, Fu D, Sengupta P, Jarnik M, Gillet JP, Vitale-Cross L, Gutkind JS, Lippincott-Schwartz J, Arias IM. LKB1/AMPK and PKA control ABCB11 trafficking and polarization in hepatocytes. *PLoS One*, **9**: e91921, 2014.

351. Prickett TD, Zerlanko BJ, Hill VK, Gartner JJ, Qutob N, Jiang J, Simaan M, Wunderlich J, Gutkind JS, Rosenberg SA, and Samuels Y. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. *J. Invest. Dermatol.*, **134**:2390-2398, 2014.
352. Smith JP, Cooper TK, McGovern CO, Gillus EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, and Matters GL. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. *Pancreas*, **43**(7):1050-9, 2014.
353. Feng K, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino M, Sodhi A, Chen Q, and Gutkind JS. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. *Cancer Cell*, **25**:831-845, 2014.
354. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, and Gutkind JS. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring *PIK3CA* and *RAS* mutations. *J. Natl. Cancer Inst.*, **106**(9) pii: dju215
355. Liu G, Yu FX, Kim YC, Meng Z, Naipauer J, Looney DJ, Liu X, Gutkind JS, Mesri EA, and Guan KL. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. *Oncogene*, **34**:3536-3546, 2014.
356. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, and Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. *Pigment Cell Melanoma Res.* **7**:10696-10709 2014.
357. Qi S, O'Hayre M, Gutkind JS, and Hurley JH. Insights into β 2-Adrenergic Receptor Binding from Structures of the N-Terminal Lobe of ARRDC3. *Protein Science*, **23**:1708-1716, 2014.
358. Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, and Gutkind JS. The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. *Oncotarget* **5**:8906-8923, 2014.
359. Gan C.P., Patel V., Mikelis C.M., Zain R.B., Molinolo A.A., Abraham M.T., Teo S.H., Abdul Rahman ZA, Gutkind JS, Cheong SC. Heterotrimeric G-protein α -12 ($G\alpha 12$). subunit promotes oral cancer metastasis. *Oncotarget* **5**:9626-9640, 2014.
360. Williams KA, Lee M, Hu Y, Andreas J, Patel SJ, Zhang S, Chines P, Elkahouloun A, Chandrasekharappa S, Gutkind JS, Molinolo AA, Crawford NP. A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes. *PLoS Genet.* **10**: e1004809, 2014.
361. Dillenburg-Pilla P, Patel V, Mikelis CM, Zárate-Bladés CR, Doçi CL, Amornphimoltham P, Wang Z, Martin D, Leelahavanichkul K, Dorsam RT, Masedunskas A, Weigert R, Molinolo AA, Gutkind JS. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/G α i/mTORC1 axis. *FASEB J.*, **29**:1056-1068, 2015.
362. Wang Z, Wang Y, Wang Z, Gutkind JS, Wang Z, Wang F, Lu J, Niu G, Teng G, Chen X. Engineered Mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. *Stem Cells*, **33**:456-467, 2015.
363. Deshapriya IK, Stromer BS, Pattammattel A, Kim CS, Iglesias-Bartolome R, Gonzalez-Fajardo L, Patel V, Gutkind JS, Lu X, Kumar CV. Fluorescent, bioactive protein nanoparticles (prodots) for rapid, improved cellular uptake. *Bioconjug Chem.* **26**:396-404, 2015.
364. Nudelman Z, Findler M, Barasch D, Nemirovski A, Pikovsky A, Kirmayer D, Basheer M, Gutkind JS, Friedman M, and Czerninski R. Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. *Cancer Chemother Pharmacol.*, **75**:969-74, 2015.
365. Degese MS, Tanos T, Naipauer J, Gingerich T, Chiappe D, Echeverria P, LaMarre J, Gutkind JS, and Coso OA. An interplay between the p38 MAPK pathway and AUBPs

- regulate *c-fos* mRNA stability during mitogenic stimulation. *Biochem J.*, **467**:77-90, 2015.
366. Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William Jr WN, Seethala RR, Ferris R, and Gutkind JS. Prevention of tumor growth driven by *PIK3CA* and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. *Cancer Prevention Res. (AACR)*, **8**:197-207, 2015.
367. Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, Masedunskas A, Weigert R, Chavakis T, Adams R, Offermanns S, Mochizuki N, Zheng Y, and Gutkind JS. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. *Nature Commun.*, **6**:6725, 2015.
368. Doçi CL, Mikelis CM, Lionakis MS, Molinolo AA, and Gutkind JS. Genetic identification of SEMA3F as an anti-lymphangiogenic metastasis suppressor gene in head and neck squamous carcinoma. *Cancer Research*, **75**:2937-2948, 2015.
369. Wang Z, Wang Y, Wang Z, Zhao J, Gutkind JS, Srivatsan A, Zhang G, Liao HS, Fu X, Jin A, Tong X, Niu G, and Chen X. Polymeric nanovehicle regulated spatiotemporal real-time imaging of the differentiation dynamics of transplanted neural stem cells after traumatic brain injury. *ACS Nano.*, **9**:6683-6692, 2015.
370. House CD, Wang BD, Ceniccola K, Williams R, Simaan M, Olender J, Patel V, Baptista-Hon DT, Annunziata CM, Gutkind JS, Hales TG, and Lee NH. Voltage-gated Na⁺ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion via Persistent MAPK Signaling. *Sci. Rep.*, **5**:11541, 2015.
371. Iglesias-Bartolome R, Torres D, Marone R, Feng X, Martin D, Simaan M, Chen M, Weinstein LS, Taylor SS, Molinolo AA, and Gutkind JS. Inactivation of a Gαs-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nature Cell Biol.*, **17**:793-803, 2015.
372. O'Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki J, Zheng Y, Lionakis MS, Molinolo AA, and Gutkind JS. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells. *Oncogene*, **35**:3771-80, 2015.
373. Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB, Sun ZJ. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. *Oncotarget*, **6**:42067-42080, 2015.
374. Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, and Sánchez Prieto R. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. *Oncotarget*, **6**:44095-44107, 2015.
375. William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, and Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. *JAMA Oncol.*, **2**:209-216, 2016.
376. Wang F, Yang K, Wang Z, Ma Y, Gutkind JS, Hida N, Niu G, and Tian J. Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter. *Nanoscale*, **8**:3991-4000, 2016.
377. Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, and Gutkind JS. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA⁺ oral cancers. *Oncotarget*, **7**:10696-10709, 2016.

378. Nohata N, Uchida Y, Stratman AN, Adams RH, Zheng Y, Weinstein BM, Mukouyama YS, Gutkind JS. Temporal-specific roles of Rac1 during vascular development and retinal angiogenesis. *Dev Biol.* **411**:183-194, 2016.
379. Zhu Z, Pang B, Iglesias-Bartolome R, Wu X, Hu L, Zhang C, Wang J, Gutkind JS, and Wang S. Prevention of irradiation-induced salivary hypofunction by rapamycin in swine parotid glands. *Oncotarget*, **7**:20271-20281, 2016.
380. Das JR, Gutkind JS, and Ray PE. Circulating Fibroblast Growth Factor-2, HIV-Tat, and Vascular Endothelial Cell Growth Factor-A in HIV-Infected Children with Renal Disease Activate Rho-A and Src in Cultured Renal Endothelial Cells. *PLoS One*, **11**: e0153837, 2016.
381. Hidayatullah Fadlullah MZ, Chiang IK, Dionne KR, Yee PS, Gan CP, Sam KK, Tiong KH, Wen Ng AK, Martin D, Lim KP, Kallarakkal TG, Wan Mustafa WM, Lau SH, Abraham MT, Zain RB, Abdul Rahman ZA, Molinolo AA, Patel V, Gutkind JS, Tan AC, and Cheong SC. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. *Oncotarget* **7**:27802-27818, 2016.
382. Alonso N, Diaz Nebreda A, Monczor F, Gutkind JS, Davio C, Fernandez N, Shayo C. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells. *Biochim. Biophys. Acta.* **1860**:1998-2007, 2016.
383. Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, and Argiris A. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. *Head Neck*, **38**:1759-1764, 2016.
384. Zhao ZL, Zhang L, Huang CF, Ma SR, Bu LL, Liu JF, Yu GT, Liu B, Gutkind JS, Kulkarni AB, Zhang WF, and Sun ZJ. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. *Sci. Rep.* **25**:24704. doi: 10.1038/srep24704, 2016.
385. Arthofer E, Hot B, Petersen J, Strakova K, Jager S, Grundmann M, Kostenis E, Gutkind JS, Schulte G. WNT stimulation dissociates a Frizzled 4 inactive state complex with Gα12/13. *Mol Pharmacol.* **90**:447-459, 2016.
386. Nohata N, Abba MC, Gutkind JS. Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection. *Oral Oncol.* **59**:58-66, 2016.
387. Porat-Shliom N, Tietgens AJ, Van Itallie CM, Vitale-Cross L, Jarnik M, Harding OJ, Anderson JM, Gutkind JS, Weigert R, Arias IM. Liver kinase B1 regulates hepatocellular tight junction distribution and function in vivo. *Hepatology*, **64**:1317-1329, 2016.
388. Deng WW, Mao L, Yu GT, Bu LL, Ma SR, Liu B, Gutkind JS, Kulkarni AB, Zhang WF, Sun ZJ. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. *Oncoimmunology.* **5**(11): e1239005, 2016
389. Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, Molinolo AA, Gutkind JS. mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model. *Carcinogenesis.* **37**:1014-1025, 2016.
390. Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Diez-Alarcia R, Juanes-García A, García-Taboada E, Hernando-Llorente R, Soriano J, Hamann S, Wenners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Urigüen L, Gutkind JS, Guzmán M, Pérez-Gómez E, and Sánchez C. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. *Oncotarget*, **7**:47565-47575, 2016.
391. Sakurai A, Doçi CL, and Gutkind JS. Using Heterologous COS-7 Cells to Identify Semaphorin-Signaling Components. *Methods Mol. Biol.* **493**:163-170, 2017.
392. Carter H, Marty R, Hofree M, Gross A, Jensen J, Fisch KM, Wu X, DeBoever C, Van

- Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman SM, Yeo G, Gutkind JS, Ideker T. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. *Cancer Discovery*. **7**:410-423, 2017
393. Gaykalova DA, Zizkova V, Guo T, Tiscareno I, Wei Y, Vataapalli R, Hennessey PT, Ahn J, Danilova L, Khan Z, Bishop JA, Gutkind JS, Koch WM, Westra WH, Fertig EJ, Ochs MF, Califano JA. Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC. *Oncotarget*, **8**:15349-15363, 2017.
 394. Doçi CL, Mikelis CM, Callejas-Valera JL, Hansen KH, Molinolo AA, Inoue A, Offermanns S, and Gutkind JS. Epidermal loss of Gαq confers a migratory and differentiation defect in keratinocytes. *PLOS One*, **12**: e0173692, 2017.
 395. Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, Pascual-Serra R, Ortega-Muelas M, Roche O, Marcos P, Garcia-Gil E, Fernandez-Aroca DM, Ramón Y Cajal S, Gutkind JS, Sanchez-Prieto R. E1a is an exogenous in vivo tumour suppressor. *Cancer Lett.* **399**:74-81, 2017.
 396. O'Hayre M, Eichel K, Avino S, Zhao X, Steffen DJ, Feng X, Kawakami K, Aoki J, Messer K, Sunahara R, Inoue A, von Zastrow M, and Gutkind JS. Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK. *Science Signaling*, **10**(484) pii: eaal3395, 2017.
 397. Raimondi F, Betts MJ, Lu Q, Inoue A, Gutkind JS, and Russell RB. Genetic variants affecting equivalent protein family positions reflect human diversity. *Sci. Rep.* **7**:12771-12777, 2017.
 398. Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov AV, Yegnasubramanian S, Kelley DZ, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, and Califano J. A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. *Cancer Res.* **77**:5248-5258, 2017.
 399. Fukusumi T, Guo T, Sakai A, Ando M, Ren S, Haft S, Liu C, Amornphimoltham P, Gutkind JS, and Califano J. The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma. *Clin Cancer Res.* **24**:619-633, 2018.
 400. Zhao X, Deng P, Iglesias-Bartolome R, Amornphimoltham P, Steffen DJ, Jin Y, Molinolo AA, de Castro LF, Ovejero D, Yuan Q, Chen Q, Han X, Bai D, Taylor SS, Yang Y, Collins MT, and Gutkind JS. Expression of an active Gαs mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. *Proc Natl Acad Sci U.S.A.* **115**: E428-E437, 2017.
 401. Collar AL, Swamydas M, O'Hayre M, Sajib MS, Hoffman KW, Singh SP, Mourad A, Johnson MD, Ferre EM, Farber JM, Lim JK, Mikelis CM, Gutkind JS, Lionakis MS. The homozygous CX3CR1-M280 mutation impairs human monocyte survival. *JCI Insight.*, **3**(3). pii: 95417, 2018. [ePub ahead of print]
 402. Lee BKB, Gan CP, Chang JK, Tan JL, Fadlullah MZ, Abdul Rahman ZA, Prime SS, Gutkind JS, Liew CS, Khang TF, Tan AC, Cheong SC. GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. *J. Dent. Res.*, Mar 1, **1-8**, 2018.
 403. Martin D, Degese MS, Vitale-Cross L, Iglesias-Bartolome R, Callejas Valera JL, Wang Z, Feng X, Yeerna H, Vadmal V, Moroishi T, Thorne R, Zaida M, Siegle B, Cheong SC, Molinolo AA, Samuels Y, Tamayo P, Guan KL, Lippman SM, Lyons JG, Gutkind JS. Assembly and Activation of the Hippo Signalome by the FAT1 Tumor Suppressor. *Nature Comm.*, **9**:2372, 2018.
 404. Iglesias-Bartolome R, Uchiyama A, Molinolo AA, Abusleme L, Brooks SR, Callejas-Valera JL, Edwards D, Doci C, Asselin-Labat M-L, Onaitis MW, Moutsopoulos NM, Gutkind* JS, Morraso* MI. (*Co-corresponding authors). Transcriptional signature primes human oral mucosa for rapid wound healing. *Sci. Transl. Med.*, **10**, eaap8798, 2018

405. Ideno N, Yamaguchi H, Ghosh B, Gupta S, Okumura T, DeLong Wood L, Singhi AD, Gutkind JS, Maitra A. GnasR201C induces pancreatic cystic neoplasms through suppression of YAP1 Signaling and Transcriptional Reprogramming. *Gastroenterology*. **155**(5):1593-1607.e12, 2018.
406. Lee BKB, Gan CP, Chang JK, Tan JL, Fadlullah MZ, Abdul Rahman ZA, Prime SS, Gutkind JS, Liew CS, Khang TF, Tan AC, Cheong SC. GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. *J Dent Res*. **97**(8):909-916, 2018.
407. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Polisenio L, Cervelli T. Development of a yeast-based system to identify new hBRAV600E functional interactors. *Oncogene*. **38**(8):1355-1366, 2019.
408. Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS. Inhibition of mTOR signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. *Clin Cancer Res*. **25**(4):1156-1164, 2019.
409. Cervantes-Villagrana RD, Adame-García SR, García-Jiménez I, Color-Aparicio VM, Beltrán-Navarro YM, König GM, Kostenis E, Reyes-Cruz G, Gutkind JS, Vázquez-Prado J. Gβγ signaling to the chemotactic effector P-REX1 and mammalian cell migration is directly regulated by Gα(q) and Gα(13) proteins. *J Biol Chem*. **11**;294(2):531-546, 2019.
410. Adame-García SR, Cervantes-Villagrana RD, Orduña-Castillo LB, Del Rio JC, Gutkind JS, Reyes-Cruz G, Taylor SS, Vázquez-Prado J. cAMP-dependent activation of the Rac guanine exchange factor P-REX1 by type I protein kinase A (PKA) regulatory subunits. *J Biol Chem*. **294**(7):2232-2246, 2019.
411. Uchiyama A, Nayak S, Graf R, Cross M, Hasneen K, Gutkind JS, Brooks SR, Morasso MI. SOX2 epidermal overexpression promotes cutaneous wound healing via activation of EGFR/MEK/ERK signaling mediated by EGFR ligands. *J Invest Dermatol*. pii: S0022-202X(19)30116-2, 2019.
412. Feng X, Arang N, Rigracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell*. **35**(3):457-472.e5, 2019.
413. Bandekar SJ, Arang N, Tully ES, Tang BA, Barton BL, Li S, Gutkind JS, Tesmer JJG. Structure of the C-terminal guanine nucleotide exchange factor module of Trio in an autoinhibited conformation reveals its oncogenic potential. *Sci Signal*. **12**(569), 2019.
414. Sahu AD, Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, Egan RK, Damon LJ, Frederick DT, Jerby-Aron L, Wagner A, Cheng K, Park SG, Robinson W, Gardner K, Boland G, Hannenhalli S, Herlyn M, Benes C, Flaherty K, Luo J, Gutkind JS, Ruppin E. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. *Mol Syst Biol*. **15**(3):e8323, 2019.
415. Annala S, Feng X, Shridhar N, Eryilmaz F, Patt J, Yang J, Pfeil EM, Cervantes-Villagrana RD, Inoue A, Häberlein F, Slodczyk T, Reher R, Kehraus S, Monteleone S, Schrage R, Heycke N, Rick U, Engel S, Pfeifer A, Kolb P, König G, Bünemann M, Tüting T, Vázquez-Prado J, Gutkind JS, Gaffal E, Kostenis E. Direct targeting of Gα(q) and Gα(11) oncoproteins in cancer cells. *Sci Signal*. **12**(573), 2019.
416. Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X, Gilardi M, Allevato M, Wu V, Steffen DJ, Tofilon P, Sonenberg N, Califano J, Chen Q, Lippman SM, Gutkind JS. 4E-BP1 Is a Tumor Suppressor Protein

- Reactivated by mTOR Inhibition in Head and Neck Cancer. *Cancer Res.* **79**:1438-1450, 2019.
417. Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, Ono Y, Shinjo Y, Ishida S, Arang N, Kawakami K, Gutkind JS, Aoki J, and Russel RB. Illuminating G-Protein-Coupling Selectivity of GPCRs. *Cell*, **177**(7):1933-1947, 2019.
 418. Singh G, Inoue A, Gutkind JS, Russell RB, Raimondi F. PRECOG: PREdicting COupling probabilities of G-protein coupled receptors. *Nucleic Acids Res.* **47**(W1):W395-W401, 2019.
 419. Raimondi F, Inoue A, Kadji FMN, Shuai N, Gonzalez JC, Singh G, de la Vega AA, Sotillo R, Fischer B, Aoki J, Gutkind JS, Russell RB. Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. *Oncogene*, **38**:6491-6506, 2019.
 420. Wu X, Yeerna H, Goto Y, Ando T, Wu VH, Zhang X, Wang Z, Amornphimoltham P, Murphy AN, Tamayo P, Chen Q, Lippman SM, Gutkind JS. Metformin inhibits progression of Head and Neck Squamous Cell Carcinoma by acting Directly on Carcinoma Initiating Cells. *Cancer Res.*, **79**(17):4360-4370, 2019.
 421. Zahra FT, Sajib MS, Ichiyama Y, Akwii RG, Tullar PE, Cobos C, Minchew SA, Doçi CL, Zheng Y, Kubota Y, Gutkind JS, Mikelis CM. Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological *in vivo* angiogenesis. *Sci Rep.* **9**(1):11666, 2019.
 422. Magen A, Das Sahu A, Lee JS, Sharmin M, Lugo A, Gutkind JS, Schäffer AA, Ruppin E, Hannehalli S. Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer. *Cell Rep.* **28**(4):938-948.e6, 2019.
 423. Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, Gutkind JS. Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. *J Biol Chem.* **294**(29):11062-11086, 2019.
 424. Zainal NS, Lee BKB, Wong ZW, Chin IS, Yee PS, Gan CP, Mun KS, Rahman ZAA, Gutkind JS, Patel V, Cheong SC. Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. *Cancer Biol Med.*, **16**(2):264-275, 2019.
 425. Demb J, Yaseyyedi A, Liu L, Bustamante R, Earles A, Ghosh P, Gutkind JS, Gawron AJ, Kaltenbach TR, Martinez ME, Gupta S. Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes. *Clin Transl Gastroenterol.*, [Epub ahead of print], 2019.
 426. Cash JN, Urata S, Li S, Ravala SK, Avramova LV, Shost MD, Gutkind JS, Tesmer JJG, Cianfrocco MA. Cryo-electron microscopy structure and analysis of the P-Rex1-Gβγ signaling scaffold. *Science Adv.*, **5**(10):eaax8855, 2019.
 427. Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Callejas-Valera JL, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. *Nature Comm.*, **10**(1):5546, 2019.
 428. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be targeted with Rimantadine in Head and Neck Cancer. *Cancer Res.* **80**(4):732-746, 2020.
 429. Dongre H, Rana N, Fromreide S, Rajthala S, Bøe Engelsen I, Paradis J, Gutkind JS, Vintermyr OK, Johannessen AC, Bjørge L, Costea DE. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. *Exp Cell Res.* **386**(1):111684, 2020.
 430. Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM. Phase 1

- dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. *Cancer*, **126**(2):354-362, 2020.
431. Pedro MP, Parra NS, Gutkind JS, Iglesias-Bartolome R. Activation of GPCR-Gai signaling increases keratinocyte proliferation and reduces differentiation, leading to epidermal hyperplasia. *J Invest Dermatol*, **140**(6):1195-1203, 2020.
 432. Rigracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, Gutkind JS, Maggiolini M. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells, *Cells*, **9**(12):2619, 2020.
 433. Sakai A, Ando M, Fukusumi T, Ren S, Liu C, Qualliotine J, Haft S, Sadat S, Saito Y, Guo TW, Xu G, Sasik R, Fisch KM, Gutkind JS, Fertig EJ, Molinolo AA, Califano JA. Aberrant Expression of CPSF1 Promotes Head and Neck Squamous Cell Carcinoma via Regulating Alternative Splicing. *PLoS One*, **15**(5):e0233380, 2020.
 434. Sugase T, Lam BQ, Danielson M, Terai M, Aplin AE, Gutkind JS, Sato T. Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. *J Transl Med*, **18**(1):208, 2020.
 435. Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. *Biomaterials*, **248**:120032, 2020.
 436. Stratman AN, Farrelly OM, Mikelis CM, Miller MF, Wang Z, Pham VN, Davis AE, Burns MC, Pezoa SA, Castranova D, Yano JJ, Kilts TM, Davis GE, Gutkind JS, Weinstein BM. Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling. *Nat Commun*, **11**(1):1204, 2020.
 437. Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation. *Clin Cancer Res*, **26**(11):2693-2703, 2020.
 438. Goto Y, Ando T, Izumi H, Feng X, Arang N, Gilardi M, Wang Z, Ando K, Gutkind JS. Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis. *Oncogene*, **39**(20):4014-4027, 2020.
 439. Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS. Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer. *Mol Cancer Ther*, **19**(7):1562-1571, 2020.
 440. Ma X, Uchida Y, Wei T, Liu C, Adams RH, Kubota Y, Gutkind JS, Mukoyama YS, Adelstein RS. Nonmuscle Myosin 2 Regulates Cortical Stability during Sprouting Angiogenesis. *Mol Biol Cell*, **31**(18):1974-1987, 2020.
 441. Lazar AM, Irannejad R, Baldwin TA, Sundaram AB, Gutkind JS, Inoue A, Dessauer CW, Von Zastrow M. G protein-regulated endocytic trafficking of adenylyl cyclase type 9. *Elife*, **9**:e58039, 2020.
 442. Patel J, Nguyen SA, Ogretmen B, Gutkind JS, Nathan CA, Day T. mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity. *Laryngoscope Investig Otolaryngol*, **5**(2):243-255, 2020.
 443. Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. *Clin Cancer Res*, **26**(13):3345-3359, 2020.
 444. Gilardi M, Wang Z, Proietto M, Chilla A, Calleja-Valera JL, Goto Y, Vanoni M, Janes M, Mikulski Z, Gualberto A, Molinolo AA, Ferrara N, Gutkind JS*, Burrows F. Tipifarnib as a

- Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. *Mol Cancer Ther*, **19**(9):1784-1796, 2020.
445. Castillo-Kauil A, García-Jiménez I, Cervantes-Villagrana RD, Adame-García SR, Beltrán-Navarro YM, Gutkind JS, Reyes-Cruz G, Vázquez-Prado J. Gas directly drives PDZ-RhoGEF signaling to Cdc42. *J Biol Chem*, **295**(50):16920-16928, 2020.
 446. Ren S, Gaykalova DA, Guo T, Favorov AV, Fertig EJ, Tamayo P, Callejas-Valera JL, Allevato M, Gilardi M, Santos J, Fukusumi T, Sakai A, Ando M, Sadat S, Liu C, Xu G, Fisch KM, Wang Z, Molinolo AA, Gutkind JS, Ideker T, Koch WM, Califano JA. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers. *Oncogene*, **39**(40):6327-6339, 2020.
 447. Sharafeldin M, Chen T, Ozkaya GU, Choudhary D, Molinolo AA, Gutkind JS, Rusling JF. Detecting cancer metastasis and accompanying protein biomarkers at single cell levels using a 3D-printed microfluidic immunoarray. *Biosens Bioelectron*, **171**:112681, 2021.
 448. Rigracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, Lappano R. Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. *Cancers (Basel)*, **13**(4):645, 2021.
 449. Gleneadie HJ, Baker AH, Batis N, Bryant J, Jiang Y, Clokie SJH, Mehanna H, Garcia P, Gendoo DMA, Roberts S, Burley M, Molinolo AA, Gutkind JS, Scheven BA, Cooper PR, Parish JL, Khanim FL, Wiench M. The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress. *Cancer Lett*, **501**:172-186, 2021.
 450. Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes FG, Arang N, Tiago M, Coma S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, Gutkind JS. Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. *Clin Cancer Res*, **27**(11):3190-3200, 2021.
 451. Schwartz RE, Shokhirev MN, Andrade LR, Gutkind JS, Iglesias-Bartolome R, Shadel GS. Insights into epithelial cell senescence from transcriptome and secretome analysis of human oral keratinocytes. *Aging (Albany NY)*, **13**(4):4747-4777, 2021.
 452. Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, Torre J, Siena M, Liu M, Klug LR, Choi YY, Hosseini M, Delgado AL, Wang Z, French RP, Lowy A, DeMatteo RP, Heinrich MC, Molinolo AA, Gutkind JS, Harismendy O, Sicklick JK. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. *Oncogene*, **40**(11):1957-1973, 2021.
 453. Wang Z, Goto Y, Allevato M, Wu V, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung B, O'Farrell A, Molinolo A, Duvvuri U, Grandis J, Califano J, Cohen E, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. *Nature Commun*, **12**(1):2383, 2021.
 454. Gutkind JS, Molinolo A, Wu X, Wang Z, Nachmanson D, Harismendy O, Alexandrov LB, Wuertz BR, Ondrey FG, Laronde DM, Rock LD, Rosin MP, Coffey CS, Butler VD, Bengtson L, Hsu CH, Bauman JE, Hewitt SM, Cohen EE, Chow HHS, Lippman SM, Szabo E. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. *JCI Insight*, **6**(17):e147096, 2021.
 455. Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Foussard H, Zeng Y, O'Keefe R, Jin N, VanLandingham NK, Von Dollen J, Herrington KA, Bouhaddou M, McGregor M, Jimenez-Morales D, Obernier K, Kreisberg JF, Kim M, Johnson DE, Jura N, Grandis JR, Gutkind JS, Ideker T, and Krogan N. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. *Science*, **74**(6563):eabf2911, 2021.
 456. Zheng F, Kelly MR, Ramms DJ, Heintschel M, Tao K, Tutuncuoglu B, Lee J, Ono K, Foussard H, Chen M, Herrington KA, Silva E, Liu S, Chen J, Churas C, Wilson N, Kratz

- A, Park J, Kuenzi B, Yu MK, Licon K, Pratt D, Kreisberg JF, Kim M, Swaney DL, Nan X, Fraley SI, Gutkind JS, Krogan NJ, and Ideker T. Interpretation of cancer mutations using a multi-scale map of protein systems. *Science*, **374**(6563):eabf3067, 2021.
457. Ando T, Arang N, Wang Z, Costea DE, Feng X, Goto Y, Izumi H, Gilardi M, Ando K, Gutkind JS. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. *Commun Biol*, **4**(1):1237, 2021.
 458. Ma S, Tang T, Probst G, Konradi A, Jin C, Li F, Silvio Gutkind J, Fu XD, Guan KL. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. *Nat Commun*, **13**(1):1061, 2022.
 459. Akwii RG, Sajib MS, Zahra FT, Tullar P, Zabet-Moghaddam M, Zheng Y, Silvio Gutkind J, Doci CL, Mikelis CM. Angiopoietin-2-induced lymphatic endothelial cell migration drives lymphangiogenesis via the β 1 integrin-RhoA-formin axis. *Angiogenesis*, **25**(3):373-396, 2022
 460. Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS. Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. *Mol Cancer Ther*, **21**(4):616-624, 2022.
 461. Rigracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Adame-Garcia SR, Arang N, Lubrano S, De Francesco EM, Belfiore A, Gutkind JS, Maggiolini M. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). *J Exp Clin Cancer Res*, **41**(1):193, 2022.
 462. Matic M, Singh G, Carli F, Oliveira Rosa N, Miglionico P, Magni L, Gutkind JS, Russell RB, Inoue A, Raimondi F. PRECOGx: exploring GPCR signaling mechanisms with deep protein representations. *Nucleic Acids Res*, **50**(W1):W598-610, 2022.
 463. Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang N-A, Al Msari R, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simo B, Fox B, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC. *Nature Commun*, **13**(1):4298, 2022.
 464. Hingorani DV, Allevato MM, Camargo MF, Lesperance J, Quraishi MA, Aguilera J, Franiak-Pietryga I, Scanderbeg DJ, Wang Z, Molinolo AA, Alvarado D, Sharabi AB, Bui JD, Cohen EEW, Adams SR, Gutkind JS, Advani SJ. Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. *Nature Commun*, **13**(1):3869, 2022.
 465. Bandekar SJ, Chen CL, Ravala SK, Cash JN, Avramova LV, Zhalnina MV, Gutkind JS, Li S, Tesmer JJG. Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1. *J Biol Chem*, **298**(8):102209, 2022.
 466. Nathan C-A, Hayes DN, Karrison T, Harismendy O, Flores J, Moore-Medlin T, Vokes E, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Olson JG, Day T, Gillison M, Wade J, Feldman L, Jha G, Kozloff M, Leary M, Worden F, Cohen EEW. A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. *Clinical Cancer Research*, **28**(23):5040-5048, 2022.
 467. Zhao X, Cohen EEW, William WN Jr, Bianchi JJ, Abraham JP, Magee D, Spetzler DB, Gutkind JS, Alexandrov LB, Cavenee WK, Lippman SM, Davoli T. Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. *Proc Natl Acad Sci U S A*, **22**:119(47), 2022.

468. Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Arang N, Lubrano S, Rigracciolo DC, Nachmanson D, Lippman SM, Mali P, Harismendy O, Gutkind JS. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-Focal Adhesion Kinase signaling circuitry. *J Biol Chem*, **299**(2):102866, 2023.
469. Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. *Nat Cancer*, **4**; (2):240-256, 2023
470. Hewitt N, Ma N, Arang N, Martin SA, Prakash A, DiBerto JF, Knight KM, Ghosh S, Olsen RHJ, Roth BL, Gutkind JS*, Vaidehi N, Campbell SL, Dohlman HG. Catalytic site mutations confer multiple states of G protein activation. *Sci Signal*, **16**(772):eabq7842, 2023.
471. Jagadeeshan S, Prasad M, Badarni M, Ben Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, Ho AL, Rosenberg AJ, Kessler L, Burrows F, Kong D, Grandis JR, Gutkind JS, Elkabets M. Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer. *Cancer Res*, **83**(7):1031-1047, 2023.
472. Wang S, Wu ZZ, Zhu SW, Wan SC, Zhang MJ, Zhang BX, Yang QC, Xiao Y, Li H, Mao L, Wang ZY, Gutkind JS, Sun ZJ. CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma. *Mol Ther*, **31**(7):2154-2168, 2023.
473. Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. *Nat Commun*, **14**(1):2744, 2023.
474. Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villafior V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S. Tipifarnib Potentiates the Antitumor Effects of PI3K α Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity. *Cancer Res*, **83**(19):3252-3263, 2023.
475. Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppini E, Mesirov JP, Gutkind JS. The GPCR-Gas-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. *Nat Immunol*, **24**(8):1318-1330, 2023.
476. Arang N, Lubrano S, Ceribelli M, Rigracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell Rep Med*, **4**(11):101244, 2023
477. Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, Yanamoto S, Miyauchi M, Kajiya M. AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma. *Oncogene*, **42**(39):2869-2877, 2023
478. Burghi V, Paradis JS, Officer A, Adame-Garcia SR, Wu X, Matthees ESF, Barsi-Rhyne B, Ramms DJ, Clubb L, Acosta M, Tamayo P, Bouvier M, Inoue A, von Zastrow M, Hoffmann

- C, Gutkind JS. Gas is dispensable for β -arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β 2-adrenergic receptor. *J Biol Chem*, **299**(11):105293, 2023
479. Arang N, Lubrano S, Rigracciolo DC, Nachmanson D, Lippman SM, Mali P, Harismendy O, Gutkind JS. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry. *J Biol Chem*, **299**(2):102866, 2023
 480. Baqai U, Kurimchak AM, Trachtenberg IV, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma. *J Biol Chem*, **299**(12):105418, 2023
 481. Chaim OM, Miki S, Prager BC, Ma J, Jeong AY, Lara J, Tran NK, Smith JM, Rich JN, Gutkind JS, Miyamoto S, Furnari FB, Brown JH. $G\alpha_{12}$ signaling regulates transcriptional and phenotypic responses that promote glioblastoma tumor invasion. *Sci Rep*, **13**(1):22412, 2023
 482. Madan S, Sinha S, Chang T, Gutkind JS, Cohen EEW, Schäffer AA, Ruppin E. Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer. *Cancers (Basel)*, **15**(19):4885, 2023
 483. Qualliotine JR, Nakagawa T, Rosenthal SB, Sadat S, Ballesteros-Merino C, Xu G, Mark A, Nasamran A, Gutkind JS, Fisch KM, Guo T, Fox BA, Khan Z, Molinolo AA, Califano JA. A Network Landscape of HPVOPC Reveals Methylation Alterations as Significant Drivers of Gene Expression via an Immune-Mediated GPCR Signal. *Cancers (Basel)*, **15**(17):4379, 2023
 484. Bracho-Valdés I, Cervantes-Villagrana RD, Beltrán-Navarro YM, Olguín-Olguín A, Escobar-Islas E, Carretero-Ortega J, Olivares-Reyes JA, Reyes-Cruz G, Gutkind JS, Vázquez-Prado J. Akt Is Controlled by Bag5 through a Monoubiquitination to Polyubiquitination Switch. *Int J Mol Sci*, **24**(24):17531, 2023
 485. García-Sáez AJ, Domingos AI, Gutkind JS, Mattoo S, Du P. Many paths lead to immunology. *Cell*. **187**(9):2117-2119, 2024.
 486. Yun J, Saddawi-Konefka R, Goldenson B, Al-Msari R, Bernareggi D, Thangaraj JL, Tang S, Patel SH, Luna SM, Gutkind JS, Kaufman D. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model. *J Immunother Cancer*. **3**;12(5), 2024.
 487. Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. *Nat Commun*. **3**;15(1):3741, 2024.
 488. Goto Y, Koshizuka K, Ando T, Izumi H, Wu X, Sato K, Ishikawa T, Ford K, Feng X, Wang Z, Arang N, Allevato MM, Kishore A, Mali P, Gutkind JS. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. *Cancer Res Commun*. **1**;4(7):1850-1862, 2024
 489. Ravala SK, Adame-Garcia SR, Li S, Chen CL, Cianfrocco MA, Silvio Gutkind J, Cash JN, Tesmer JJG. Structural and dynamic changes in P-Rex1 upon activation by PIP3 and inhibition by IP4. *Elife*. **31**;12, 2024.
 490. Allevato MM, Trinh S, Koshizuka K, Nachmanson D, Nguyen TC, Yokoyama Y, Wu X, Andres A, Wang Z, Watrous J, Molinolo AA, Mali P, Harismendy O, Jain M, Wild R, Gutkind JS. A genome-wide CRISPR screen reveals that antagonism of glutamine

- metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. *Cancer Lett.* 28;598:217089, 2024.
491. Trogdon M, Abbott K, Arang N, Lande K, Kaur N, Tong M, Bakhoum M, Gutkind JS, Stites EC. Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation. *NPJ Syst Biol Appl.* 16;10(1):75, 2024.
 492. Arora C, Matic M, Bisceglia L, Di Chiaro P, De Oliveira Rosa N, Carli F, Clubb L, Nemati Fard LA, Kargas G, Diaferia GR, Vukotic R, Licata L, Wu G, Natoli G, Gutkind JS, Raimondi F. The landscape of cancer-rewired GPCR signaling axes. *Cell Genom.* 8;4(5):100557, 2024.
 493. Saddawi-Konefka R, Schokrpur S, Gutkind JS. Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology. *Cancer Cell.* 10;42(6):930-933, 2024.
 494. Wu X, Adame-Garcia SR, Koshizuka K, Vo PTT, Hoang TS, Sato K, Izumi H, Goto Y, Allevato MM, Wood KC, Lippman SM, Gutkind JS. Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism. *Cancer Prev Res (Phila).* 17(12):571-583, 2024
 495. Novoplansky O, Jagadeeshan S, Prasad M, Yegodayev KM, Marripati D, Shareb RA, Greenshpan Y, Mathukkada S, Ben-Lulu T, Bhattacharya B, Porgador A, Kong D, Brägelmann J, Gutkind JS, Elkabets M. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer. *J Exp Clin Cancer Res.* 43(1):308, 2024.
 496. Mortaja M, Cheng MM, Ali A, Lesperance J, Hingorani DV, Allevato MM, Dhawan K, Camargo MF, McKay RR, Adams SR, Gutkind JS, Advani SJ. Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment. *Molecules.* 29(23):5618, 2024
 497. Weitz J, Nishizaki D, Liao J, Patel J, Ng I, Sun S, Ramms D, Zou J, Wishart B, Rull J, Baumgartner J, Kelly K, White R, Veerapong J, Hosseini M, Patel H, Botta G, Gutkind JS, Tiriach H, Kato S, Lowy AM. Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. *J Clin Oncol.* 16:JCO2400511, 2024
 498. Faraji F, Ramirez S, Clubb LM, Sato K, Burghi V, Hoang TS, Officer A, Anguiano Quiroz PY, Galloway WMG, Mikulski Z, Medetgul-Ernar K, Marangoni P, Jones KB, Cao Y, Molinolo AA, Kim K, Sakaguchi K, Califano JA, Smith Q, Goren A, Klein OD, Tamayo P, Gutkind JS. YAP-Driven Malignant Reprogramming of Oral Epithelial Stem Cells at Single Cell Resolution. *Nature Communications.* 16 (498), 2025
 499. Sato K, Faraji F, Cervantes-Villagrana RD, Wu X, Koshizuka K, Ishikawa T, Iglesias-Bartolome R, Chen L, Miliani de Marval PL, Gwaltney SL, Adler B, Gutkind JS. Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. *Cancer Lett.* 612:217467, 2025.
 500. He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, Wu J, Feng B, Sun J, Rui W, Ze S, Fu Y, Zhao Y, Zhang Y, Zhang Y, Liu M, Liu C, She M, Hu X, Ma X, Yang H, Li D, Zhao S, Li G, Zhang Z, Tian Z, Ma Y, Cao L, Yi B, Li D, Nussinov R, Eng C, Chan TA, Ruppin E, Gutkind JS, Cheng F, Liu M, Lu W. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. *Nat Immunol.* 26(3):391-403, 2025.
 501. Ferry A, Mempel KM, Monell A, Reina-Campos M, Scharping N, Heeg M, Takehara KK, Schokrpur S, Kuo N, Saddawi-Konefka R, Gutkind JS, Goldrath A. The XCL1-XCR1 1 axis supports intestinal tissue residency and anti-tumor immunity. *J. Exp. Med.,* 222(2):e20240776. 2025.
 502. Wang CP, Yu KJ, Chen TC, Tsai MS, Kang CJ, Chien CY, Engels EA, Hua CH, Hsu WL, Chang YL, Dawsey SM, Wentzensen N, Shi J, Mao F, Cheung LC, Katki HA, Boyd E, Wu CT, Gutkind JS, Molinolo A, Limbach AL, Lingen MW, Lou PJ, Chen CJ, Hildesheim A,

- Chaturvedi AK. Multistate oral carcinogenesis-A prospective cohort study and a parallel case-control study in Taiwan. *Oral Oncol.* **162**:107210, 2025.
503. Mortaja M, Adams SR, McKay RR, Gutkind JS, Advani SJ. Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies. *NPJ Precis Oncol.* **4**;9(1):97, 2025.
 504. Li R, Strilic B, Jin YJ, Shao J, Peng Y, Wang L, Quan Q, Wang Z, Graumann J, Gutkind JS, Wettschureck N, Offermanns S. The tumor suppressor FAT1 controls YAP/TAZ protein degradation and tumor cell proliferation through E3 ligase MIB2. *PLoS One.* **6**;20(6), 2025.
 505. Koshizuka K, Wu X, Sato K, Vo PTT, Murawska GM, Ishikawa T, Wang Z, Molinolo AA, Dennis EA, Nathan CO, Mali P, Gutkind JS. Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. *Cancer Res.*, **85**(16):3032-3051, 2025.
 506. Lubrano S, Cervantes-Villagrana RD, Faraji F, Ramirez S, Sato K, Adame-Garcia SR, Officer A, Arang N, Rigracciolo DC, Anguiano Quiroz PY, Martini C, Wang Y, Ferguson FM, Bacchiocchi A, Halaban R, Coma S, Holmen SL, Pachter JA, Aplin AE, Gutkind JS. FAK inhibition combined with the RAF/MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer Cell*, **43**(3):428-445, 2025.
 507. Fu C, Saddawi-Konefka R, Chinai JM, Kim SY, Kammula AV, Perera JJ, Jiang A, Tiwari P, Kistler EN, Tang S, Luna SM, Colvin KJ, Dubrot J, Anderson S, Fetterman RA, Chuong CL, Lane-Reticker SK, Cheruiyot CK, Muscato AJ, Alipour Z, Adkins DR, Griffin GK, Bernstein BE, Egloff AM, Yates KB, Chernock RD, Gutkind JS, Uppaluri R, Manguso RT. In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. *Nat Commun.*, **16**(1):8572, 2025.
 508. Wang B, Saddawi-Konefka R, Clubb LM, Tang S, Wu D, Mukherjee S, Sahni S, Dhruba SR, Yang X, Patiyal S, Day CP, Desai PA, Allen C, Wang K, Gutkind JS, Ruppin E. Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma. *Nat Commun.*, **16**(1):8161, 2025.
 509. Lee HY, Kim JY, Wang Z, Amornphimoltham P, Gutkind JS, Jeong WJ. Noncanonical Pathways of Proteasome Inhibition in HPV-Negative Head & Neck Cancer. *Mol Carcinog.* **64**:1838-1850, 2025.
 510. Saddawi-Konefka R, Msari RA, Tang S, Philips C, Sadat S, Clubb LM, Luna S, Fassardi S, Jones R, Pietryga IF, Faraji F, Schokrpur S, Yung BS, Allevato MM, Decker KE, Nasamran CA, Chilin-Fuentes D, Rosenthal SB, Jensen SM, Fox BA, Bell RB, Gutkind JS, Sharabi A, Califano JA. The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy. *Nat Commun.* **16**(1):6578, 2025.
 511. Lubrano S, Cervantes-Villagrana RD, Arang N, Officer A, Adame-Garcia SR, Cuesta-Margolles G, Aplin AE, Gutkind JS. Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma. *J Biol Chem.* **301**:110712, 2025.
 512. Wang B, Saddawi-Konefka R, Clubb LM, Tang S, Wu D, Mukherjee S, Sahni S, Dhruba SR, Yang X, Patiyal S, Day CP, Desai PA, Allen C, Wang K, Gutkind JS, Ruppin E. Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma. *Nat Commun.* **16**:8161, 2025.
 513. Lesperance J, Yung BS, Allevato MM, Cheng MM, Camargo MF, Saddawi-Konefka R, Dhawan K, Sharma AK, Mortaja M, Bice S, Scanderbeg DJ, Alvarado D, Mayadev J, Eskander RN, Adams SR, Cospier PF, Gutkind JS, Advani SJ. Interactions of Antibody

Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy. *Adv Sci (Weinh)*. Oct 24:e06552. doi: 10.1002/advs.202506552. [Online ahead of print], 2025.

514. Chakraborty AK, Kroehling L, Raut RD, Choudhury C, Kukuruzinska MA, Gutkind JS, Varelas X, Sahay B, Monti S, Bais MV. LSD1 Inhibition Induces MHC-I and Dendritic Cell Activation to Promote Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. *Cancer Res*. Oct 9. doi: 10.1158/0008-5472.CAN-24-3239. [Online ahead of print], 2025.

Peer Reviewed Review Articles

515. Gutkind JS. The pathway linking G protein-coupled receptors to divergent MAP kinase cascades. *J. Biol. Chem.*, Minireview **273**:1839-42, 1998.
516. Gutkind JS. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. *Oncogene*, **17**:1331-1342, 1998.
517. Winn DM, Sandberg AN, Horowitz AM, Diehl SR, Gutkind JS, and Kleinman DV. Reducing the burden of oral and pharyngeal cancers. *J. Calif. Dental Assoc.*, **26**:445-54, 1998.
518. Gutkind JS. Regulation of Mitogen-Activated Protein Kinase signaling networks by G protein-coupled receptors. *Science STKE series*, Science's STKE -- Gutkind 2000 (40): 1re, 2000.
519. Marinissen MJ, and Gutkind JS. G Protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol. Sci.*, **22**:368-76, 2001.
520. Pece S, and Gutkind JS. E-cadherin and Hakai: signalling, remodeling or destruction? *Nature Cell Biol.*, **4**:E72-4, 2002.
521. Sodhi A, Montaner S, and Gutkind JS. Viral hijacking of G-protein-coupled-receptor signalling networks. *Nature Rev. Mol. Cell. Biol.*, **12**:998-1012, 2004.
522. Vázquez-Prado J, Basile J, and Gutkind JS. Modular Architecture and Novel Protein-Protein Interactions Regulating RGS-Containing RhoGEFs. *Methods in Enzymology*, **390**:259-285, 2004
523. Dennis PA, Van Waes C, Gutkind JS, Kellar KJ, Vinson C, Mukhin AG, Spitz MR, Bailey-Wilson JE, Yeh GC, Anderson LM, and Wiest JS. The Biology of Tobacco and Nicotine: Bench to Bedside. *Cancer Epidemiol. Biomarkers Prev.*, **14**:764-767, 2005.
524. Marinissen MJ and Gutkind JS. Scaffold proteins dictate Rho GTPase-signaling specificity. *Trends Biochem. Sci.*, **30**:423-426, 2005.
525. Castellone MD, Teramoto H, and Gutkind JS. COX-2 and colorectal cancer: The β -catenin connection. *Cancer Research*, **66**:11085-11088, 2006.
526. Gavard J and Gutkind JS. VE-cadherin takes a walk on the wild side. *Med Sci (Paris)*, **23**:119-121, 2007.
527. Turjanski AG, Vaqué JP, and Gutkind JS. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.
528. Dorsam R and Gutkind JS. G protein-coupled receptors and cancer. *Nature Rev. Cancer*, **7**:79-94, 2007.
529. Gavard J and Gutkind JS. VE-Cadherin and Claudin-5: It takes two to tango. *Nature Cell Biology*, **10**:883-885, 2008.
530. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, and Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. *Oral Oncology*, **45**:324-334, 2009.
531. Gutkind JS and Offermanns S. A new G_q-initiated MAPK signaling pathway in the heart. *Dev. Cell*, **16**:163-164, 2009.
532. Vitale-Cross L, Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, and Gutkind JS. Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. *Cancer Prevention Research*, **2**:419-422, 2009.

533. Martin D and Gutkind JS. Kaposi's sarcoma virally encoded, G-protein-coupled receptor: a paradigm for paracrine transformation. *Methods in Enzymology* **460**:125-150, 2009.
534. El-Naggar AK, Kaye FJ, Shirazi Y, Gutkind JS, Forastiere AA. Meeting report--the NIDCR 2(nd) Salivary Gland Tumor Meeting. *Head Neck* **31**:1542-1543, 2009.
535. Martin D and Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. *Oncogene* **27**, Suppl 2: S31-S42, 2009.
536. Rusling JF, Kumar CV, Gutkind JS, and Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst*, **135**:2496-2511, 2010.
537. Iglesias-Bartolome R and Gutkind JS. Keeping the epidermal stem cell niche in shape. *Cell Stem Cell*, **7**:143-145, 2010.vastan
538. Iglesias-Bartolome R and Gutkind JS. Signaling circuitries and stem cell fate: To be or not to be. *Curr. Opin. Cell Biol.*, **23**:716-723, 2011.
539. Patel V., Iglesias-Bartolome R, Siegele B, Marsh CA, Leelahavanichkul K, Molinolo AA, and Gutkind JS. Cellular systems for studying human oral squamous cell carcinomas. *Adv. Exp. Med. Biol.* **720**:27-38, 2011.
540. Sakurai A, Doci C, and Gutkind JS. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. *Cell Research*, **22**:23-32, 2012.
541. Nguyen SA, Walker D, Gillespie MB, Gutkind JS, and Day TA. mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma. *Curr. Treat Options Oncol.* **13**:71-81, 2012.
542. Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, and Wells SI. Future directions and treatment strategies for head and neck squamous cell carcinomas. *Translational Research*, **160**:167-177, 2012.
543. Iglesias-Bartolome R and Gutkind JS. Exploiting the mTOR paradox for disease prevention. *Oncotarget*, **3**:1061-1063, 2012.
544. Montaner S, Kufareva I, Abagyan R, and Gutkind JS. Molecular Mechanisms Deployed by Virally Encoded G Protein Coupled Receptors in Human Diseases. *Annual Review in Pharmacology and Toxicology*, **53**:17.1–17.24, 2013.
545. Castilho R, Squarize C, and Gutkind JS. Exploiting PI3K/mTOR signaling to accelerate epithelial wound healing. *Oral Dis.*, **19**:551-558, 2013.
546. Iglesias-Bartolome R, Callejas-Valera JL, and Gutkind JS. Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity. *Curr. Opin. Cell Biol.*, **25**:162-169, 2013.
547. Blelloch R, and Gutkind JS. Epigenetics, noncoding RNAs, and cell signaling-crossroads in the regulation of cell fate decisions. *Curr. Opin. Cell Biol.* **25**:149-151, 2013.
548. Iglesias-Bartolome R, Martin D, and Gutkind JS. Exploiting the head and neck cancer oncogenome: Widespread PI3K-mTOR pathway alterations and novel molecular targets. *Cancer Discovery*, **3**:722-725, 2013.
549. O'Hayre M, Degese MS, and Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. *Curr. Opin. Cell Biol.*, **27**:126-135, 2014.
550. Feng X, Chen Q, and Gutkind JS. Oncotargeting G proteins: The Hippo in the room. *Oncotarget* **5**:10997-10999, 2014.
551. Laukkanen MO, Gutkind JS, and Castellone MD. Sonic Hedgehog in SCLC. *Aging* **7**:605-606, 2015.
552. Heldin CH, Lu B, Evans R, and Gutkind JS. Signals and Receptors. *Cold Spring Harb Perspect Biol.* **8**(4). pii: a005900, 2016.
553. Sakurai A, Doçi CL, and Gutkind JS. Using Heterologous COS-7 Cells to Identify Semaphorin-Signaling Components. *Methods Mol. Biol.* **1493**:163-170, 2017.
554. Nohata N, Goto Y, Gutkind JS. Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer. *J. Hum. Genet.*, **62**:87-96, 2016.

555. Gutkind JS and Bui JD. The Next Frontier: Head and Neck Cancer Immunoprevention. *Cancer Prev. Res.* **10**:681-683, 2017.
556. Wang Z, Callejas Valera J, Zhao X, Chen Q, Gutkind JS. mTOR co-targeting strategies for head and neck cancer therapy. *Cancer & Metastasis Rev*, **36**:491-502, 2017.
557. Nör JE, Gutkind JS. Head and Neck Cancer in the New Era of Precision Medicine. *J Dent Res*, **97**:601-602, 2018.
558. Gutkind JS, Kostenis E. Arrestins as rheostats of GPCR signaling. *Nat. Rev. Mol. Cell Biol*, **10**:1038, 2018.
559. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano J, Mell LK, Cohen EEW, Sharabi AB. Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. *Clin. Cancer Res.* pii: clincanres.0871.2019, 2019.
560. D'Silva NJ, Gutkind JS. Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision. *Adv Dent Res*, **30**(2):45-49, 2019.
561. Gutkind JS, Day TA, Lippman SM, Szabo E. Targeting mTOR in Head and Neck Cancer-Response. *Clin Cancer Res*, **25**(21):6555, 2019.
562. Iglesias-Bartolome R, and Gutkind JS. Unleashing immunotherapy by targeting cancer stem cells. *Cell Stem Cell*, **27**(2):187-189, 2020.
563. Arang N, Gutkind JS. G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. *FEBS Lett*, **594**(24):4201-4232, 2020.
564. Ramms DJ, Raimondi F, Arang N, Herberg FW, Taylor SS, Gutkind JS. Gas-Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gas-PKA Signaling. *Pharmacol Rev*, **73**(4):155-197, 2021.
565. Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer. *Cells*, **11**(8):1370, 2022.
566. Wood KC, Gutkind JS. Challenges and Emerging Opportunities for Targeting mTOR in Cancer. *Cancer Res*, **82**(21):3884-3887. 2022.
567. Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer. *Cancer J*, **28**(5):339-345, 2022.
568. Ando T, Okamoto K, Shintani T, Yanamoto S, Miyauchi M, Gutkind JS, Kajiya M. Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. *J Pers Med*. **12**(10):1544, 2022.
569. Zhou J, Liu C, Amornphimoltham P, Cheong SC, Gutkind JS, Chen Q, Wang Z. Mouse Models for Head and Neck Squamous Cell Carcinoma. *J Dent Res*. **103**(6):585-595, 2024.
570. Hangauer MJ, Gutkind JS, Ferguson FM. Pan-RAF:MEK Molecular Glues Take Center Stage. *Cancer Discov*. **1**;14(7):1143-1144, 2024.
571. Stagg J, Gutkind JS. Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies. *Annu Rev Pharmacol Toxicol*. **65**:18.1–18.17, 2025.
572. Kuo N, Shinn CK, Schokrpur S, Idoyaga J, Handel T, Gutkind JS. Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity. *J Pharmacol Exp Ther*. **392**:10372, 2025.

Book Chapters and Proceedings

573. Castren E, Kurihara M, Gutkind JS, and Saavedra JM. Atrial natriuretic peptide receptors in thymus and spleen of young spontaneously hypertensive rats. In "Advances in Atrial Peptide Research". *ASH Symposium Series* volume II, 243-247, 1988.

574. Gutkind JS, Kurihara M, Castren E, and Saavedra JM. Atrial natriuretic peptide receptors in rat sympathetic ganglia: alterations in genetically hypertensive rats. In "Advances in Atrial Peptide Research", ASH Symposium Series volume II, 261-265, 1988.
575. Saavedra JM, Castren E, Gutkind JS, Kurihara M, and Nazarali AJ. Atrial natriuretic peptide and the autonomous nervous system. In "Atrial Natriuretic Peptides". Edited by R. Quirion and W.K. Samson. Boca Raton, Florida: CRC press, Inc., 209-220, 1989.
576. Saavedra JM, Castren E, Gutkind JS, and Nazarali AJ. Regulation of brain atrial natriuretic peptide and angiotensin receptors: Quantitative autoradiographic studies. *Internatl. Rev. of Neurobiol.*, **31**:257-296, 1989.
577. Gutkind JS, Lacal PM, Benhamou M, Siraganian RP, and Robbins KC. Evidence for protein-tyrosine kinase involvement in non-proliferative signal transduction. *Proc. II Internatl. Symp. on Oncogenes*, Spain, 101-132, 1991.
578. Siraganian RP, Benhamou M, Stephan V, Gutkind JS, and Robbins KC. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. *Proc. XIV Internatl. Cong. Allergy and Clinical Immunology*. In "Progress in Allergy and Clinical Immunology". Vol. 2. Edited by T. Miyamoto and M. Okuda. Toronto: Hogrefe and Huber, 354-359, 1992.
579. Gutkind JS, Crespo P, Coso O, Kalinec G, and Xu N. Proliferative signaling through muscarinic acetylcholine receptors: a model for receptors coupled to heterotrimeric G Proteins. In "*Molecular Mechanisms of Muscarinic Acetylcholine Receptor Function*". Edited by Jurgen Wess. R.G Landes, Publisher, 103-141, 1995.
580. Gutkind JS, Crespo P, Coso O, and Xu N. Signaling from heterotrimeric G proteins to MAP kinase involves $\beta\gamma$ subunits acting on a *ras*-dependent pathway. In "The Molecular Basis of Cancer and Their Clinical Applications", Spanish Association for Cancer Research. Edited by J. C. Lacal, E. B. Olaetxea and R. Perona, pp. 137-146, 1996.
581. Gutkind JS and Vitale-Cross L. The pathway linking small GTP-binding proteins of the Rho Family to cytoskeletal components and novel signaling kinase cascades. *Seminars Cell. Dev. Biol.*, **7**:683-690, 1996.
582. Gutkind JS, Vitale-Cross L, Crespo P, Xu N, Teramoto H, and Coso OA. The pathway connecting G protein-coupled receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. In "Studies in Stomatology and Craniofacial Biology". Edited by M.M. Cohen, Jr., and B. Baum, IOS Press, pp. 39-57, 1997.
583. Gutkind JS, Coso OA, Xu N. G_{12} and G_{13} α subunits of heterotrimeric G proteins: A novel family of oncogenes. In "G Proteins, Receptors, and Disease". Edited by A.M. Spiegel. Humana Press, pp. 101-117, 1998.
584. Teramoto H and Gutkind JS. The pathway connecting muscarinic acetylcholine receptors to the nucleus involves small GTP-binding proteins. *Tanpakushitsu Kakusan Koso*, **43**:35-41 1998.
585. Gutkind JS. Signaling from the Membrane to the Nucleus through Divergent MAP Kinase Cascades. In *Cell Signal Transduction, Implications for Drug Discovery*. IBC Library Series. Edited by Minden S.A. and Guttry P., pp. 39-60, 1998.
586. Chiariello M and Gutkind JS. Regulation of MAP Kinases by G Protein-Coupled Receptors. *Methods in Enzymology*, **345**:437-47, 2002.
587. Gutkind JS. Editor, *Book on Signaling Networks and Cell Cycle Control*. Humana Press, 2000.
588. Fukuhara S, Marinissen MJ, Chiariello M, and Gutkind JS. The pathway linking G protein-coupled receptors to the nucleus. In "*Signaling Networks and Cell Cycle Control*", Humana Press, Totowa, NJ, JS Gutkind Ed., 83-98, 2000.

589. Todd R, Gutkind JS, Shillitoe EJ, and Wong DT. Solid Tumors: Microarray analysis of oral cancers. In "*Microarrays and Cancer Research*", *Biotechniques Press*, Westborough, MA, JA Warrington, R. Todd, and D Wong, Eds., 139-153, 2002.
590. Sodhi A, Montaner S, and Gutkind JS. Molecular mechanisms of cancer. In "Signal Transduction and Human Disease". Edited by T. Finkel and J.S. Gutkind. Hoboken, NJ: John Wiley & Sons, pp 71-142, 2003.
591. Patel V, Leethanakul C, Amornphimoltham P, and Gutkind JS. Squamous carcinomas of the head and neck: Novel genomic approaches. In "Head and Neck Cancer Emerging Perspectives". Edited by JF Ensley, JS Gutkind, JR Jacobs, and SM Lippman. Academic Press, San Diego, CA. pp. 509-522, 2003.
592. Rosenfeldt H, Marinissen MJ, and Gutkind JS. G-protein-coupled receptors, cell transformation, and signal fidelity. In "Handbook of Cell Signaling", Edited by R.A. Bradshaw and EA Dennis. Elsevier Publishing Co., pp 589-599, 2003.
593. Crespo P and Gutkind JS. Activation of MAPKs by G Protein-Coupled Receptors. *Methods Mol. Biol.*, **250**:203-210, 2004.
594. Teramoto H and Gutkind JS. The Mitogen-Activated Protein Kinase family. In "Encyclopedia of Biological Chemistry". Edited by W.J. Lennarz and M.D. Lane Elsevier, Oxford, **2**:737-742, 2005.
595. Sodhi A and Gutkind JS. Endothelial cell transformation by the Kaposi's Sarcoma Herpesvirus. In "Encyclopedia of the Microvasculature", Edited by D Shapro and JA Madri. Elsevier Science U.S.A., **147**:993-998, 2006.
596. Montaner S and Gutkind JS. The vascular endothelium as a target for hemorrhagic fever viruses. In "Encyclopedia of the Microvasculature", Edited by D Shapiro and JA Madri. Elsevier Science U.S.A., **102**:689, 694, 2006.
597. Marinissen MJ and Gutkind JS. Regulation of JNK by small GTPases. In "The JNK Signaling Pathway". Edited by A. Lin. Landes Bioscience, Georgetown, TX, **2**:13-28, 2006.
598. Gavard J and Gutkind JS. A Molecular Crosstalk between E-cadherin and EGFR Signaling Networks. In "Signaling Network in Cancer Therapy". Edited by JD Haley and WJ Gullick. Humana Press Inc, **20**:139-154, 2008.
599. Palmby TR, Rosenfeldt H, and Gutkind JS. G Protein-coupled receptors, signal fidelity and cell transformation. In "The Handbook of Cell Signaling Second Edition", Edited by R Bradshaw and E Dennis. Elsevier Science U.S.A., **201**:1635-1648, 2009.
600. Amornphimoltham P, Patel V, Molinolo AA, and Gutkind JS. Head and Neck Cancer and the PI3K/Akt/mTOR signaling network: Novel Molecular Targeted Therapies. In "Signaling Pathways in Squamous Cancer." Edited by C VanWaes and A Glick. Springer Science & Business Media U.S.A., 407-430, 2011.
601. Chiariello M, Vague JP, and Gutkind JS. Activation of MAPKs by G Protein-Coupled Receptors. *Methods Mol Biol.* **661**:137-50, 2010.
602. Vázquez-Prado J and Gutkind JS. RGS-RhoGEFs and other RGS multidomain proteins as Effector Molecules in GPCR-Dependent and GPCR-independent Cell Signaling. In "G Protein Coupled Receptors." Edited by S. Siehler and G. Milligan. Cambridge University Press, U.K., 160-186, 2011.
603. Leelahavanichkul K, Gutkind JS. Oral and Pharyngeal Epithelial Keratinocyte Culture. *Methods in Molecular Biology*, **945**:67-79, 2013.
604. Castilho RM, and Gutkind JS. The Wnt β -catenin Signaling Circuitry in Head and Neck Cancer. In "*Molecular Determinants of Head and Neck Cancer*." Edited by E Golemis and B Burtneess. Springer Science, N.Y., **10**: 199-215, 2014.
605. Doçi CL and Gutkind JS. Targeting the PI3K-mTOR Signaling Circuitry in HPV-Associated Oral Malignancies: Novel Precision Molecular Therapies in "*Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer*." Edited by Daniel L Miller and M Sharon Stack. Springer International Publishing Switzerland, **7**: 153-170, 2016.

- 606. Gutkind JS and Sodhi A. Chapter 145 Molecular Genetics of Choroidal Melanoma *Ryan's Retina*, 6th Edition, **Volume 3**, Part 2, Section 2 Tumors of the Retina, Choroid, and Vitreous. Pages 2533-2539. 2018.
- 607. Wu V and Gutkind JS. Chapter 10 Targeting GPCR in HNC, 1st Edition, **Volume 6**, Improving the Therapeutic Ratio in Head and Neck Cancer, 2019.
- 608. Rothlin CV and Gutkind JS. Chapter 39 Immunosuppressants, Immunomodulation, and Tolerance, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, 2023.
- 609. Yung BS & Gutkind JS. *Briefing*: A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure in mice. *Nature Immunology* **24**, 1232–1233. <https://doi.org/10.1038/s41590-023-01567-1>, 2023.
- 610. Rothlin C, Gutkind JS. A special collection on targeting the immune system-Editorial. *J Pharmacol Exp Ther.* **392**:103771. Epub ahead of print. PMID: 41273897.2025